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Abstract 
Non-governmental organizations and transnational networks have been increasingly 
successful at gaining influence within issue areas traditionally controlled by the state. In many 
instances, non-state actors have been instrumental in forcing issues onto the global agenda, have 
aided in the development or transformation of global regimes, and have participated in securing 
state compliance for the adoption of new international norms. 
This paper argues that, consistent with social constructivist theory, ideas are important in 
influencing state preferences and change may be possible when certain factors are present. If 
non-state actors can influence states, it is meaningful to understand how this happens. 
This paper focuses on a campaign led by Medecins Sans Frontieres that began in the late 
1990s to acquire affordable medicines for patients in developing states that could not afford 
patented drugs. The campaign reached a measure of success in that member states of the World 
Trade Organization re-negotiated contested terms and meanings within the trade agreement for 
intellectual property rights and allowed concessions that would benefit lower income states. 
What factors contributed to the success of the campaign? And what were the most important 
factors - the issue, the actors or the mechanisms used? 
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Chapter 1 
Non-governmental organizations and transnational networks have been increasingly 
successful at gaining influence within issue areas traditionally controlled by the state. In 
many instances, non-state actors have been instrumental in forcing issues onto the global 
agenda, have aided in the development or transformation of global regimes, and have 
participated in securing state compliance for the adoption of new international norms. 
Some of the most successful campaigns by advocacy groups that have resulted in the 
internalization of new norms at the global level have been those that resonate with a 
human rights framework or that deal with the environment. I This would suggest that 
state behavior may not be fixed and that other factors may influence their behavior at the 
intemationallevel. 
This paper will focus on a campaign that began in the late 1990s to acquire reasonably 
priced pharmaceuticals for patients in developing states that could not afford patented 
brand name medicines. Led by non-governmental organizations, the campaign, it can be 
argued, reached a measure of success in that member states of the World Trade 
Organization (WTO) re-negotiated contested terms and meanings within the trade 
agreement for intellectual property rights and allowed new concessions that would 
benefit lower income states. If non-state actors can influence states, it is meaningful to 
understand how this happens. What factors contributed to the success of the campaign? 
And what were the most important factors - the issue, the actors or the mechanisms used? 
One of the leaders of the campaign was a non-governmental organization, Medecins 
Sans Frontieres (MSF). This paper will argue that MSF has been effective in impacting 
pharmaceutical access and the trade policy between states, and that there are several 
I Margaret E. Keck and Kathryn Sikkink, Activists beyond Borders: Advocacy Networks in International 
Politics (US: Cornell University Press, 1998), 9, 26-28. 
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factors that make MSF unique as an organization contributing to its success in this issue-
area. First, the simultaneous use of advocacy and confrontation has been embedded in 
the culture of MSF since its inception. Second, it is a transnational organization with 
offices and ongoing operational missions in a large number of states. This allowed MSF 
to reach a wide constituency and draw support quickly. Third, MSF has an excellent 
reputation as a leading humanitarian organization with expertise in health issues affecting 
developing states. MSF uses moral authority to make demands and draw attention to 
what it considers to be errant behavior. Fourth, MSF maintains a policy of independence 
from political and religious powers, and is financially supported primarily by the private 
sector. This has allowed MSF to pursue principled ideas without concern for its future 
funding. Fifth, MSF dedicated substantial resources to its Campaign for Access to 
Essential Medicines and formed an epistemic community to support it. The epistemic 
community was able to provide evidence-based research and had the credentials to gain 
access to policy-makers within international organizations and governments. Sixth, MSF 
has used the media and the internet effectively to mobilize public opinion, to contest 
actions and claims that are in opposition to its goals, and to provide education about the 
issue of pharmaceutical access. Seventh, MSF was a member of the access network, 
coalition and social movement and provided leadership throughout. The goals of the 
network and coalition were consistent with the goals of MSF and it was able to graft its 
agenda to the larger movement. 
Finally, MSF used carefully crafted strategies to frame the access issue with lenses 
tailored to different stakeholders. MSF employed the framing of a basic human right to 
health and gained grassroots support by invoking norms rooted in social justice by 
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contrasting the wealth of transnational pharmaceutical corporations with the suffering of 
those dying because they could not afford essential medicines. Alternately, when dealing 
with international organizations and wealthy governments, MSF reinforced the sovereign 
right of governments to provide for their populations, and advocated that governments, 
particularly in lesser developed states, be allowed to take necessary measures to protect 
public health. 
Organization of the Paper 
In this chapter, I will provide a brief overview ofthe issue concerning intellectual 
property rights and pharmaceuticals access. This is followed by a review of the literature 
that theorizes the behavior of states and the role of non-state actors in international 
politics, and a discussion to determine how the arguments in this paper are situated within 
the literature. In the second chapter, I will review the history of intellectual property 
rights and how IP rights became entrenched in international trade rules. This includes a 
discussion of certain rules contained in the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) under the WTO and the problems that arose 
specifically in the area of pharmaceuticals. The positions argued by both the corporate 
coalition and the transnational access coalition will be examined, as will the 
modifications made to the TRIPS Agreement. 
The third chapter is structured to provide the historical context for the formation of 
MSF and to discuss the assumptions that underpin its conception of humanitarian action. 
This is followed by an overview of the changing nature of global health in the 1980s and 
1990s and by an explanation of the link between MSF and the pharmaceutical issue. I 
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will examine the focus and actions of the Campaign for Access to Essential Medicines, 
its partnering and strategies, and MSF's continuing commitment to the issue. 
The fourth chapter will provide an analysis ofthe access campaign and strategies used 
by MSF to frame the issue and influence state behavior, and I will examine some ofthe 
outcomes to determine their implications for theorizing in international relations. In 
addition, I will consider alternate explanations for shifts in state behavior and compliance 
with new norms for pharmaceutical access. Finally, I will conclude with suggestions 
about which factors might be most important for successful campaigns and propose areas 
for further research. 
Research Methodology 
This paper uses a case study approach to determine the factors that contributed to 
establishing and re-assessing the multilateral TRIPS Agreement and the impact of actions 
taken by MSF and other actors to alleviate the barriers for accessing essential medicines. 
The case study approach is a contextual examination of a phenomenon used for 
explaining or theorizing about an aspect of an event through inferential reasoning.2 Case 
studies are useful for studying in rich and intricate detail decision-making processes of an 
individual or organization, tipping points affecting outcomes, and social factors including 
discourse and identity for both exploratory and explanatory investigations.3 By 
incorporating process-tracing, a method that attempts to link "possible causes with 
observed outcomes,,,4 the researcher relies on multiple sources of material to understand 
2 Alexander L, George and Andrew Bennett, Case Studies and Theory Development in the Social Sciences 
(Massachusetts: MIT Press, 2005), 17-18. 
3 Ibid. 9-10. 
4 Ibid., 6. 
4 
complexity in sequences and actions. Process-tracing can therefore help to mitigate some 
of the pitfalls of the case study method including case selection bias, over- or 
understatement of linkages and estimating the relevance of accumulated data. 5 
By analyzing the role ofMSF through the case study method, the paper will also 
consider the existing theories in international relations and determine which theories can 
best explain the processes and outcomes of the campaign. It will be shown that a 
constructivist approach offers a more complete explanation. 
The research materials for this paper include sources such as books and peer-reviewed 
journals, as well as websites maintained by some of the main actors in the study. In 
addition, I have employed content analysis of the web-based 'listserv' hosted by 
Consumer Project on Technology (CP Tech) during the early years of the campaign, 
archived web pages and websites maintained by various non-state actors including non-
governmental and international organizations. Triangulation of some information was 
mandatory to sort through conflicting reports for dates and sequencing, statistics, and 
actions attributed to various actors. 
Some of this research was generated from ideas and information from two conferences 
I attended at the University of Toronto: "Global Health Research," May 2004,6 and 
IDEA &UAEM's "Universities, Innovation and Global Medicine Access," Apri12009.7 I 
5 Ibid., 22-27. 
6 The idea for this research project was stimulated by attending the 2nd Annual Global Health Research 
Conference, "Mobilizing Research to Action: A Canadian Contribution," May 14-15,2004 at the Centre 
for International Health, Faculty of Medicine, University of Toronto. Stephen Lewis gave the opening 
address which focused on the numbers of orphans from neglected diseases in Africa and MSF maintained 
an extensive poster display decrying the lack of medicines for neglected diseases. The posters were highly 
effective; they drew much attention from conference attendees and elicited the emotive response which 
they were designed to do. On a personal note, I gathered up their offered materials and embarked on this 
research quest. 
7 The Initiative for Drug Equity and Access is at the Leslie Dan Faculty of Pharmacy, University of 
Toronto, and Universities Allied for Essential Medicines is a student-based organization with chapters 
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also gained insight into the broader issue at seminars sponsored by the Comparative 
Program on Health and Society at the Munk Centre including a panel on "Canada's 
Reform ofIP Law," December 2004, and several featuring the research of Post-Doctoral 
Fellow, Lisa Forman, which were particularly informative for my work. 
Overview of the Global Access to Medicines Regime 
For more than a decade, the relationship between intellectual property rights and the 
ability to access necessary medicines has been a concern for states and non-governmental 
organizations involved in health policy. The catalyst for the debate on the issue was 
twofold: the invention of anti-retroviral medicines that could potentially treat and 
prevent the spiraling number of infections and deaths related to HIV / AIDS in developing 
countries, and the formation of the World Trade Organization, an international 
organization formed to standardize and enforce trade laws between states. 
Although the human immunodeficiency virus (HIV) and acquired immunodeficiency 
syndrome (AIDS) were first recognized in 1981, the rapid spread of the related diseases 
was most notable in the 1990s. By 2001, UNAIDS and the World Health Organization 
estimated that 40 million persons globally were living with HIV / AIDS and approximately 
20 million had already died from AIDS-related illnesses making the virus the fourth 
leading cause of death. 8 The spread of the virus was most prevalent in developing 
across the United States and Canada. Both are committed to promoting equitable access to inventions 
stemming from technology and molecule discoveries that originate in University laboratories. More about 
UAEM is available from their website at http://essentialmedicine.org! 
8 UNAIDS/WHO, "AIDS epidemic update," December 2001, 1. 
http://www.who.intlhiv/facts/en/isbn9291731323.pdf (accessed May 1,2010). It should be noted here 
that many statistics are truly estimates. Reporting systems for HIV I AIDS were poor or non-existent in 
most developing states due to a lack of health infrastructure and because of the stigma of self-reporting or 
seeking treatment, particularly in the early years. Reporting problems are well-documented in the 
document, WHO, Regional Office for Africa, "HIV Surveillance Report for Africa 2000," November 2001, 
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countries,9 particularly in those located in sub-Saharan Africa which accounted for 28 
million cases (70% globally) of those living with HIV, and the incidence of new 
infections and deaths was rising annually. to 
Because the virus was affecting a large proportion of the population in sub-Saharan 
Africa at the height of their working and childbearing years, II multiple social and 
economic problems arose, including reduced productivity in the industrialized and 
agricultural sectors, plummeting life expectancyl2 and increased individual poverty. In 
poor countries, public health resources were underfunded or not accessible for a variety 
of reasons, including the introduction of user fees and privatization under structural 
adjustment programs, insufficient numbers of health care providers, and the lack of 
facilities in rural settings. 13 Personal assets frequently had to be sold to pay for 
medicines, medical care and for burials; children were often withdrawn from education 
systems to care for the ill or to provide an alternate income to buy basic needs such as 
food. 14 
http://data.unaids.orglPublications/External-Documents/hiv%20surv%20rpt%202000 en pdf.pdf 
(accessed May 1,2010). 
9 For the purpose ofthis paper, the term "developing countries" includes low and middle income states as 
defined by the World Bank based on Gross National Product. The 2009 figures per capita cite low income 
as $995 or less (includes 49 states: 33 located in Africa, 15 in Asia, plus Haiti), lower middle income as 
$996 - $3945 and upper middle income as $3946 - $12195. High income is currently defined as having a 
GNP per capita of at least $12,196. See World Bank, "Data: How We Classify," 
http://data. worldbank.orglaboutlcountry-c1assifications (accessed November 20, 2010). 
\0 UNAIDS/WHO, "AIDS epidemic," 2-3. In 2001, it was estimated that there was about 5 million new 
infections and 3 million deaths globally, with 3.4 and 2.3 million respectively occurring in Africa. 
II WHO, "HI V Surveillance," 17. Peak age for males was reported to be 30-34, and females to be 25-29. 
12 UNAIDS/WHO, "AIDS epidemic," 8-9. Life expectancy for Botswana, Malawi, Mozambique and 
Swaziland had dropped from about 62 years to less than 40, while South Africa dropped from 67 to 47 
years from 1990-2000. 
13 Ross P. Buckley and Jonathan Baker, "IMF Policies and Health in Sub-Saharan Africa," in Global 
Health Governance: Crisis, Institutions and Political Economy, ed. Adrian Kay andOwain David 
Williams (UK: Palgrave Macmillan, 2009), 214-215. 
14 UNAIDS/WHO, "AIDS epidemic." 7. 
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In Africa, where the virus affected men and women equally, mother-to-child 
transmissions of HIV were increasing and in some countries such as Botswana and 
Zimbabwe, antenatal clinics had reported that a third of the pregnant women tested were 
HIV positive. IS In addition, with an accumulated 16.4 million HIV-related deaths having 
occurred in the sub-Saharan region, it was estimated that more than 12 million children 
had already been orphaned. 16 
The first drug to combat HIV, Retrovir or AZT, was produced by Glaxo-SmithKline 
in 1987, but it was not until 1996 when protease inhibitors used in combination with AZT 
were introduced that HIV / AIDS became viewed as a potentially manageable illness. 
However, new international trade rules had been recently institutionalized and protected 
the originator drug companies from unauthorized use of their invention under patent· 
laws. 
Embedded in the WTO package of trade rules was the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). When the TRIPS Agreement took effect 
in 1995, patent laws that were previously enshrined in a patchwork of non-binding 
treaties became harmonized and enforceable for both the invention of products and 
processes. In the case of pharmaceuticals, the originator's rights were protected for 
twenty years under patent, and this soon became perceived as a barrier for the access of 
affordable essential drugs in lower income states. 
Because the TRIPS Agreement was to be phased in over five years, pharmaceutical 
companies in some developing states could continue to manufacture certain drugs until 
2000 when all states were to be "TRIPS" compliant. Some drug patents would also 
15 WHO. "HIV SUTveiJIance," 13. 
16 Ibid., 17. 
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expire during that period allowing for ongoing production. However, the terms of this 
limited production did not allow for the newer discoveries of anti-retroviral (ARV) 
medicines. Under patent, the ARV drugs that appeared in the late 1990s would command 
a very high price and would remain outside the financial reach of countries whose 
populations were most profoundly affected by the HIV virus. 
For several years leading up to the negotiations, the U.S. had strengthened its own 
laws at the behest of transnational corporations who invested heavily in research and 
development in high technology and knowledge-intensive industries. Corporations were 
anxious to protect their investments from 'free-riders', manufacturers in newly 
industrializing states that could realize profits by producing inexpensive copies of goods 
without bearing the burden of development costs. Unable to reach their objectives 
through the World Intellectual Property Organization (WIPO), representatives of the 
most affected industries had convinced the U.S. government that intellectual property 
rights were trade issues and should be included in the Uruguay Round of trade 
negotiations. 
Although there was resistance to the TRIPS Agreement from developing countries, the 
benefits of the new trade package outweighed the disadvantages, and opposition was 
ineffectual. In addition, the potential consequences of an entrenched intellectual property 
rights regime went largely unnoticed by most non-governmental organizations who, 
during the years leading up to "TRIPS", were immersed in emergency assistance and 
reconstruction work in the wake of the growing number of civil conflicts. 
The TRIPS Agreement was in force for more than 18 months when Health Action 
International, a transnational network, convened the first conference for non-
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governmental organizations to discuss the implications of the TRIPS Agreement on 
health issues. This set in motion a series of conferences that focused on access to 
essential medicines and included non-governmental organizations, international 
organizations, health officials from states, and representatives from the pharmaceutical 
industry. Through the conferences, a transnational advocacy coalition formed that would 
pursue access to affordable drugs for patients in developing states. 
The debate surrounding the impact that intellectual property rights had on the access 
to pharmaceuticals was divided into two opposing arguments. Wealthier states and 
transnational pharmaceutical corporations claimed that patents were necessary to protect 
and reward innovation and to facilitate future research and development. The corporate 
group insisted that patents were not relevant to the problem of access in lower income 
states and frequently identified poverty and lack of infrastructure as the primary barriers. 
In addition, they viewed the use of compulsory licensing and parallel importing permitted 
under the TRIPS Agreement to be invalid. 
The opposing side, the access coalition, was comprised mainly of non-governmental 
health and human rights organizations, developing states, and generic drug manufacturers 
who argued that patents were responsible for keeping drug prices high and prevented 
access to less expensive generics. They challenged the correlation between patents and 
profits for research and development, and claimed that in spite of other barriers, lives 
could be saved if medicines were accessible. Finally, they advocated that states had a 
right to protect public health by using the flexibilities permitted within the TRIPS 
Agreement. 
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A crucial point in the debate was when South Africa attempted to enact its Medicines 
and Related Substances Control Amendment Act, 1997 and was challenged in court by 
the Pharmaceutical Manufacturers Association and the drug companies it represented. 
The suit was supported by the D.S. and the European Union who tried to coerce South 
Africa into withdrawing its legislation. This gave the Access coalition a platform on 
which to mobilize civil society on a global scale, taking the fonn of a transnational social 
movement. Under intense pressure, the U.S. and E.D. withdrew their support of the 
lawsuit and eventually the legal challenge was withdrawn by the drug companies. The 
African Group of states asked the "TRIPS" Council to clarify the use of compulsory 
licensing and parallel importing, and this led to the Doha Declaration on the TRIPS 
Agreement and Public Health in 2001 supporting the right to protect public health and 
use the flexibilities outlined in "TRIPS". 
Early in the campaign, Medecins Sans Frontieres assumed one of the leading roles for 
the transnational access coalition. As an emergency medical agency, MSF worked in 
many of the countries with the largest populations suffering from HIV/AIDS and other 
neglected diseases. They had a practical understanding that access to medicines was 
severely limited in lower income countries and had an interest in overcoming the barriers 
that prevented treatment for their patients. 
MSF was awarded the Nobel Peace Prize in 1999 and made a commitment to the 
pharmaceutical issue by formalizing their Campaign for Access to Essential Medicines. 
The main actors from MSF who piloted the Access Campaign were professionals in the 
fields of medicine, pharmaceuticals and trade law. Supported by MSF's team of 
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researchers and experts in the field they constituted an epistemic community 17 which 
strengthened their ability to contest opposing claims and influence pharmaceutical policy 
through multiple access points. In addition, MSF was able to graft its agenda to that of 
the larger coalition and social movement to promote access to drugs for several diseases 
other than HIV / AIDS. MSF collaborated with various actors which led to lower drug 
prices and access to generics, and they published comparative selling prices for patented 
and generic drugs to increase leverage. MSF engaged in clinical trials, provided 
technical assistance to governments, and worked with intergovernmental organizations to 
promote access. Through the effective use of media and internet, MSF sustained pressure 
on pharmaceutical corporations and governments and mobilized civil society through 
several online petitions to oppose policies. Finally, the MSF campaign has continued to 
collaborate with multiple stakeholders to seek out innovative ideas to stimulate research 
and development for neglected diseases, and to push for access to the newer second and 
third line treatments. 
Theoretical Approaches for the Study of International Relations 
In order to examine the impact that non-state actors have on state behaviour, this paper 
relies on analytical premises that are typically associated with a constructivist framework 
found within liberal theories of international relations. Unlike traditional realist and 
neoliberal theories, liberalism opens a space for the examination of domestic politics and 
non-state actors to consider their influence on state preferences. A core assumption is 
17 An epistemic community is defined by Peter Haas as "a network of professionals with recognized 
expertise and competence in a particular domain or issue area." Peter M. Haas, "Introduction: epistemic 
communities and international policy coordination," International Organization 46, no. I (Winter 1992), 3. 
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that state identity and interests are formed as a result of domestic political structures or 
processes, and these in turn inform state preferences and actions at the international level. 
Traditional theories of international relations are less suitable for this paper and its 
emphasis on the impact of non-state actors because they perceive states as the only valid 
unit of analysis, and assume that state behaviour is the result of rational self-interest. The 
discussion will begin with a review of the primary assumptions that underpin traditional 
theory to establish the deficiencies that constructivist approaches can better address. 
Realism and Neorealism 
Primarily founded on the structural distribution of capabilities, classical realist theory 
has concentrated on the balance of power between states at the international level. The 
perpetual pursuit of power is understood to be inherent in human activity as a means to 
pursue specific interests. 
Classical theorists, such as E.H. Carr and Hans Morgenthau, have argued that at the 
international level states pursue their interests and that order is maintained through a 
balanced but ongoing struggle for power. State interests are not assumed to be 
necessarily similar to, nor in harmony with, the interests of other states and may change 
due to the effects of time and place. In the absence of universal moral principles to guide 
state actions, military and other material capabilities are considered to be the key element 
in this systems-level approach that perceives states as rational actors competitively 
seeking means to sustain or increase power. 18 
IS Hans Morgenthau and Kenneth W. Thompson, Politics Among Nations: the Struggle/or Power and 
Peace, 6th edition (New York: McGraw-Hili, 2006): 4-13. See also E.H. Carr, The Twenty Years' Crisis, 
1919-1939 (New York: Palgrave, 2001), particularly chapters 3 and 4 for the rationale underlying the 
realist assumptions. 
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Neorealism, or structural realism, arose from the debate about why states seek power 
and re-conceptualizes the pursuit of power as a means to ensure their existence. 
Although neorealists such as John Mearsheimer, Stephen Walt and Kenneth Waltz 
disagree about how much power is desirable, they reject the classical view that the 
pursuit of power is a result of human nature. Rather, neorealism concentrates on the 
structure of the international system to explain state behaviour and maintains that states 
are rational unitary actors existing in anarchy, which drives them to act in similar ways to 
ensure their own survival. 19 Without the benefit of a central overarching authority, and 
because states cannot predict how other states will behave in the future, the concept of 
self-help must be adopted. To survive, states will protect their interests and therefore 
their actions would be expected to reinforce sovereignty and security. The main political 
tool is the threat or use of force.2o 
Empowerment of the state and security are based on material factors - not just 
militarily, but also through generating wealth economically, technologically and 
territorially.21 Neo-realists argue that the accumulation of wealth is viewed as a zero-sum 
competition between states so that each seeks relative gains. For this reason, states are 
threatened by actions that could diminish the advantages they maintain over others. This 
also makes it difficult for states to develop mutual trust and co-operate.22 
19 Kenneth N. Waltz, Theory o/International Politics (US: Addison-Wesley Publishing Company, 1979), 
91-96. As a defensive realist, Waltz warns against the pursuit of hegemonic power, whereas offensive 
realists argue that strategically states should pursue as much power as possible. See J.J. Mearsheimer, The 
Tragedy o/Great Power Politics (New York: Norton, 2001) for a discussion of offensive realism. 
20 John J. Mearsheimer, "Structural Realism," in International Relations Theories: Discipline and 
Diversity, ed. Tim Dunne, Milja Kurkiand Steve Smith (UK: Oxford University Press, 2007),72-74. 
21 Ibid., 72-73. Mearsheimer refers to this as latent power. . 
22 Ibid., 72-75. 
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In this case study, realist theory may explain why powerful states dominated the 
Uruguay Round of negotiations and insisted on stringent intellectual property rights to 
protect their economic position and advanced level of technology. Realists would expect 
powerful states to continue to protect their major industries including lucrative 
transnational pharmaceutical corporations in order to benefit from their technical 
knowledge and financial investment. Therefore, realism cannot adequately address why, 
under pressure, powerful states appeared to change their preferences, weakening the 
TRIPS Agreement to accommodate health concerns exclusive to developing states. Nor 
does realism explain why major states backed down from supporting or pursuing legal 
challenges in the case of South Africa and Brazil when faced with rising opposition from 
non-state actors advocating for the access to medicines for developing states. 
Liberalism 
Based on the Kantian philosophy of peace, liberal theories accept that states are 
formed with the consent of citizens and that ideational factors affect how states are 
individually constructed. While cooperation between states in areas such as collective 
security and economic interdependence may be evidence of a common desire to avoid 
conflict, differences in state interests and identities persist, and a variety of liberal 
theories have devolved that focus on how state interests and identities are formed and 
transformed and consider which variables are important in the formation.23 
Liberalism continues to view states as primary rational actors at the international level 
although state preferences and identities are understood as being constituted by their 
domestic politics. State structures and policy are assumed to be formed from the 'bottom 
23 Diana Panke and Thomas Risse, "Liberalism" in International Relations Theories: Discipline and 
Diversity, ed. Tim Dunne, Milja Kurki and Steve Smith (UK: Oxford University Press, 2007), 90-93. 
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up' as a cumulative reflection of the demands from a rational and risk-averse pOlity.24 
Consequently state preferences and identity may be transformed due to social factors 
such as re-distribution of resources or political power, or because of changing ideas and 
beliefs. State officials are considered to be constrained in their policy choices by 
competing demands from within the state and by pressures exerted from outside.25 
At the international level, states are also seen as being subject to constraints imposed 
by the costs of pursuing interests in the global arena. States are not assumed to be 
innately in conflict, although conflict is more likely to occur when the interests pursued 
and strategies employed in a specific policy area constrain or threaten the preferences and 
strategies of other states. 26 
Liberal approaches tend to be based on the particularities of either structure or 
agency. Those that emphasize structure as a defining factor may examine how domestic 
features including political and economic institutions shape state preferences, whereas 
those that focus on agency may consider the interests and identities of relevant actors and 
groups within a society, including corporations and civil society organizations, as more 
important in the construction of policies that guide state actions.27 
Neoliberal Institutionalism 
Neoliberals such as Robert Keohane and Joseph Nye argue that cooperation between 
states is not only possible, but is frequently desirable when benefits can be shared and 
mutual (absolute) gains realized. However, because anarchy exists, collective-action 
problems will arise given that states need to self-regulate compliance with international 
24 Andrew Moravcsik, "Taking Preferences Seriously: A Liberal Theory of International Politics,~' 
International Organization 51 no.4 (Autumn 1997): 516-517. 
25 Ibid., 516-517. 
26 Ibid., 517-521. 
27 Panke and Risse, 92-93. 
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agreements. States in this model are considered to be rational actors that pursue their 
interests based on a cost-benefit analysis, although preferences and immediacy of returns 
may vary. Because there are incentives to defect or deviate from agreements in order to 
maximize individual gains, states cannot know how others will react, and therefore 
international regimes may be adopted to cope with the problems associated with 
cooperation.28 
International regimes are defined by Stephen Krasner as "principles, norms, rules, and 
decision making procedures around which actor expectations converge in a given issue-
area, ,,29 and can be designed as formal or informal arrangements between states to 
facilitate sustained cooperation. Regimes may seek to standardize expectations in a 
defined area such as trade by defining the scope of the agreement, enumerating the rules 
of behavior, monitoring compliance, and regulating sanctions that can be used against 
defectors. 
Some regimes may be managed by forming international organizations, defined as 
"multi-level linkages, norms and institutions.,,3o They may be created to minimize the 
transaction costs of cooperation by providing a forum where states can negotiate for 
similar understandings of the terms of cooperation, facilitate ease of monitoring other 
states' compliance with the terms of agreements, and offer a transparent adjudication 
mechanism.3l 
28 Lisa L. Martin, "Neoliberalism," in International Relations Theories: Discipline and Diversity, ed. Tim 
Dunne, Milja Kurki and Steve Smith (UK: Oxford University Press, 2007), 111-112. 
29 Stephen D. Krasner, "Structural causes and regime consequences: regimes as intervening variables," 
International Organization 36, no.2 (Spring 1982): 185. 
30 Robert O. Keohane and Joseph S. Nye, Power and Interdependence, 3rd ed. (US: Longman, 2001), 47. 
31 Martin, 111-112. 
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The neoliberal view of state behavior within international organizations is 
conceptualized as a structural approach, where states are the principals and the 
organization provides an agency function for member states. However, marked 
differences exist between international organizations, and some potential problems are 
worth noting. First, the discretionary powers of international organizations are varied, 
and their degree of autonomy may be strategically linked to the preferences of powerful 
states.32 Second, although international organizations tend to be rule-based, there is 
evidence that political bargaining frequently results in outcomes that reflect the 
preferences of the more powerful states. Evidence also shows that even at the WTO 
where enforcement mechanisms are not related to state power, the threat of future action 
is generally effective in producing outcomes that favour the more powerful.33 Third, 
regime compliance may require adjustments that cannot be uniformly achieved without 
concessions or assistance, which produces the problem of moral hazard, and conditions 
are often placed on recipient states to compel them to meet their obligations.34 
In this case study, neoliberal theory can account for why states supported the 
structural framework of the World Trade Organization and may explain why states would 
agree to be constrained to the extent that benefits outweighed the costs of membership. 
However, the explanation for why the US withdrew its case against Brazil at the WTO's 
Dispute Body, and why the more powerful states would make concessions under the 
"TRIPS" regime for resource-poor states to access pharmaceuticals remains problematic 
within neoliberal thought. 
32 Ibid., 119-120. The example cited by the authors relates to the World Bank's environmental policy as 
closely mirroring that of the U.S., however, it could be argued that the same principle is present in the 
World Trade Organization. 
33 Ibid., 115-117. 
34 Ibid., 118-119. 
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The approaches used in theories of realism, neorealism and neoliberal institutionalism 
concentrate on states as the primary unit of analysis and draw on rationalist assumptions 
to explain or predict state behaviour. The next section will examine some theoretical 
concepts that consider the role of non-state actors in international relations. 
Approaches for the Study of Non-State Actors in International Relations 
Attention to the role played by non-state actors at the international level can be traced 
back to observations that transnational relations in the 1970s were not limited to military 
considerations but were increasingly embedded in arrangements involving international 
trade and economics. Theorists such as Keohane and Nye.challenged the claim that 
states were the only important actors at the international level, arguing that cooperation 
between states and growing interdependence had changed the concept of power beyond 
the military to include political and economic power.35 There was an increasing number 
of multilateral instruments and institutions that provided rules and regulatory frameworks 
for states and other transnational actors in issue-areas such as the environment, trade and 
monetary policy, and the activities of transnational corporations.36 
The Role o/Corporations in International Relations· Theory 
Initial studies that examined the role of non-state actors focused on corporations, 
which are sometimes referred to as the second sector: private non-state actors that wield 
an abundance of economic rather than political power. As industrialized states moved 
away from the model of the welfare state that was popular after World War II and instead 
35 Keohane and Nye, 9-10. The authors refer to this dynamic as 'complex interdependence.' 
36 Ibid., 17. 
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adopted classical economic theories37 of markets unencumbered by government 
participation and regulation, corporations were presented with increased opportunities to 
expand both within and outside the home state.38 
Domestically, as states implemented neoliberal economic policies39 there was a 
movement toward a more limited role for government in the supply of goods and 
services, and the separation of responsibilities between the public and private spheres 
became more pronounced.4o Business interests based mainly on maximizing profits filled 
the void left by states, yet theorists studying non-state actors noted that the rise in private 
authority was mostly considered to be legitimate through the consent of the people.41 
At the intemationallevel, the rise of transnational corporations was encouraged by the 
liberalization of national markets and trade policies, rising competition between firms, 
and the reduction of barriers previously attributed to borders, means of transportation and 
movement of capital. Rapidly evolving technologies and modes of communication in 
particular facilitated the flow of capital for foreign direct investment. 42 
In response to claims that transnational corporations were gaining too much power 
and driving economic globalization, theorists such as Robert Gilpin and Susan Strange 
examined the relationship between markets and states and the role of transnational 
corporations on the changing nature of the state. From a state-centric viewpoint, Gilpin 
37 Notable classical theorists include Adam Smith ("invisible hand" of the market) and David Ricardo 
(comparative advantage), and more recently Friedrich Hayek and Milton Friedman. 
38 Virginia Haufler, "Global Governance and the Private Sector," in Global Corporate Power, ed. 
Christopher May (US: Lynn Reinner Publishers, 2006), 89-90. 
39 Neoliberal economic policy is based on classical liberal theories of IPE. See David N. Balaam and 
Michael Veseth, Introduction to International Political Economy, 4th edition, Chapter 3 (US: Pearson, 
2008), 37-61. 
40 Haufler, 89. 
41 Rodney Bruce Hall and Thomas J. Biersteker, The Emergence o/Private Authorilyin Global 
Governance (Cambridge: Cambridge University Press, 2002), 4-5. 
42 Balaam and Veseth, 367-368. 
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argued that states have remained the primary actors that establish the rules that 
corporations must follow and since the rules reflect the domestic interests of the most 
powerful states, these along with market forces influence economic outcomes.43 
According to Gilpin, ''the extent and impact of globalization are greatly overstated" and 
that it is a movement consented to by governments that is prevalent only in North 
America, Western Europe and Pacific Asia.44 
Strange acknowledged that structural power can influence market behaviour but 
because markets are impersonal and reflexive, outcomes sometimes may have unintended 
consequences such as a reduction in state authority in specific areas.45 She argued that 
states had lost some of their prior exclusivity and increasingly had to cooperate, 
coordinate or share policy decision-making with non-state actors.46 
Rather than recognizing transnational corporations as a threat to state power, states 
that adopt neoliberal economic policies generally regard corporations as agents for the re-
allocation of resources and as a vehicle to correct inefficiencies in the global market. 47 
However, the relationship between states and corporations can be both harmonious and 
contentious as each tries to maximize returns while gaining an advantage over competing 
states and businesses. States benefit from the ability of businesses to generate and invest 
financial wealth, invent and disseminate new technologies, provide employment 
43 Robert Gilpin, Global Political Economy: Understanding the International Economic Order (US: 
Princeton University Press, 2001), 18-23. 
44 Ibid., 294 & 364. 
45 Susan Strange, The Retreat of the State: The diffusion of power in the world economy (Cambridge: 
Cambridge University Press, 1996), 29. It is interesting to note that Strange examined ten issues that she 
identified as the traditional purview of the state and concluded that only two areas had not been overly 
compromised: providing a social safety net for those who could not compete and building infrastructure to 
further support the market. See 73-82. 
46 Ibid., 73. 
47 Rhys Jenkins, "Theoretical Perspectives on the Transnational C~oration," in International Political 
Economy: State-Market Relations in a Changing Global Order, 2 Edition, ed. C. Roe Goddard, Patrick 
Cronin and Kishore C. Dash (US: Lynne Reinner Publishers, 2003),416-417. 
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opportunities, and develop natural resources.48 In addition, states require the tax revenue 
generated by business activities to implement their own policies.49 Similarly, 
transnational corporations depend on states for access to markets, labour and natural 
resources, and legal frameworks to support production and investment. 
At the international level, corporate goals may depend on the cooperation of several 
states. The removal of trade barriers has required states to create new frameworks for 
regulatory or voluntary compliance in areas such as biosafety and environmental 
sustainability.5o For other areas, such as intellectual property rights, corporate alliances 
have lobbied and convinced powerful states to institutionalize new international rules.51 
Corporate power tends to vary between sectors and can be a result of industry specific 
command of resources, capital, or specialized technologies. Larger firms that appear 
highly mobile may be able to use this as leverage for gaining favourable policies from 
home states. The power of business can also be enhanced both domestically and globally 
through industry associations and effective lobbying tactics, particularly when political 
processes are open at multiple access points and interests can be aligned. 52 Finally, 
because of the specialized knowledge some firms hold, they may be directly involved in 
the formulation of state policy in an advisory or research capacity, and may be able "to 
contest, dilute, and shape the detail,,53 of international obligations. 
48 A. Claire Cutler, Virginia Haufler and Tony Porter, "Private Authority and International Affairs," in 
Private Authority and International Affairs, ed. A. Claire Cutler, Virginia Haufler and Tony Porter (NY: 
State University of New York Press, 1999),5-6. 
49 Peter Newell and David Levy, "The Political Economy of the Firm in Global Environmental 
Governance," in Global Corporate Power, ed. Christopher May (US: Lynne Reinner Publishers, 2006), 
161. 
50 Ibid., 162-163. 
51 Hautler, 91. 
52 Newell and Levy, 163-164. 
53 Ibid., 164. 
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Theorists studying the features affecting the management of health at the global level 
have noted that the liberalization of the market has broadened consumer access to 
different products and services, increased competition between providers and 
manufacturers, and facilitated the shift of health services from the public sphere to the 
private domain. 54 However, the benefits and outcomes have been uneven. 
Alan Ingram argues from a structuralist approach that the legacies of colonialism, 
structural adjustment policies, and the Cold War have contributed to the underlying 
burden of disease in poor countries and the inadequate response by governments to health 
crises. 55 International organizations, particularly the Bretton Woods institutions, are 
viewed as constraining policy choices that national governments could adopt for health 
because their programs continue to link state spending and poverty reduction to the 
funding and loans available through the World Bank and the International Monetary Fund 
(lMF).56 
It is also noted that the commodification of health produces externalities; for example, 
the absence of public control over the allocation of health resources can create greater 
inequities for access between rich and poor individuals within a state and between states 
in the North and South. 57 A cogent example of this lies in the access to antiretroviral 
54 Adrian Kay and Owain David Williams, "Introduction: The International Political Economy of Global 
Health Governance," in Global Health Governance: Crisis, Institutions and Political Economy, ed. Adrian 
Kay and Owain David Williams (UK: Palgrave Macmillan, 2009), 7-11. 
5S Alan Ingram, "The International Political Economy of Global Responses to HIVIAIDS," in Global 
Health Governance: Crisis, Institutions and Political Economy, ed. Adrian Kay and Owain David 
Williams (UK: Palgrave Macmillan, 2009), 84-86. 
56 Kay and Williams, 13-14. Ingram, 91 
57 Kay and Williams, 6, 11. The authors note that inequities can arise within states due to liberal policies, 
and as evidence, point to the US where 50 million people have no health insurance to ensure access. 
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treatment; while widely available in states of the North, it is estimated that in 2004, only 
2% of those in need living in Sub-Saharan Africa were receiving treatment.58 
Theories that examine the role of the corporation add to the explanation for why 
powerful states and large pharmaceutical corporations desired strengthened trade regimes 
and how industry can influence the political process. Although pharmaceutical 
corporations incur substantial costs throughout the production cycle for the development 
of new drugs, they are among the most profitable in the business sector. During the 
period 1995-2002. they were ranked first in the United States, falling to fourth place after 
2003.59 By 2002, global drug sales were estimated to be US$430 billion; half of the top 
twenty pharmaceutical corporations had their headquarters in the United States, while the 
remaining ten were scattered in Germany, Switzerland, France, Britain and Japan.60 The 
considerable investment made by the companies in research and development, product 
promotion, and human resources directly benefited the domestic economies of the home 
state and the host countries of their subsidiaries. A strong patent regime protecting both 
product and process was an important factor for retaining profits and continuing 
investment in research and development. 
Industry associations were also particularly strong in this case. The major U.S. 
pharmaceutical corporations Merck and Pfizer joined forces with entertainment and 
software representatives to form the ,Intellectual Property Committee that lobbied U.S. 
58 Ingram, 81. 
59 World Health Organization, Public health, innovation and intellectual property rights: Report of the 
Commission on Intellectual Property Rights, Innovation and Public Health, 2006, 18, 
http://www. who. int/intellectualproperty/documents/thereportlENPublicHealth Report.pdf (accessed April 
18,2009). 
60 L.J. Sellers, ed., "Special Report: Fourth Annual Pharm Exec 50," Pharmaceutical Executive (May 
2003),42-52' 
http://pharmexec.findpharma.com/pharmexec/dataiarticlestandard/ /pharmexec/182003/55215/article.pdf 
(accessed July 20, 2010). 
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Congress to increase protections.61 Simultaneously, Merck and Pfizer were members of 
the Pharmaceutical Research and Manufacturers Association, which added pressure and 
also persuaded their counterpart organizations in Europe and Japan to launch similar 
appeals.62 Through careful framing, they were successful in aligning their interests with 
those of powerful states for the creation of the TRIPS Agreement. 
Yet, as this case will demonstrate, corporate power and the pursuit of purely economic 
interests are not always the dominant considerations informing state behaviour at the 
international level. In spite of strong opposition and seemingly persuasive arguments 
from pharmaceutical corporations, states affirmed the right to protect health and to use 
measures contained in the TRIPS Agreement, and made concessions that would assist 
resource-poor states in obtaining less expensive medicines. Some states further 
responded to the revised rules for "TRIPS" by making significant domestic regulatory 
provisions to allow for the export of generic medicines under compulsory licensing to 
less developed states, although no economic gain would be realized. 
Rather than being swayed by economic interests, states in this case study appear to be 
more responsive to the position rendered by the access coalition including a commitment 
to health and to the moral principles of social justice that medicines were possible and 
human suffering was needless. This would seem to be consistent with constructivist 
claims that states are concerned about identity and human rights concerns. 
61 Susan K. Sell, Private Power, Public Law (UK: Cambridge University Press, 2003), 2, [online book], 
https:llproxy.library.brocku.ca/login?qurl=http%3a%2fUIo2fsite.ebrary.com%2flib%2foculbrock%2tDoc%3 
fid%3d10070207 (accessed January 6, 2010). 
62 Heinz Klug, "Law, Politics, and Access to Essential Medicines in Developing Countries," Politics and 
Society 36, no.2 (June 2008): 212. 
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Beyond Corporations: "The Third Force ,,63 of Transnational Non-State Actors 
The rise of transnational corporations and some of their activities created issues that 
caught the attention of a variety of non-governmental stakeholders including civil society 
organizations and consumers. Based on the (contested) assumption that corporations 
have responsibilities beyond profit and duty to shareholders, there has been a movement 
to hold business accountable for the negative impacts their activities may have on 
societies. Pressure exerted by states and civil society organizations on corporations 
concerning practices and outcomes has resulted in the development in many industries of 
a guiding set of principles and norms that constitute corporate social responsibility.64 
As John Ruggie argues, the push for corporate responsibility is partially due to the 
perception that while rules that promote the market have progressed rapidly, they have 
not been balanced against other valid social concerns.65 Therefore, actors that were not 
previously engaged in issues such as trade have been prompted to enter into new arenas 
to become proponents for change.66 The range of actors now participating in governance 
(sets of rules, institutions and practices) at the international level has created what he 
calls a new global public domain where "expectations regarding legitimate social 
purposes, including the respective roles of different social sectors and actors, are 
articulated, contested, and take shape as social facts.,,67 
63 From the title ofa book edited by Ann M. FIorini, The Third Force: The Rise o/Transnational Civil 
Society (Tokyo: Japan Center for International Exchange and US: Carnegie Endowment for International 
Peace, 2000). 
64 A. Claire Cutler, "Transnational Business Civilization, Corporations, and the Privatization of Global 
Governance," in Global Corporate Power, ed. Christopher May (US: Lynne Reinner Publishers, 2006), 
200. 
65 John Gerard Ruggie, "Reconstituting the Global Public Domain - Issues, Actors, and Practices," 
European Journal o/International Relations 10, no.4 (2004): 511. 
66 Ibid., 508. 
67 Ibid., 504. 
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The actors participating and competing in the global public domain now include 
states, international organizations and a host of non-state actors including corporations, 
civil society organizations, consumers and citizens. To understand the impact they may 
have on state behaviour, we will now consider social constructivist theory. 
Social Constructivism 
In much of the recent international relations literature, social constructivist theory has 
been the framework employed to analyze the contribution of non-state actors toward state 
behavior. Considered to be a meta-theory, "constructivism is concerned with human 
consciousness,,68 and the effect this has on state identities and interests. Ruggie traces the 
underlying premise to Max Weber and John Searle who argued that humans have the 
ability to give "significance" to their existence and have created "social facts" to guide 
their interactions.69 Therefore, the core assumption of constructivism is that human 
actions are founded on intersubjective understandings of the world around them. 70 
Constructivism holds that social interactions are underpinned by collectively shared 
beliefs or meanings, which are rooted in ideational rather than material factors, and that 
the formation of identities and interests is intrinsically linked to these beliefs.71 The 
belief system is not viewed as individually held, rather it is perceived as a "collective 
intentionality" that brings legitimacy to the reality it constructs. Further, constructivists 
suggest that constitutive rules logically precede the construction of institutions. Through 
68 John Gerard Ruggie, "What Makes the World Hang Together? Neo-utilitarianism and the Social 
Constructivist Challenge," International Organization 52, no. 4 (Autumn 1998), 878. 
69 Ibid., 856. 
70 Ibid., 856. 
71 Martha Finnemore and Kathryn Sikkink, "Taking Stock: The Constructivist Research Program in 
International Relations and Comparative Politics," Annual Review in Political Science 4 (2001), 393. See 
also Friedrich V. Kratochwil, Rules. Norms and Decisions: On the Conditions 0/ Practical and Legal 
Reasoning in International Relations and Domestic Affairs (Cambridge: Cambridge University Press, 
1989) and Alexander Wendt, Social Theory o/International Politics (Cambridge: Cambridge University 
Press, 1999). 
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constitutive rulemaking the agreed-upon constructed reality is first shaped and reinforced. 
This reality may become formalized by the creation of institutions that will craft and 
promulgate regulative rules, further affecting state identities, interests and relationships.72 
Constructivists argue that the "international structure is determined by the 
international distribution of ideas.,,73 International norms, defined as "a standard of 
appropriate behavior for actors with a given identity,,,74 provide the collective 
understandings that promote international order. Norms require both belief and action 
consistent with the belief to be internalized; however, states' interpretation of and 
compliance with international norms may not be static but reflective of their domestic 
processes and actors. 75 
Within the constructivist framework of analysis, structure and agent are considered to 
be mutually constitutive, without prior and fixed positions. Subsequently, the role of 
ideas, norms and culture becomes increasingly important in explaining individual state 
preferences and shifts in policy.76 If the reality in which states operate is socially 
constructed, it is possible that the introduction of different ideas, knowledge or practices 
could allow for the re-conceptualizing of a state's identity and interests. When a critical 
mass of states similarly adjust their beliefs or practices, new international norms may be 
accepted and institutional change may follow. 
72 Ruggie, "What Makes," 869-870. 
73 Martha Finnemore and Kathryn Sikkink, "International Norm Dynamics and Political Change;" 
International Organization 52, no.4 (Autumn 1998),891-894. 
74 Ibid., 89] -894. 
75 Thomas Risse and Kathryn Sikkink, "The socialization of international human rights norms into 
domestic practices: introduction," in The Power of Human Rights: International Norms and Domestic 
Change, ed. Thomas Risse, Stephen C. Ropp, and Kathryn Sikkink (UK: Cambridge University Press, 
1999), 7. . 
76 Finnemore, "Taking Stock," 392-393. 
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Constructivists have begun to analyze factors that may contribute to changes in state 
behaviour, and a body of literature specifically around the role of civil society and 
transnational advocacy has emerged. Consistent with the claim that advocacy groups 
seek "to create, strengthen, implement, and monitor international norms,'.77 the literature 
includes a typology of the groups and the scope of the activities that individuals 
participate in to effect change, the type of issues they address and the techniques that are 
used by non-state actors to encourage states to redefine roles and adopt new norms. 
For the purpose of this paper, I have adopted the distinctions made by Khagram et al. 
who argue that there are four ideal types involved in transnational advocacy. All types 
include actors that are somehow connected across state borders, but how they are 
organized and the mechanisms they employ add to the distinction between groups. The 
first, international nongovernmental' organizations, "have a decision-making structure 
with voting members from at least three countries, and their aims are cross-national 
and/or international in scope.,,78 The second type, transnational advocacy networks, are 
usually identified as having less formalized relationships but are connected by shared 
values around an issue. Networks can include a variety of actors and their most 
important resource is the ability to facilitate a rapid and accurate "dense exchange of 
information.,,79 Networks do not normally ~oordinate other kinds of collective action, 
rather, when a transnational advocacy group becomes more formalized and adopts 
strategies such as forming campaigns and organizing conferences, this third type is 
77 Sanjeev Kbagram, James V. Riker, and Kathryn Sikkink, "From Santiago to Seattle: Transnational 
Advocacy Groups Restructuring World Politics," in Restructuring World Politics: Transnational Social 
Movements, Networks, and Norms, ed. Sanjeev Khagram, James V. Riker, and Kathryn Sikkink (US: 
University of Minnesota Press, 2002), 4. 
78 Ibid., 6. 
79 Ibid., 7, 9. 
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identified as a transnational coalition. The members of the coalition can also include a 
wide variety of actors from international and domestic locales who are likely to maintain 
close contact in order to coordinate their efforts toward a specific goal. so 
The final type identified by Khagram et al. are transnational social movements and are 
defined as "sets of actors with common purposes and solidarities linked across country 
boundaries that have the capacity to generate coordinated and sustained social 
mobilization. "SI Transnational social movements are less common because their 
activities require a high degree of coordination to be jointly mobilized in at least three 
states. The tactics used to publicly promote change typically include protests and other 
disruptive activities designed to bring attention to the issue. S2 
Advocacy groups are assumed to lack traditional power and must instead rely on the 
ability to create influence through the strategic use of information and to act as moral 
entrepreneurs. By creating a specific discourse in an issue-area, advocacy groups use 
what some authors refer to as softS3 or communicative power to introduce new norms or 
use persuasion to re-shape existing norms. S4 Comprised mainly of non-governmental 
organizations, they are seen as part of the third sector of international actors, who unlike 
states and businesses, conduct their activities primarily based on principled beliefs that 
invoke notions of what 'ought to be.,S5 In contrast, states have military and economic 
80 Ibid. 
81 Ibid., 8. 
82 Ibid. 
83 Joseph Nye defines soft power as including "culture, beliefs, values and ideals" in contrast to hard power 
which is typically military or economic means used to coerce or influence behaviour. See Balaam and 
Veseth, 11. 
84 Kathryn Sikkink, "Restructuring World Politics: The Limits and Asymmetries of Soft Power," in 
Restructuring World Politics: Transnational Social Movements, Networks, and Norms, ed. Sanjeev 
Khagram, James V. Riker, and Kathryn Sikkink (US: University of Minnesota Press, 200"2), 303-304. 
85 Khagram, II. 
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power that can be used as coercive mechanisms, while businesses may enjoy economic 
resources and participation in industry networks that can influence governments. 
Keck and Sikkink categorized the mechanisms used by advocacy groups into four 
types of political actions: information, symbolic, leverage and accountability. 86 
Information politics includes the relevant and timely gathering of facts, statistics, 
alternate interpretations, and testimony that may be used to frame an issue, refute claims, 
and build legitimacy for the advocacy group in the issue-area.87 Framing is used by 
advocacy groups to "define the issues at stake and the appropriate strategies for action,,88 
and must be crafted to resonate with the targeted audience in order to persuade them of 
what ought to be. Symbolic politics may involve using one or more events to frame an 
issue and raise awareness within a wider audience, and may be used by groups to raise 
their own profiles to create a perception oflegitimacy.89 The third category, leverage 
politics, is in response to the asymmetrical power structure that issues are negotiated 
within. Advocacy groups will seek leverage over more powerful actors through material 
or moral means, which may include linking policy options to "money or goods" or 
exposing actors' behaviors to scrutiny through "shaming.,,90 Finally, accountability 
politics is used by advocacy groups to call attention to the disparity between an actor's 
commitment in principle and its actual practice, and is based on the assumption that states 
are more likely to comply when they risk being embarrassed.91 
86 Keck and Sikkink, Activists beyond Borders, 16. 
87 Ibid., 18-22. 
88 Finnemore and Sikkink, ''Taking Stock," 409. 
89 Keck and Sikkink, Activists beyond Borders, 22-23. 
90 Ibid., 23. 
91 Ibid., 24. 
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One area of theoretical disagreement arises in Keck and Sikkink's defining advocacy 
networks as different from interest groups in that they are motivated by "principled 
beliefs or values.,,92 Sell and Prakash argue that analytically there is no difference 
between interests and ideas, and that many instrumental actors also demonstrate 
principled beliefs while advocacy networks similarly may be concerned with the 
material. 93 They argue that although business networks are profit-oriented, they can also 
be viewed as competing interest groups that use strategies similar to advocacy networks 
to pursue their policy goals. For Sell and Prakash, 
Success in influencing policy processes lies not in claimed moral superiority 
of the agenda but in the network's superior abilities to create and make the 
most of political opportunities by exploiting a crisis, constructing a problem, 
mobilizing a coalition, and grafting its agenda onto policy debates.9 
For the purpose of this paper, I will continue to use advocacy networks as defined by the 
former, but in terms of outcomes and strategies, I concur with the latter point. 
Keck and Sikkink have argued that networks tend to be more successful when the 
issue involves ideas of right and wrong, especially when there is "bodily harm to 
vulnerable individuals,,95 and blame can be assigned to parties responsible. This would 
suggest that issues that employ a human rights perspective may be more effective. 
Human rights norms have been increasingly accepted by the international community 
in concept and practice since the Universal Declaration of Human Rights was adopted in 
1948. The main body of rights that have been forwarded as being universal and 
extending to all humans in order to protect human dignity are included in nine core 
92 Ibid., 1. 
93 Sell and Prakash, 147-149 
94 Ibid., 149. 
95 Keck and Sikkink, Activists beyond Borders, 26-27. 
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international treaties monitored by the United Nations.96 By ratifying participation in a 
treaty, states are bound "to protect, to respect and to fulfil" the enjoyment of human 
rights contained within and to implement necessary measures to facilitate states' 
obligations toward this end.97 
However, human rights are contested by some as being a construct of the "West" and 
parochial in nature because they "reflect (1) an arbitrarily restricted set of moral values; 
or (2) an arbitrary ranking of certain moral values.,,98 In spite of these objections, all 
member states of the UN have ratified at least one major treaty and 80% of states have 
ratified at least four.99 This implies that the understandings of the obligations undertaken 
by states may not be uniform and that different conceptualizations may be present. 
Negotiations are often lengthy with results that exceed the capacity or desire of many 
states and enforcement mechanisms are weak. Therefore, the adoption of human rights 
treaties by states is frequently interpreted as signaling a long term aspiration toward 
respecting rights rather than a guarantee of rights. 100 
There are two significant considerations in recognizing rights. First, rights imply that 
the individual has a claim against the state for the recognition of both positive and 
negative rights. Negative rights mean the right-holder assumes there is an obligation by 
the state to refrain from certain violations against an individual, such as the right not to be 
tortured. Positive rights assume that the state will take certain actions to provide 
96 United Nations High Commissioner for Human Rights, http://www2.ohchr.org/english/law/ (accessed 
Sept. 10,2010). 
97 United Nations, International Human Rights Law, 
http://www .0hchr.org/EN/ProfessionallnterestlPages/IntemationaILaw .aspx (accessed May 14, 2010). 
98 Allen Buchanan, Human Rights, Legitimacy, and the Use of Force (NY; Oxford University Press, 20 I 0): 
72. 
99 United Nations, Human Rights Bodies, 
http://www.ohchr.org/EN/HRBodies/Pages/HumanRightsBodies.aspx (accessed May 14,2010). 
100 Eric Neumayer, "Do International Human Rights Treaties Improve Respect for Human Rights?" Journal 
of Conflict Resolution 49, no.6 (Dec.2005): 928. 
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something for the individual, such as the creation of a public health care system to enjoy 
the right to health. This places a burden on the state that may not coincide with state 
resources and capacity economically or administratively. 
The second problem with recognizing human rights as guaranteed is that rights may 
conflict with other interests a state needs to pursue. The state may justify violating 
individual human rights for cultural reasons or for the benefit of a larger constituency. 101 
More importantly, state preferences will hierarchically determine policy concerns and the 
allocation of resources accordingly. For realists, the main policy concern is security and 
all other policies would be subservient to the preservation of security. In contrast, liberal 
theorists claim that human rights norms are prominent on the agendas of liberal states and 
are important in how states identify themselves to others as a "member of the community 
of liberal states.,,102 However, when viewed through a constructivist lens, states are not 
merely rational actors, but generally "try to do the right thing.,,103 Therefore, pressure on 
governments from below through domestic processes or from above by transnational 
advocacy networks may be effective in moving states closer to internalization and 
compliance of human rights norms. 104 
Several international treaties and documents include the right to health as a 
fundamental human right, in some cases noting its prerequisite status for the realization 
of other rights. First appearing in the Constitution of the World Health Organization 
(WHO) in 1946, the right to health is generally framed as "the right to the enjoyment of 
10\ Buchanan, 72-73. 
102 Risse and Sikkink. 8-9. 
\03 Thomas Risse, " "Let's Argue!": Communicative Action in World Politics," International Organization 
54, no. 1 (2000): 4. . 
104 Neumayer, 930-932. 
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the highest attainable standard of physical and mental health,,105 and is enumerated in 
Article 12.1 of the International Covenant on the Economic, Social and Cultural Rights 
(ICESCR). As a social right, the right to health has been most clearly qualified by the 
United Nations Social and Economic Council in a report released in August 2000.106 The 
document notes that the right to health is not absolute, rather it is subject to state 
resources and socio-economic factors, and still is for millions "a distant goal.,,107 
However, the report clarifies that all states are required to steadily work towards 
realization of the goal, and in recognizing the inequality of resources between states, 
reminds the international community that it has an obligation to assist other states, 
particularly developing countries, in attaining health goals. This obligation includes 
ensuring the right to health is not restricted through other international agreements, nor 
constrained by economic sanctions or other punitive measures.108 Finally, the right to 
health is conceptualized in the report as including access to affordable medicines as 
defined on the WHO Model List of Essential Drugs. 109 
Hogerzeil et al. report that over 150 countries have ratified the ICESCR and over 100 
states have taken the additional step of embedding the right to health into their 
constitutions. In their analysis of 71 cases that were litigated in national courts mostly in 
105 For example, the same or similar wording is included in the Universal Declaration of Human Rights, 
1948, the International Convention on the Elimination of All Forms of Racial Discrimination of 1965, the 
Declaration of Alma-Ata (Health for All), 1978, and the Covenant of the Rights of the Child, 1989. 
106 United Nations Economic and Social Council, "The right to the highest attainable standard of health: 
1 1/08/2000." EIC.121200014. General Comments, 
http://www.unhchr.ch/tbs/doc.nsfl(symbol)!E.C.12.2000.4.En (accessed May 1,2010). 
107 Ibid., pt. 4, 5. 
108 Ibid., pt. 38, 39. 
109 Ibid., Pt. 43(d). The World Health Organization is an agency ofthe United Nations. It began the Model 
List of Essential Medicines in 1977 and updates the list every two years, the most recent being March 2009. 
According to WHO, the list is not intended to comprise a global standard, rather, it is a framework for 
national governments to adapt their individual needs to based on burden of disease and economic factors 
affecting health policy .. Drugs on the list are considered the most necessary for ongoing global health, and 
are generally expected to be accessible, affordable and of appropriate quality and dosages· at all times. 
More about the selection of essential medicines is available at http://www.who.intiselection medicines/en! 
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Central and Latin America, the authors note that 80% argued a linkage between the right 
to health and the right to life, and a quarter of the successful cases invoked an 
international human rights treaty as evidence of state responsibility. I JO This suggests that 
the right to health may be gaining wider international recognition in both principle and 
practice and is inserting itself into customary international law that is accepted by states 
with a variety of resource capacities. 
In this case study, the role of epistemic communities is also considered. An epistemic 
community consists of experts and researchers who have "specialized knowledge" in an 
issue-area and who may be instrumental in constructing new norms. Epistemic 
communities often have shared understandings of an issue and how it should be 
addressed and can use their knowledge to add a perception of authority to their assertions. 
In addition, their technical expertise 'may be sought by relevant policy-making actors and 
may provide access points within governments and international organizations that 
advocacy groups may otherwise find difficult to gain. III 
The advocacy campaign addressed in this paper is a relevant case study to explore the 
identity and role of advocacy groups and the mechanisms used, and to identify key 
factors that added to the salience ofthe campaign and its effect on state behaviour. For 
the purpose ofthis paper, I adopt Keck and Sikkink's definition of campaigns as 
"processes of issue construction" where "activists identify a problem, specify a cause, 
1 \0 Hans V. Hogerzeil, Melanie Samson, Jaume Vidal Casanovas and Ladan Rahmani-Ocora, "Is access to 
essential medicines as part of the fulfilment of the right to health enforceable through the courts?" Lancet 
368 (July 2006): 306-311. Of the 71 cases, 59 were successful in the courts, and of these, 10 were 
supported and in some cases financed by NGOs. . 
III Finnemore and Sikkink, "Taking Stock," 401-402. 
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and propose a solution, all with an eye toward producing procedural, substantive, and 
normative change." 1 12 
112 Keck and Sikkink, Activists beyond Borders, 8. 
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Chapter 2 
The World Trade Organization (WTO) was created during the Uruguay Round of 
negotiations which occurred from 1986 to 1994 between the contracting state parties to 
the General Agreement on Tariffs and Trade (GATT). When it entered into legal 
existence on January 1, 1995, the WTO was designed to overcome many deficiencies 
evident in the previous multilateral trade agreement, and it incorporated additional areas 
of trade including intellectual property rights and trade in services. 
As World War II came to a conclusion in the mid-1940s, the allied states recognized 
the need to formalize trade rules that would enhance efforts of reconstruction and 
promote international economic cooperation. The United Nations Economic and Social 
Committee assumed the leadership to design a charter for the proposed International 
Trade Organization (ITO). Simultaneously, the United States and its allies negotiated the 
GATT as a provisional multilateral trade agreement which came into force in 1947, and it 
remained the primary treaty concerning trade rules and tariffs when plans for the ITO 
were ultimately abandoned. However, the GATT's ability to act as a binding legal entity 
was undermined because it lacked the institutional framework that was to have been 
realized through the ITO. Consequently, the GATT did not have the mechanisms 
necessary for effective oversight and enforcement of trade agreements, including 
adjudication of disputes and enforcement of decisions. 
The terms of the GATT also allowed for inconsistencies in the observance of trade 
rules. While the GATT existed as a multilateral treaty, it contained exemptions that 
permitted states to "grandfather" some types of domestic legislation that had been in 
force prior to accession, further weakening the ability to regulate trade. I 13 Another 
1\3 Mitsuo Matsushita, Thomas J. Schoenbaum, and Petros C. Mavroidis, The World Trade Organization, 
Law, Practice, and Policy (New York: Oxford University Press, 2003), 2-3. 
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factor affecting consistency was that new trade measures and amendments to existing 
rules under the GATT were negotiated as separate treaties and states were not obliged to 
accept and abide by all provisions. This practice was similar to entering into other 
international treaties where states could accept in principle the terms within the treaty, yet 
could register reservations on particular aspects. In 1990, states considered the 
"Canadian proposal" which addressed the problems posited by the piecemeal structure of 
trade treaties and agreed to form a new trade organization that would "be acceded to as a 
single undertaking." I 14 Under this proposal, contracting states would have to agree to be 
subject to all provisions to gain and retain membership in the new World Trade 
Organization. 
To avoid the weaknesses within the GATT, the formation of the World Trade 
Organization was supported by a charter and a single body of law comprised of a revised 
GATT plus various trade related agreements and legal instruments. All member states 
are now obliged to observe the rules of the WTO, and additional agreements or 
amendments to trade policies are reached through consensus during negotiating rounds 
and become binding. In addition, structural mechanisms are in place to enable the WTO 
to perform specific responsibilities on behalf of the Members including trade 
negotiations, dispute resolution, and policy monitoring, as well as the authority to engage 
in collaborative undertakings with other international organizations such as the 
International Monetary Fund and the World Bank. I IS 
114 Klug, 216. 
115 Matsushita, 7-9. 
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Intellectual Property Rights and the relationship to trade 
Included in the 1994 documents negotiated during the Uruguay Round was the 
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). This 
document provides international harmonization of IP rights and obligations, including the 
"scope, subject matter and duration ofIP protection" I 16 as well as a mandate for 
supporting civil and criminal procedures. While recognition and protection of intellectual 
property rights had been a consideration of states for more than a century, it was never 
addressed under the GATT. Prior to inclusion within WTO agreements, intellectual 
property rights were primarily administered at the international level through a special 
agency of the United Nations, the World Intellectual Property Organization (WIPO). 
WIPO was established in 1967 with a primary objective "to promote the protection of 
intellectual property throughout the world through cooperation among States,,,117 and it 
oversaw twenty-three treaties pertaining to patents, inventions, industrial design and 
copyright. Recognition of the need for IP protection in these instruments dates back to 
the1883 Paris Conventionfor the Protection of Industrial Property dealing with the 
protection of inventions, trademarks and industrial design, and the1886 Berne Convention 
for the Protection of Literary and Artistic Works acknowledging copyright. I 18 However, 
revisions to IP agreements under WIPO were difficult to achieve and to administer 
because ofthe need for consensus among member states, and similar to the deficiencies 
116 Sell, Private Power, 12. 
m WIPO, "Convention Establishing the World Intellectual Property Organization," Article 3(1), 
http://www.wipo.intltreaties/enlconventionltrtdocswo029.html#P68 3059 (accessed March 27, 2010). 
118 Information about and texts of the treaties administered by the World Intellectual Property Organization 
are accessible on the website at www.wipo.intltreaties/en 
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experienced under the GATT, treaties and international conventions lacked enforcement 
mechanisms and provided no forum for grievances between states. 1 19 
More importantly, intellectual property rights were assured only through individual 
state preferences, policies and regulatory frameworks. As Sell notes, states were free to 
decide the extent of protection offered based on individual stages of development and 
capacity for "either innovation or imitation.,,12o This led to marked inconsistencies in 
domestic laws for both the issuing of patents and the enforcement of patent law. Most 
states traditionally viewed intellectual property rights as a form of protectionism or as an 
instrument used to secure a monopoly over a product or invention, so were cautious in 
adopting broad legislation that would recognize rights. In essence, patent holders had 
considerable control over where a product or process could be worked, its output and 
price, and could even decline to allow its use. 121 Even in the u.S. until the early 1980s, 
intellectual property rights were viewed as a "grant of privilege" and anti-trust laws were 
designed to ensure fair competition.122 
The recognition of IP rights between states originated in Europe in the 1800s as 
concerns arose over reproduction of books and copying of new industrial inventions. 
Some states entered into bilateral treaties which eventually led to the Paris and Berne 
Conventions. 123 Under the Paris and Berne Conventions states were not specifically 
required to recognize or regulate intellectual property rights, however, when states did 
choose to adopt regulations, they were then expected to extend that protection to 
nationals and foreigners alike. In addition, there was no commonly recognized approach 
119 Matsushita, 398. 
120 Sell, Private Power, 12. 
121 Ibid., 13-14. 
122 Ibid., 5 
123 Ibid., 11. 
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or minimum standard set by the Conventions, so states were allowed flexibility to 
interpret which industries were to be included under their regulatory framework and to 
what extent they were to be regulated. 124 
Pharmaceuticals posed a particularly difficult problem for establishing IP rights under 
the Paris Convention. Some states would not extend any protection to pharmaceuticals, 
preferring to view them as a public good. Many states drew a regulatory distinction 
between the invention of a product and the process through which the invention was 
manufactured, and allowed different treatment of the two. In some states,such as India, 
patenting was available for process but not for product, and reverse engineering allowed 
for the growth of a dynamic generic industry.125 Many less developed countries did not 
issue patents for pharmaceuticals because they lacked the research or manufacturing 
capacity to warrant the cost of providing IP protection, and it was estimated at the 
beginning of the Uruguay Round that about forty states were in this category that did not 
grant patents for the invention of medicines. 126 
In states where patents were issued for pharmaceuticals, the length of time for 
enforcement varied, and medicines were frequently granted a shorter patent life than 
other less essential inventions and products. 127 Many governments were concerned that 
patents would create a barrier to accessing necessary medicines during an outbreak or 
health crisis, and had at one time incorporated aspects of parallel importing and 
124 Klug, 211. 
125 Jan Peter Wogart, "From Conflict over Compromise to Cooperation? Big Pharma, the HIV/AIDS Crisis 
and the Rise of the Countervailing Power in the South," in Global Health Governance and the Fight 
Against HIVIAIDS, ed. W. Hein, S. Bartsch and L. Kohlmorgen (Basingstoke U.K.: Pal grave Macmillan, 
2007),71. 
126 Klug, 211. 
127 Pedro Roffe, Christoph Spennemann and Johanna von Braun, "From Paris to Doha: The WTO Doha 
Declaration on the TRIPS Agreement and Public Health," in Negotiating Health: Intellectual Property and 
Access to Medicines (U.K.: Earthscan, 2006), 11. 
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compulsory licensing provisions within their legislation. However, most states had 
revised their laws and had removed these flexibilities under pressure from the U.S. in the 
years leading up to the Uruguay Round. 
Further complicating IP protection, was that the patent regime relied on a registration 
system and enforcement mechanisms, both judicial and administrative, that fell under the 
purview of the individual state. Not all states had the institutional capacity to create and 
maintain a registry or the political will to follow through with regulatory enforcement. 
Linking Trade Issues to the Protection of Intellectual Property 
The inclusion of intellectual property rights on the trade agenda for the Uruguay 
Round was primarily at the insistence of the United States. Carlos Correa has identified 
four major factors influencing the U.S. 's urgency to standardize IP laws internationally, 
which include its increasing trade deficit, a weak international IP regime, newly emerging 
export markets, and the pressure of an intense lobby effort by a coalition of affected 
industries. 128 
The U.S. had experienced a rapidly escalating trade deficit in the early 1980s, and 
international trade in high-technology goods became increasingly important to all 
industrialized countries for maintaining comparative advantage. Private sector industry 
responded by investing in research and development of more advanced products and 
services, and the number of transnational corporations was flourishing. 129 
Secondly, the U.S. had increased IP protection domestically in recognition of the high 
externalities generated by research and development in areas such as computer software 
and biotechnology, and had sought to enhance exclusivity rights internationally. This 
128 Carlos M. Correa, Intellectual Property Rights, the WTO andDeveloping Countries (London: Zed Book 
Ltd., 2000), 3-4. . 
129 Ibid., 3. 
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was frustrated by the many developing states that had little interest in, or benefit from, 
regulating and enforcing patents. The U.S. sought, mostly through bilateral trade 
agreements, to pressure other states into adopting its standards. 130 
Thirdly, because the U.S. was actively engaged in creating bilateral and regional free 
trade agreements, new export markets had emerged. As international trade barriers 
decreased, transnational corporations saw attractive new options for reducing the burden 
of technology transfer and localized production. 131 
Finally, and more importantly to this paper, powerful business groups had successfully 
lobbied the government for a decade leading up to the Uruguay Round and had convinced 
policy makers that the declining position of U.S. firms in knowledge-intensive areas was 
directly related to a weak intellectual property regime. This was viewed not only as 
contributing to the increasing U.S. trade deficit, but also as a major threat to future 
investment in research and development. 132 
Through their lobby effort, transnationals were able to convince U.S. policy makers 
that the interests of government and corporations had increasingly converged throughout 
the late 1970s and 1980s, and the impact of the interconnectedness between trade issues, 
financial investment and economic stability was beginning to emerge. 133 By pressuring 
the U.S. Congress to revise its trade laws, the lobbyists succeeded in institutionalizing the 
link between trade and intellectual property rights. 134 
130 Ibid., 3-4. 
131 Ibid., 4. 
132 Ibid. 
133 Klug, 212. 
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The Corporate Initiative and the United States Trade Representative 
In 1986, the U.S. based Intellectual Property Committee was fonned by 
representatives from industries most affected by weak IP protection including 
phannaceuticals, chemicals, computer software, and entertainment. 135 Their claim was 
that the inability to adequately protect products and processes through patent and 
copyright laws had resulted in an increase in the production of counterfeit goods, 
particularly in newly industrializing countries. As the availability of less expensive 
counterfeit or generic products increased, trade in legitimate goods had declined.136 
In addition, industry lobbyists promoted forum-shifting to seek better IP protection. 
They advocated for the movement of IP protection from WIPO to the GATT because of 
their perception that structurally, WIPO was too sympathetic to developing states. Pfizer, 
one of the largest phannaceutical corporations and leader of the lobby group, had 
previously attempted to institute refonns to the Paris Convention within this venue. 
However, because each of the contracting state parties is allowed one vote under WIPO, 
developing countries formed the majority of Member states and could prevent initiatives 
attractive to the corporate interests of the wealthier states. Frustrated in its bid to 
influence change at WIPO, Pfizer and other corporations fonned a coalition which turned 
its attention to U.S. Congress, and in conjunction with the Pharmaceutical Research and 
Manufacturers Association, began to lobby for changes in the GATT. 137 
Sell and Prakash argue that IP business interests were skillfully framed as property 
rights, and as such, were perceived as "somehow natural, unassailable, and automatically 
135 Sell, Private Power, 2. Sell notes that the pharmaceutical companies on the IPC in 1986 included Pfizer, 
Merck, Johnson and Johnson and Bristol-Meyers. 
136 Sell and Prakash, 153. 
137 Klug, 212. 
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deserved.,,138 This was an important perceptual shift from a "grant of privilege," 
bestowed by government, to the claim of a right that was somehow being violated, 
through technically legal means.139 The lobby group adopted language that presented 
themselves and by extension, the U.S. economy and American public, as victims ofa 
form of ''piracy'' that could be prevented by a strengthened IP regime. Advances in 
technology meant that ideas and inventions were more vulnerable to appropriation by 
firms that had not invested in the research phase, and these firms were viewed as free-
riders that could undermine the legitimate market by producing copies or 'similars' 
inexpensively.140 Citing a study conducted by the U.S. International Trade Commission, 
the corporate lobby noted that industry had lost US$43 - 61 billion in 1986 alone due to 
poor international IP protection. 141 
Persuaded by the lobby group's arguments, the U.S. Congress had passed amendments 
to their domestic trade laws in 1979, 1984 and 1988 that had strengthened IP protection. 
The latter of these defined the role of the United States Trade Representative (USTR) and 
created Section 301 powers commonly referred to as Special and Super 301 which could 
be used to put pressure on, and retaliate against, states that did not comply with U.S. trade 
expectations. Section 301 compelled the U.S. Trade Representative to investigate and 
report annually on IP laws and compliance, and "watch lists" were created to add to the 
pressure placed on states that the U.S. perceived as engaging in unfair practices or that 
were offering weak intellectual property enforcement. 142 
138 Sell and Prakash, 157. 
139 Ibid., 157-158. 
140 Sell, Private Power, 14. Also, Sell and Prakash, 154-157. 
141 Sell and Prakash, 155. The authors note that the study may be inaccurate due to incentives to exaggerate 
losses in this study that relied on self-reporting, however, they note that there was no real challenge to the 
figures. 
142 Klug, 213. 
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In addition, under the revised U.S. trade law, the private sector was permitted to 
petition the USTR to take measures to protect their IP rights. The pharmaceutical 
industry, for example, skillfully pursued this option and was particularly successful in its 
bid, through the USTR, to influence revision of IP laws affecting medicines in several 
states between 1987 and 1993, including South Korea, Thailand and Canada. 143 
Industry executives also recognized the need to lobby beyond the U.S. government to 
ensure international IP protection. The Intellectual Property Committee developed a 
proposal for a more comprehensive IP treaty and submitted it to the GATT Secretariat in 
1988, laying the foundation for its inclusion in trade talkS. 144 In addition, the Committee 
networked with similar organizations in Europe and Japan. Together they developed a 
strategy to persuade their home governments to support the inclusion of IP in 
negotiations during the Uruguay Round. 145 
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
During the Uruguay Round, a number of developing and lesser developed countries 
initially resisted the TRIPS Agreement because they recognized that stricter adherence to 
IP rights was primarily in the interest of developed countries. However, many of the key 
states needed to strengthen the opposition were not aligned because the U.S. Trade 
Representative had engaged in coercive tactics for several years prior, threatening Section 
301 economic sanctions against states with poor or no IP laws. As a result, states such as 
Thailand, Chile and South Korea, and many of the more industrialized countries, had 
143 Ibid., 212-213. 
144 Sell, Private Power, 2. 
145 Sell and Prakash, 157. 
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been pressured into making IP revisions or had entered into bilateral trade agreements 
with the u.s. that already exceeded proposed international IP standards. 146 
Furthermore, the TRIPS Agreement was to be included as part of the total trade 
package under the WTO. Other benefits of the new regime were to include the 
recognition of "most favoured nation," new and expanded markets in agriculture and 
textiles, and opportunities for technology transfer. Most states were persuaded that the 
advantages of the package outweighed the drawbacks of the TRIPS Agreement, and 
eventually the opposition to "TRIPS" by developing states was diminished. 147 
The TRIPS Agreement, Annex 1 C of the Marrakesh Agreement Establishing the 
World Trade Organization, came into force on January 1, 1995. The preamble states that 
the purpose is ''to reduce distortions and impediments to international trade" and "to 
ensure that measures and procedures to enforce intellectual property rights do not 
themselves become barriers to legitimate trade.,,148 The agreement attempts to 
standardize for Member states their minimum obligations to other states in their treatment 
of patent holders in all areas of technology, as well as covering copyright, industrial 
designs, trademarks and other areas of intellectual property. It incorporates the standards 
of the Paris and Berne Conventions, as well as new requirements. The agreement 
initially allowed developing countries to phase in the rules, with all state parties to be 
compliant by January 1,2005, although the timeline was later extended in the area of 
pharmaceuticals for developing countries, with the least developed not required to adapt 
until 2016. 
146 Klug, 213-217. 
147 Ibid. 
148 WTO, "Uruguay Round Agreement: TRIPS, Preamble," 
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Compliance required that states adopt domestic legislation and establish a regulatory 
framework for substantive minimum standards of intellectual property rights, including 
enforcement and remedies, judicial review, border procedures that allow for control, and 
an office for IP application and management. In addition, member states became subject 
to multilateral dispute and adjudication mechanisms established at the WTO through the 
Dispute Settlement Body. 149 
The TRIPS Agreement and Pharmaceuticals 
The TRIPS Agreement required states to grant patent rights for pharmaceuticals for 
both product and process for a twenty year period. ISO This time frame was viewed as the 
minimum necessary to provide incentives for future investment in research and 
development. Pharmaceutical companies defended the position by arguing that drug 
research and development is an extremely expensive and longer term proposition, 
whereas producing a generic drug from an already developed invention and technology 
can be achieved very cheaply by those with no interest in re-investment. Pharmaceutical 
producers relied on patent protection to recover their research costs by generating profits 
from the distribution and sales of medicines to the first generation of users. In addition, 
they claimed that financial investment in drug research is higher than in any other 
knowledge intensive industry. lSI 
The TRIPS Agreement contained some flexibilities, although their interpretation 
remained contentious and eventually led to further negotiations. The principles as 
outlined in Article 8 permitted states to consider their individual policy interests and to 
149 Matsushita, 405-406 
150 WTO, "Uruguay Round Agreement: TRIPS, Section 5," http://www.wto.org/english/docs e/legal e/27-
trips 04c e.htm (accessed October 6,2010). 
151 Phillipe Cullet, "Patents and medicines: the relationship between TRIPS and the human right to health," 
International Affairs 79, no. 1 (2003): 141. 
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interpret the TRIPS Agreement in a manner that allowed them to protect public health. 
Article 27.1 stated patents were for 'inventions' that were 'new' and 'inventive' but did 
not provide definitions, which allows room for interpretation at the national level. IS2 The 
inventions being protected included products and processes, but did not include 'uses' 
which is a distinction that could be invoked to disallow extending a patent for an existing 
drug for new indications or applications. IS3 
Article 31 dealt with the rules for compulsory licensing under which a state can 
override a patent holder's monopoly on the product or invention for a limited period of 
time, usually on an urgent or emergency basis. Before issuing a compulsory license, 
states would normally attempt to get permission from the patent holder to proceed and 
must give the holder some remuneration for its use. In the case of pharmaceuticals, this 
seemed to imply that during a self-identified health crisis, a developing state could issue a 
compulsory license for the manufacture of necessary medications without permission of 
pharmaceutical companies holding patents. However, there were also limitations in the 
agreement that proved to be unhelpful for most of the developing world which lacked 
manufacturing capacity. The product manufactured under compulsory licensing was to 
be restricted to domestic use and could not be made primarily for the export market. IS4 
An additional flexibility available to states was that the TRIPS Agreement did not 
prohibit the use of parallel importation. Parallel importation allows a state to purchase a 
product from another state that has legally obtained goods under patent. Also, Article 6 
of the TRIPS Agreement stated that parallel importing could not be considered grounds 
152 Correa, 51. 
153 Ibid., 55-57. 
154 WTO, "Uruguay Round Agreement: TRIPS, Section 5 and 6," 
http://www.wto.org/englishidocse/\ega\e/27-trips04ce.htm (accessed October 6,2010). 
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for complaints to the WTO for dispute resolution. This provision followed "doctrine of 
exhaustion" case law from the U.S. and E.U., which held that a patent holder may not 
maintain rights over products and processes past their origin of legal sale or use, where it 
is assumed that the right holder has already received adequate remuneration. 155 In the 
case of pharmaceuticals, permitting parallel importing under the TRIPS Agreement 
implied that states without manufacturing capacity could legally obtain drugs made under 
patent from other states and could purchase more affordable generic versions when 
patents expired. Furthermore, because transnational corporations frequently sold 
pharmaceuticals with differential pricing, states would be able to 'shop around' for the 
best prices. 
Article 30 of the TRIPS Agreement also allowed for limited exceptions for the use of 
patented inventions to further research and development, and states can implement 
legislation to provide for this flexibility. This is referred to by the WTO as a research or 
regulatory exception, or a 'Bolar' provision. IS6 In the case of pharmaceuticals, this 
exception could allow generic manufacturers to expedite testing and domestic marketing 
approval in advance of production for a drug coming off patent, and allows the use of 
data by researchers to build upon existing medicines to formulate more advanced or 
combined therapies. 157 
However, state governments that attempted to enact legislation to facilitate access to 
medicines quickly ran into interference. Two cases, one that played out in the South 
155 Correa, 81-88. 
156 Ibid., 77-81. He notes there is substantial case law, particularly in the US allowing Bolar exceptions. 
157 Ibid. See also WTO, "TRIPS Fact Sheet: TRIPS and Pharmaceuticals, Obligations ano Exceptions," 
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African courts and another against Brazil where a complaint was filed at the WTO, 
highlighted the problems associated with the intellectual property rights regime. ISS 
South Africa 
In 1998, the Pharmaceutical Manufacturer's Association and 39 national and 
transnational pharmaceutical companies joined together to challenge implementation of 
the South African government's Medicines and Related Substances Control Amendment 
Act, 1997. South Africa had the largest popUlation of people living with HIV/AIDS, 
estimated to be over 4 million, and the post-apartheid Mandela government sought to 
revise its health policies to deal with the crisis. Implementation of the Act would provide 
the legal framework for the state to override patent rights under compulsory licensing to 
produce anti-retroviral drugs for the treatment of HI VIA IDS and to make use of parallel 
importing in order to access less expensive medicines. In addition, the Act contained 
regulations that placed limitations on certain practices and encouraged transparency for 
the marketing, distribution and pricing of pharmaceuticals. 
Because the WTO system is for state members and not private entities, the corporate 
alliance pursued its case in the South African Pretoria High Court rather than through 
WTO Dispute Settlement Body, arguing that certain parts of the Act contravened the 
state's Constitution and was in violation of state obligations under WTO membership. 
As David Barnard points out, the lawsuit was more about securing future interests than 
about immediate threats to sales. At the time that the lawsuit was filed, it was estimated 
158 Although it will not be discussed in this paper, there is a third case of interest contesting the 
interpretation of the flexibilities in "TRIPS." The European Community brought Canada to Dispute 
Settlement at the WTO in 1997 claiming that Canada's provision for the research exception for 
pharmaceuticals and allowing for stockpiling by competitors prior to a drug coming off patent was 
inconsistent with "TRIPS." In 2000, the WTO Panel ruled that use ofthe research exception was permitted 
however, stockpiling was considered to be a violation. Further information is available at WTO Dispute 
Settlement: DS 114, "Canada - Patent Protection of Pharmaceutical Products," . 
http://www.wto.org/english/tratop e/dispu e/cases e/ds 114 e.htm (accessed April 24, 2010). 
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that Africa represented about 13% of the world population, yet accounted for only 1 % of 
the global trade in pharmaceuticals. South Africa's legislation however, was seen as a 
threat to corporate interests due to its potential to serve as a template for other countries 
for future trends in health policy, particularly on drug prices with sustained pressure from 
the threat of compulsory licensing. Drug companies argued that they relied on patents for 
protecting their market share which generates the profits needed to recover the costs of 
research. Furthennore, without appropriate compensation, incentives would not exist for 
the development of new products. 159 
The lawsuit drew the attention of several domestic and international civil society 
groups, many of which were already engaged in activities focused on pharmaceutical 
access and treatment for HIV/AIDS. Health Action International160 had alerted non-
governmental organizations in 1996 about the issues that could arise for health as a result 
of the TRIPS Agreement and had organized conferences in conjunction with other NOOs 
to explore aspects of compulsory licensing, parallel importing and drug price 
reductions. 161 A loose coalition of organizations had fonned around the broad issue of 
access to medicines. When the South African case was launched, transnational 
organizations including Medecins Sans Frontieres and OXF AM, along with South 
African based Treatment Action Campaign (TAC), and political actors from several 
states actively lobbied against the pharmaceutical companies' claim. 
Civil society groups argued that the actions taken by the wealthy pharmaceutical 
companies prevented governments from providing medicines to the most poor and 
159 David Barnard, "In the High Court of South Africa, Case No. 4138/98: the Global Politics of Access to 
Low-Cost AIDS Drugs in Poor Countries," Kennedy Institute of Ethics Journal 12, no.2 (2002): 164. Also, 
Sell, Private Power, 14. 
160 Health Action International is a non-profit global network of organizations, consumers: and researchers. 
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53 
vulnerable populations. The campaign claimed that a basic right to health existed and 
governments must be allowed to provide care for their people. Because medicines were 
too expensive and governments were prevented from taking measures to access cheaper 
medicines, the coalition claimed that people were dying unnecessarily. The campaign 
urged corporate interests to consider their moral obligations and weigh this against 
economic considerations.162 
The campaign also asserted that there was no significant correlation between the 
protection of patented pharmaceuticals in developing countries and profits generated for 
research and development because new drugs were primarily developed for the wealthy 
populations of the industrialized world. MSF reported that only 11 of the 1,223 new 
drugs developed between 1975 and 1996 were indicated for tropical diseases that 
predominantly affected developing countries. 163 In addition, many drugs were at least 
partially developed in publicly funded institutions and laboratories, and several newly 
patented medicines were actually improved versions of older drugs or were indicated for 
different uses. 
The U.S. government initially sided with corporate interests and threatened trade 
sanctions, urging South Africa to repeal the Act. In June 1998, the USTR withdrew GSP 
trade benefits l64 and placed South Africa on its Special 301 Watch List. This prompted 
HIV/AIDS activists from ACT UP in the US to stage a series of protests in several large 
cities, and during the summer of 1999, demonstrators targeted U.S. Presidential candidate 
162 Thomas Olesen, "In the Court of Public Opinion: Transnational Problem Construction in the HIV/AIDS 
Medicine Access Campaign, 1998-2001," International SOCiology 21 , no. 1 (January 2006): 14-15. 
163MSF_ Canada, Campaign for Access to Essential Medicines. "How Politics is Failing the Dying," 
Brochure, date unknown: 3. 
164 GSP is the USTR's Generalized System of Preferences which allows specific products "from designated 
countries as duty-free. The goal ofGSP is to promote economic development in the developing world. 
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Al Gore, whose campaign was supported by the pharmaceutical industry, disrupting 
speeches and Democratic rallies. 165 South Africa was removed from the Watch List in 
the fall and President Clinton announced a change in U.S. policy on the issue of drug 
access for African states during the WTO Ministerial meeting in Seattle; African states 
would not be penalized for invoking compulsory licensing. 166 The Bush government 
confirmed this stance shortly after taking office in 2001. 167 
The European Union was also protective of its transnational pharmaceutical industry 
and had backed the U.S. position threatening sanctions against South Africa. Heads of 
states from France, Switzerland and Germany, as well as the vice-president of the E.U., 
had visited South Africa in a bid to persuade government leaders to withdraw the 
legislation. 168 Finally, as the lawsuit returned to court in March 2001, the E.U. Trade 
Commissioner responded to an open letter from MSF and publicly supported the right of 
governments to use compulsory licensing in discretionary circumstances. Under 
mounting public pressure, the E.U. Parliament changed its position and openly urged the 
drug companies to withdraw their suit. 1.69 
Some of the companies participating in the lawsuit offered to voluntarily reduce prices 
on specific drugs or to donate certain drugs for specialized treatment, such as for the 
prevention of mother to child transmission of HIV. The offers tended to be limited in 
scope and were criticized by NGOs who argued that goodwill was temporary and did not 
support a government's right to protect the health of its people. The NGOs insisted that 
165 James Orbinski, An Impelject Offering: Humanitarian Action in the Twenty-first Century (Canada: 
Doubleday, 2008), 356-357. 
166 Sell, Private Power, 152-153. Olesen,21. Orbinski, An Imperfect Offering, 356-357. 
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169 Olesen, 21. 
55 
sustainability for drug access was tied to the ability of a state to produce or import 
essential drugs at an affordable price. 170 
The global reach of the access campaigns brought negative publicity on the drug 
companies and a lot of pressure from both the North American and European public. 
MSF International had been awarded the Nobel Peace Prize in 1999 and had launched a 
new initiative from its Geneva office, the "Access to Essential Medicines Campaign." 
In conjunction with the British NGO Oxfam, they organized a global "Cut the Costs 
Campaign." Both organizations had extensive media expertise and garnered international 
support for their opposition to the lawsuit. The campaign participated in "naming and 
shaming" individual corporations, as they targeted specific companies that were party to 
the suit. l7l 
In addition, the access group was· pursuing price reductions and licensing agreements 
in several venues. MSF independently negotiated with Indian drug manufacturer Cipla to 
purchase a generic supply of triple combination therapy drugs for HIV/AIDS in February 
2001. Cipla agreed to supply MSF with the drug for $350 per patient per year, and to 
governments for $600 per patient per year, which was considerably less than the $10,400 
GlaxoSmithKline was charging under patent in the U.S. When the announcement was 
featured in The New York Times, the price discrepancy between patented and generic 
drugs was forced into the spotlight and supported the N GO's claim that patented drugs 
170 Sell, Private Power, 154. 
171 MSF also publicized a list of20 multinational drug companies in March 2001, with contact names and 
addresses. See MSF, "Field News: . List of the Pharmaceutical Companies Suing South Africa in the 
Medicines Act Case," 8 March 2001, http://www.doctorswithoutborders.orglnews/article:cfm?id=824 
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were unnecessarily expensive. 172 Cipla and MSF followed up by requesting from South 
Africa licenses for other ARV drugs; Merck responded by also lowering its prices. 173 
Simultaneously, MSF requested that Yale University and Bristol-Myers Squibb lower 
the price of their ARV d4T on patent in South Africa and permit generic production 
under voluntary license. With the support of the founding pharmacologist, students held 
protests urging the administration and drug company to relax the patent, and the 
announcement was made to do this in March 2001. A second outcome of the publicity 
was to support the civil society argument that there is not always a correlation between 
patents and research costs. In the case of d4T, the drug had been developed at Yale with 
public funding before being licensed to the drug company for manufacture. 174 
When the South African case finally reached the Court in March 2001, it was found 
that one of the articles being challenged was substantively based on text from WIPO's 
Committee of Experts. This was damaging to the case brought by the pharmaceutical 
companies. 175 In addition, the Court granted TAC amicus curiae (friend of the court) 
status on behalf of African civil society. As a South African grassroots organization, 
TAC was primarily interested in promoting access to treatment and was critical of both 
the government's lack of action and the corporate position. TAC was prepared to testify 
about the dire need for drug access, the lack of drug research for tropical illnesses and the 
172 Yves Beigbeder, "HIV/AIDS and Global Regimes: WTO and the Pharmaceutical Industry," in AIDS 
and Governance, ed. Nana K. Poku, Alan Whiteside, and Bjorg Sandkjaer (UK: Ashgate Publishing, 
2007),207. 
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failure of infrastructure for the delivery of health care. The corporate coalition requested 
and was granted a six week recess to reconsider their approach. 176 
During the recess, MSF and Oxfam began an online petition and sent open letters to 
organizations and individuals encouraging them to oppose the lawsuit. In about four 
weeks, MSF collected almost 300,000 signatures and support from about 140 
organizations worldwide in their online campaign, "Drop the Case."I77 
Before the case returned to court in April 2001, the pharmaceutical companies 
withdrew their lawsuit. As a concession from the South African government, they 
received a guarantee that the government would respect WTO rules under the TRIPS 
Agreement. 178 However, the rules for the use of compulsory licensing and parallel 
importing remained unclear. 
Brazil 
Brazil recognizes health as "a right of all and a duty of the State" in its Constitutionl79 
and has fostered a strong domestic pharmaceutical industry through its statutory 
commitment to procure generic medicines for use in its public health system.180 With the 
publicly funded provision of medicines to be estimated at 25% of national consumption, 
the use of generics has allowed the government to realize substantial savings in its bid to 
provide universal health care. 181 This became even more crucial for treating HIV I AIDS. 
176 Olesen, 13-14. 
177 MSF-USA, "Alert: Campaign Update, Access to HIV/AIDS Medicines" (June 1,2001), 
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During the 1990s, Brazil had over 200,000 reported cases of HIV / AIDS among its 
population and with the assistance of the World Bank began an innovative plan of action, 
the National AIDS Program, to provide antiretroviral drugs at no charge for all who were 
affected. 182 The success of this policy was due in part to Brazil's manufacturing capacity, 
which provided a strong incentive for pharmaceutical companies to provide patented 
drugs at a reasonable price or risk their manufacture under compulsory license. Local 
production of ARV drugs already accounted for almost half of the medicines used in the 
program. 183 
In addition, Brazil's Industrial Property Law, 1996, required patent holders to 
manufacture their product in Brazil within three years of patenting and made provision 
for compulsory licensing to be granted when a patent was not worked in Brazil for three 
consecutive years. The law also allowed for parallel importation if patent holders 
produced their product elsewhere. In the case of pharmaceuticals, Brazil argued that the 
threat of compulsory licensing had persuasively kept the cost of antiretroviral drugs under 
control and within the government's economic means. I 84 
Merck was a key supplier of ARVs and the Pharmaceutical Research and 
Manufacturers of America asked the USTR to oppose Brazil's law at the WTO. The 
company claimed that importing its drugs into Brazil was the equivalent of working the 
patent and compulsory licensing should be disallowed. 185 In 2000, the United States filed 
a case against Brazil requesting consultation with the Dispute Settlement Body. The U.S. 
charged that the wording of the Industrial Property Law, Article 68, with regard to 
182 't Hoen, "TRIPS," 44-45~ Also Sell, Private Power, 136-137. 
183 Cohen and Lybecker, 217. 
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compulsory licensing was inconsistent with the TRIPS Agreement and was 
discriminatory towards U.S. patent holders.186 
Non-governmental organizations in Brazil and international NOO's including MSF, 
rallied against the U.S. challenge to Brazilian law. Brazil's treatment program of 
universal access to ARVs had been successful in decreasing by half the mortality rate 
from AIDS related illnesses and in providing an improved quality oflife for survivors. 187 
MSF issued a press release that warned that U.S. action would interfere with the program 
and dissuade other states from seeking assistance from Brazil. 188 
In addition, Brazil was very active with international organizations that were focusing 
on drug policy, including the World Health Assembly (WHA)189 and the "TRIPS" 
Council at the WTO. At the WHA meeting in May 2001, Brazil was instrumental in 
linking human rights to the access of medicines, promoting an international monitoring 
system for drug prices, and gaining recognition for the use of generics as a valid strategy 
to combat HIV/AIDS, in spite of strong opposition by the U.S. 190 At the same time, 
developing states had approached the "TRIPS" Council to clarify that they could use the 
flexibilities in the agreement to protect public health without fear of sanction. During a 
meeting of the "TRIPS" Council in June 2001, a delegation from Brazil made a 
presentation about the success of their program and offered the necessary transfer of 
technology for developing states to build their own manufacturing capacity. This offer 
186 WTO, "Dispute Settlement: DS199, Brazil- Measures Affecting Patent Protection," 
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was further supported by NODs such as MSF who offered technical assistance to the 
governments. 191 
In July 2001, the U.S. government, subject to intense public pressure, announced that 
it would withdraw its complaint against Brazil, noting that Brazil had not actually used 
the law. The U.S. indicated that it would continue discussions with Brazil should the 
need arise to invoke a compulsory license in the future. 192 The two states issued a joint 
submission to the WTO, posted on the website that the dispute had been resolved with a 
"Mutually Agreed Solution.,,)93 
A month later, Brazil issued a compulsory license to produce a drug under patent after 
negotiations with Hoffmann-La Roche seemed unsatisfactory, however an agreement was 
reached and the license ultimately abandoned. I94 The threat of compulsory licensing was 
widely persuasive; Merck also significantly lowered prices on two of its ARVs. 195 
The cases involving South Africa and Brazil were instrumental in re-opening 
discussion on the meaning and implications of the TRIPS Agreement for public health 
policy at the WTO Ministerial Conference in November 2001. 
Declaration on the TRIPS Agreement and Public Health 
Few developing countries had attempted to engage the flexibilities contained in the 
TRIPS Agreement, but it was evident that the interpretation of the provisions was still 
contested by both pharmaceutical companies and developed states. The non-
191 Sell, Private Power, 158 
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governmental coalition that included MSF and the outcry from developing countries 
forced public health interests onto the agenda at the WTO Ministerial Conference in 
Doha, Qatar in November 2001. 
A couple of months prior to the Doha meeting, the African Group of states, supported 
by NOOs from the access coalition, made a proposal for a ministerial declaration 
supporting public health when applying the TRIPS Agreement, and the document that 
was developed at the Conference was initiated by this proposal. It attempted to address 
three overarching concerns including "the nature and scope of the flexibility in the TRIPS 
Agreement" and "whether this flexibility would be interpreted by the WTO and its 
members in a broad, pro-public-health way.,,196 The third concern was whether states 
could use these mechanisms without the threat of coercive measures from WTO members 
and the pharmaceutical industry.197 
The Pharmaceutical Researchers and Manufacturers Association responded that 
patents were not relevant to access and that the larger problem was a result of poverty and 
the lack of government investment in health and supporting infrastructure. MSF and the 
access coalition countered this claim, acknowledging that while poverty and 
infrastructure were factors, patents were the primary cause of high drug prices and 
patents prevented generic access to cheaper medicines.198 
The issue was further advanced when just weeks before the Doha meeting, some 
deaths occurred in the US due to anthrax spores in mail. Canadian health officials 
threatened to invoke compulsory licensing to manufacture generic supplies of Bayer's 
196 WTO, "TRIPS: TRIPS and Public Health," 
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ciproflaxin. Members of the U.S. Congress also briefly considered it. Faced with the 
possibility, Bayer agreed to lower its prices,199 and it was obvious that Canada had 
successfully employed the same tactics used by Brazil to access less expensive ARVs. 
When the Doha negotiations were underway, the African Group, Brazil and India led 
the coalition that sought a legally binding revision to the TRIPS Agreement, while the 
U.S. and Switzerland remained opposed.20o The result of the WTO negotiations was the 
Doha Declaration, adopted by 142 member states that confirmed the need to consider 
public health over commercial interests and that sought to clarify and reaffirm the rules 
already in the TRIPS Agreement. 201 
The Doha Declaration on the TRIPS Agreement and Public Health is set out in seven 
paragraphs. It acknowledges the severity of the problems facing developing countries 
afflicted by high infection rates of HIV / AIDS, tuberculosis and malaria and states that the 
TRIPS Agreement should be part of the solution.202 It confirms the need for the 
protection of intellectual property for continuing research and development but 
acknowledges the effect this may have on the cost of medicines.203 It states that the 
TRIPS Agreement "does not and should not prevent Members from taking measures to 
protect public health,,204 and that they may use the flexibilities to their full extent. The 
Declaration reiterates the right of individual states to define national emergency and to 
determine the grounds to grant compulsory licenses.205 In addition, the Declaration 
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202 WTO, "Doha WTO Ministerial 2001: Declaration on the TRIPS Agreement and Public Health," 
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extended the timeline for the least-developed states to become "TRIPS" compliant in the 
area of pharmaceuticals to January 1,2016.206 
Finally, the Declaration recognized in Paragraph 6 that there were some unresolved 
issues because the flexibilities were of no value to member states without manufacturing 
capacity. As noted by Correa, capacity requires technical expertise, equipment and 
compounds not easily acquired in developing states.207 Therefore states wanting to 
acquire a necessary drug and states agreeing to manufacture the drug would both have to 
grant a compulsory license, however, the exporting state would still be in violation of the 
TRIPS Agreement because Article 31(f) limits the license to production for the domestic 
market. The Council for "TRIPS" was directed to provide alternatives to the General 
Council by the end of 2002.2°8 It was not until August 2003 before an agreement about 
Paragraph 6 was reached. 
Decision on implementation of paragraph 6, Section 31(1) of the Doha Declaration on 
the TRIPS Agreement and Public Health 
As in past negotiations for IP protection, the United States and European Union 
initially presented a position weighted in favour of industry interests. The African Group 
and other developing countries drew a great deal of support from a very vocal coalition of 
NGO's and generic drug manufacturers and therefore produced a stronger negotiating 
front than in past meetings.209 
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The debate among WTO members focused on identifying a list of diseases and 
medicines to be included in the exception to Article 31 (t). Moreover, there was a need to 
agree on which countries could use the exception to import, and which countries would 
be allowed to produce generic drugs for export. In addition, safeguards were needed to 
protect the patented drug industry and to discourage·re-exportation of the generic drugs to 
a third party, so rules were needed that would force exporting states to clearly identify 
generic drugs under compulsory license by their unique labeling, packaging and physical 
characteristics.2 JO 
The African Group was opposed to the restricted list of illnesses as proposed by the 
u.s., which included only HIV/AIDS, tuberculosis and malaria, and was also opposed to 
restricting compulsory licensing privileges to only the least developed, rather than to all 
who were without manufacturing capacity. Disagreement also arose over which 
countries would be allowed to manufacture and export the medicines and over the added 
economic burden of special packaging and product identifiers such as pill colour, 
markings and shape. 2 I I 
In the end, member states agreed to a temporary waiver of Article 31 (t) of the TRIPS 
Agreement. Rather than list specific drugs, the waiver granted to importing states more 
autonomy to determine what measures should be included on a case by case basis by 
covering all patented pharmaceutical products necessary to alleviate a public health 
problem. The use of the waiver for importing generics was made available to the least 
developed countries and any others lacking appropriate manufacturing capacity in a 
210 Ibid., 92. See also Wolfgang Hein, "Global health Governance and WTOffRIPS: Conflicts B~tween 
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health emergency. In addition, it was agreed that all WTO members could be exporters, 
but when utilizing the waiver, there was a duty by exporters to use special packaging or 
identifiers to discourage trade diversion from the intended recipient state.212 
The waiver also requires that permission from the patent holder be sought before 
issuing a compulsory license. In addition, to avoid duplicate payments to patent holders, 
only the exporting country would be responsible to provide adequate remuneration, and 
both importing and exporting states were required to disclose on a dedicated WTO 
website the quantity to be manufactured and identifying characteristics of the medicines 
to be supplied. While the exporting country had to ensure that the product under 
compulsory license went only to the recipient state as disclosed, lesser developed 
countries were permitted to form a regional trading block (where at least half of the states 
are considered least developed) to utilize economies of scale for buying larger quantities 
of needed drugS.213 
Although the waiver was considered a win for developing states, the Access coalition 
that was monitoring the negotiations was critical. A statement signed by fourteen NOO's 
called it "a 'gift' bound tightly in red tape" that contained complicated and ambiguous 
conditions for its use.214 Some of the conditions would make use of the waiver both 
time-consuming and expensive. An example cited by Correa is the requirement to 
negotiate with the patent holder, and the need for a generic supplier to get a compulsory 
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license in both the importing and exporting state before submitting a bid to manufacture, 
an expense he argues that few companies would risk without a contract of sale.2lS 
Recent Outcomes Stemming/rom the Implementation 0/ Paragraph 6 
The Article 31 (f) waiver is still in effect but in 2005 the WTO Council proposed that it 
be incorporated into a permanent amendment to the TRIPS Agreement. Member states 
initially had until December 2007 for two thirds of the 151 members to ratify acceptance, 
however, when this became clearly unattainable, the deadline was extended to December 
2009. A couple of weeks before the deadline, the "TRIPS" Council again extended the 
deadline, and it is now set for December 31, 2011. By the end of September 2010, only 
thirty states plus the European Union had formalized their support for the amendment.216 
A second outcome from Paragraph 6 stems from the need for states with 
manufacturing capacity to put in place the necessary domestic legislation and regulatory 
framework to allow for the export of pharmaceuticals under compulsory license. Only 
Canada, Norway, India, the Netherlands, Iceland and the European Union have passed 
legislation for this purpose.217 
Use of the waiver has been limited to one case; in July 2007, Rwanda was the first to 
announce that it would invoke the waiver to import a fixed-dose combination HIV / AIDS 
drug from Canada. Canada posted its intention to supply the drug under compulsory 
license in October 2007 and the medicines were manufactured by Apotex Inc., Canada's 
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largest pharmaceutical company.2lS Although Apotex met the commitment in September 
2008 and September 2009, the company has been critical of the process, citing regulatory 
complications and excessive administrative costs, and has urged the Canadian 
government to amend the legislation allowing for exportation.219 
Next Chapter 
The role of non-governmental organizations in pursuing access to medicines was 
instrumental in forcing the issue back onto the international trade agenda for policy 
revision, impacting state preferences in the interpretation of intellectual property rules, 
and in reducing prices on patented drugs. In the next chapter, I will examine one of the 
key contributors to the access debate, Medecins Sans Frontieres. I will argue that the 
success of MSF is due in part to the culture of the organization, the reputation it has 
earned, and the resources it has managed. In addition, I will argue that the Campaign for 
Access to Essential Medicines, a creation of MSF International, has evolved into an 
epistemic community of professionals that have been able to successfully navigate 
through the intellectual property rules, present evidence based opposition to the claims 
made by states and corporations, and to engage with multiple stakeholders to encourage 
innovation and cooperation for drug access in the developing world. 
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Chapter 3 
Mededns Sans Frontieres is an international humanitarian medical aid organization 
dedicated to providing assistance to persons "whose survival is threatened by violence, 
neglect or catastrophe.,,22o During 2009, MSF was active in more than 60 states, and the 
organization has grown to include sections in nineteen countries with an international 
office located in Geneva. In addition to setting up emergency medical aid missions, MSF 
maintains the Campaign for Access to Essential Medicines and is a founding member of 
the Drugs for Neglected Diseases initiative?21 In 1999, MSF was the recipient of the 
Nobel Peace Prize. 
From the beginning, MSF used a bold new approach for a non-governmental 
organization, and earned a reputation among other agencies and governments for 
engaging in unilateral action and unusual risk-taking. Frequently working in regions 
where other agencies would not operate, MSF would withdraw its volunteers only when 
absolutely necessary for their safety. Last to leave, MSF would typically be the first to 
return when the situation was more secure.222 
Implicitly, MSF's charter challenged traditional notions of sovereignty and assumed 
the right to intervene to relieve suffering and preserve human dignity. Using extensive 
media coverage and web-based forums, MSF publicly confronts what it perceives as 
injustice. Several factors have influenced the adoption of MSF' s underlying principles 
and assumptions, contributing to the culture and success of the organization. 
220 MSF, "About Us. History and Principles," http://www.doctorswithoutborders.org!aboutus!?ref=main-
menu (accessed January 10,2010). 
221 MSF Intemational,www.mfs.org (accessed July 5, 2006). 
222 Dan Bortolotti, Hope in Hell: Inside the World of Doctors Without Borders (Canada: Firefly Books, 
2004),61. 
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The Founding of Medecins Sans Frontieres 
MSF was founded in 1971 by a group of French doctors and journalists led by Bernard 
Kouchner and Raymond Borel. Each of the founding groups contributed to MSF's 
underlying humanitarian principles based on their experiences in the field. 
A small group of young doctors, including Bernard Kouchner, were serving as 
emergency aid physicians for the International Committee of the Red Cross (ICRC) in 
1968 during the Biafran-Nigerian crisis. Kouchner and his colleagues believed that their 
humanitarian efforts were being undermined by the political actions of the Nigerian 
government. Government troops trying to stop the secessionist movement and flush out 
the rebel leaders had surrounded the Biafran territory preventing delivery of goods. The 
ICRC and UNICEF had negotiated with the government for supplies to be delivered 
equally to both sides of the conflict; but food aid quickly dwindled when the Nigerian 
government withdrew its permission for airlifts into the Biafranregion. Kouchner and 
his colleagues were outraged because in their view the government was complicit in the 
starvation of the Biafran people.223 
The ICRC policy of neutrality and confidentiality does not permit its volunteers to 
engage in public criticism of parties involved in a conflict because the organization has 
always been dependent on the goodwill and consent of governments to engage in aid 
efforts. Kouchner and other witnesses to the Biafran crisis rejected this policy, and upon 
their return to France sought out and granted interviews to the media. Kouchner has 
223 Tim Allen and David Styan, "A Right to Interfere? Bernard Kouchner and the New Humanitarianism," 
Journal of International Development 12 (2000): 829. 
70 
defended this action stating that, "By keeping silent, we doctors were accomplices in the 
systematic massacre of a population.,,224 
As international media interest grew in the Biafran crisis, the televised images of 
starving children created intense public pressure on humanitarian agencies to intervene. 
In response, Oxfam, the IeRe, and other NGO's resumed unauthorized air shipments of 
food and supplies into the Biafran region; estimates suggest that as many as 7800 relief 
flights occurred before the conflict ended in 1970.225 Kouchner and his associates were 
participants in this initiative. Having abandoned the constraints of the IeRe, they had 
formed a new organization, the International Committee Against Genocide in Biafra, and 
were responsible for launching at least three aid missions in 1969.226 
After the Biafran conflict ended, it became apparent that the Nigerian government was 
not solely responsible for the food shortages. Rebel leaders were accused of having 
strategically blocked supplies and of using the images of starving people to garner 
support for their cause through the Western media.227 In light of this information, 
evidence suggested that the unauthorized humanitarian action may have extended the 
crisis for eighteen months contributing to prolonged suffering and casualties of some 
180,000 people.228 Most NGOs regretted their participation in unauthorized intervention 
and returned to the policy of respecting sovereign borders until invited in. However, 
224 Ibid., 830. 
225 Ibid. 
226 Ibid. 
227 James Orbinski, "Global Health, Social Movements and Governance," in Governing Global Health: 
Challenge, Response, Innovation, ed. Andrew F. Cooper, John J. Kirton and Ted Schrecker (England: 
Ashgate Publishing, 2007), 70. . 
228 Allen and Styan, 830. 
71 
Kouchner and his group were not deterred by the controversy, and their experience 
greatly influenced the philosophical underpinnings of MSF, formed a year later.229 
The second founding member, Raymond Borel, also contributed to the underlying 
principles of MSF. Borel was a physician and was the editor of a medical journal in 
France. The journal encouraged French physicians to volunteer their skills to assist in 
several natural disasters, and Borel had started a relief agency, Secours Medical Francais. 
In 1970, they volunteered to assist in Eastern Pakistan after a devastating cyclone that 
claimed about 500,000 lives. Borel and his group, along with other aid agencies, waited 
for some time for the Pakistani government's permission to enter their territory to assist 
in relief efforts. Frustrated by the constraints placed on humanitarian action, Borel 
sought to achieve a faster response time for the delivery of medical aid in natural 
disasters. In 1971, his group joined with Kouchner under the banner of MSF. 230 
The Culture of Medecins Sans Frontieres 
Medecins Sans Frontieres was based on a founding charter and mission statement that 
declared that it would be an international humanitarian agency that would respond to 
medical emergencies arising from both natural and man-made disasters. The charter 
declared that MSF respected the right of all people to receive humanitarian assistance, 
impartially and ethically delivered by its medical personnel and vowed to treat the 
victims "irrespective of race, religion, creed or political affiliation.,,231 MSF recognized 
the need to remain "independent from political, economic and religious powers,,232 in 
229 Ibid. 
230 Bortolotti, 46. Also Orbinski, An Imperfect Offering, 68. 
231 MSF-Canada, www.mfs.ca (accessed July 5, 2006). 
232 Orbinski, "Global Health," 68. 
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order to maintain its neutrality and independence. Over time, the mission statement has 
evolved to include victims of "armed conflict, epidemics and healthcare exclusion. ,,233 
Tong has argued that non-governmental organizations that are active in relief work are 
quite diverse in how they perceive humanitarianism, and she suggests that their 
differences can be better understood by examining four basic features that influence their 
responses including the organization's tradition, typology, political and cultural heritage, 
and mandate for action.234 Tong notes that the organizing principles of neutrality, 
impartiality and independence from religious and political structures were entrenched in 
the MSF charter from the beginning and are consistent in the tradition promoted by Henri 
Dunant, founder of the ICRC. These principles are considered to be the basis of classical 
humanitarianism and tend to be adopted by organizations that specialize in projects 
involving shorter term commitments, such as emergency relief operations. In general, 
classical humanitarian NGOs can usually exercise more autonomy, tend to receive a 
larger portion of their funding from private sources and operate on a more defined 
mandate.235 This seems to aptly describe the tradition of MSF. which guards its 
independence from other powers, consistently raises more than 80% of its overall funding 
from the private sector, and has kept a selective operational mandate in the area of health. 
In locating the typology ofMSF among non-governmental organizations, Tong draws 
on a model by O'Malley and Dijkzel based on a vertical and horizontal axis. In their 
model, the vertical axis has as its opposing points "total independence from religious and 
233 MSF International, htt.p:llwww.msf.org/ (accessed December 18,2009). 
234 Jacqui Tong, "Questionable Accountability: MSF and Sphere in 2003," Disasters 28,00.2 (2004): 177. 
235 Ibid., 177-178. Tong contrasts classical humanitarianism with Wilsonian and faith based NGOs. 
73 
political powers" to "a willingness to accept public service contracts.,,236 The bisecting 
horizontal axis represents a continuum from "the willingness to deliver aid impartially 
according only to need" through "delivery based on the identity or affiliation of a 
particular group." Tong suggests that MSF's typology lies in the outermost sector where 
the value of total independence converges with that of complete impartiality. She argues 
that, for MSF, "independence is viewed as a necessary condition to be able to deliver 
humanitarian assistance in an impartial manner. ,,237 
Cultural differences may also contribute to the relationship that NOD's have with 
governments. Tong argues that Anglo-Saxon organizations are more likely to engage in 
collaborative and participatory relationships with political powers whereas those with 
Latin roots, like the French MSF, tend to adopt adversarial roles. Tong notes that 
political life in Europe has been characterized by "a mixture of evolution and 
revolution,,238 which has been used as a catalyst to promote change in the power structure 
of the system. She argues that MSF fits within this pattern because it attempts to effect 
change (revolution) by speaking out and drawing attention to the victims, but continues to 
work within the system in an effort to assist in the transitions (evolution) brought about 
by political processes.239 
The revolution Tong is referring to is the controversial practice oftemoignage. Based 
on his experience with the ICRC policy of silence, Kouchner intended that volunteers 
working under Medecins Sans Frontieres would practice temoignage, the act of 
236 The model is found in A. Stoddard, "Humanitarian NGOs: Challenges and Trends," HPG Report on 
Humanitarian Action and the Global War on Terror: A Review of Trends and Issues (London: Overseas 
Development Institute, 2003). 
237 Tong, ] 79. 
238 Ibid., 178. 
239 Ibid., 178-179. 
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"witnessing and speaking out,,240 to the media and other a~diences. He hoped to draw 
widespread attention to the plight of those needing assistance and to those who were 
victims of human injustice. Borel, however, was opposed to this action fearing that 
governments would prohibit the group rather than risk ridicule hence the original Charter 
explicitly said MSF would "refrain from making judgement or expressing public 
opinions.,,24I It was not for several years, and after Kouchner's departure from the 
organization, that the important concept oftemoignage became an intrinsic part ofMSF 
culture.242 Temoignage, often defined in the MSF literature as raising aWareness, is now 
considered to be the second function that MSF performs after providing medical 
assistance and is recognized in the Annual Activity Report as a justified expense with its 
own line in the budget.243 Although it was praised by the Nobel Prize Committee, there 
have been cases where the practice has resulted in MSF being expelled by a 
government. 244 Yet speaking out is defended by MSF as necessary to engage civil 
society and for its continued autonomy and solidarity with the victims. When 
appropriate, it can serve to highlight root causes of injustice and put pressure on persons, 
governments or institutions that should be held accountable. Tong notes that although the 
practice is sometimes perceived as advocacy of human rights or lobbying, temoignage 
would be more accurately defined as a testimonial based on what is actually seen and 
experienced by the MSF volunteers. Recognizing that their expulsion from a territory 
could result in patients receiving no health care,MSF uses speaking out as a last resort. 
240 Ibid., 181. 
241 Bortoiotti,47. 
242 Ibid., 46-56. 
243 MSF, "The Annual Activity Report," http://www.msf.org (accessed Feb 13,2010). 
244 In 1985, MSF was expelled from Ethiopia for speaking out against the government for worsening 
conditions during a famine. As one of the few NGOs ever admitted into North Korea, it was expelled in 
1998 for criticizing the government's diversion of aid. Recently in 2009, two sections ofMSF were 
expelled from Darfur. 
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It is usually employed when it has become apparent that humanitarian assistance has 
reached its limits of effectiveness or when aid has become a catalyst for further violence 
in the region.245 
The politics in France in the 1960s and 1970s also had an enduring effect on the 
cultural identity ofMSF. Taithe argues that MSF was created in the aftermath of the 
student revolution in France, when the atmosphere was characterized by militancy and 
group solidarity. By the mid-1970s, political events in East Asia and Eastern Europe had 
begun to erode European support for Marxist ideology, and this trend was evident among 
the intellectuals based in the Latin Quarter in Paris. Kouchner, a charismatic speaker and 
familiar personality from his involvement in the student revolution, was able to gamer 
support from the political Left by promoting an image that appealed to existentialist 
ideology. Kouchner insisted that outcomes could be altered by intervening in human 
tragedies and that "individual emotive responses rather than institutional ones,,246 were 
what was needed. Referring specifically to Biafra, he claimed that the original 
intervention was launched by just a few doctors and characterized their stand as one of 
"free agents against institutions".247 Many influential academics and media personalities 
were persuaded and supported Kouchner in the formative years of MSF, contributing to 
key principles such as the sense of solidarity with the victims because it captured the 
French "existentialist notion of 'engagement. ",248 
Another French influence that may have contributed to the culture of MSF provides 
the basis for the notion of quick intervention. From its inception, MSF sought to obtain a 
245 Tong, 181. 
246 Bertrand Taithe, "Reinventing (French) universalism: religion, humanitarianism and the 'French 
doctors,'" Modern and Contemporary France 12, no.2 (2004): 149. 
247 Ibid., 149. 
248 Ibid. 
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rapid deployment to get to the victims and Taithe argues that this is derived from the 
"original notion of 'urgence. ",249 Taithe explains that French medical aid movements in 
the late 1950s and 1960s developed national emergency response services that would 
bring the physician and medical team to the site of an accident in order to avoid time lost 
while transporting the injured to a waiting hospital-based team. This proactive form of 
medical intervention that underscored the importance of getting to the victim quickly was 
adopted by MSF in the early years. Small teams of volunteers made up of medical 
personnel and journalists would be deployed to a crisis along with a few supplies, and 
teams frequently had to wait for the appropriate tools to arrive before any relief could 
occur. However, this was consistent with Kouchner's assertion that simply being there in 
solidarity with the victims affirmed human dignity and could promote change. 
Tong notes that some organizations adopt multiple mandates providing both short 
term relief and long term development, but she argues that through most of its history 
MSF has been a single mandate organization focused on providing medical relief. MSF 
maintains universal ethical standards in its delivery of medical aid250 and insists on 
unhindered access to the victims. MSF is selective in its missions and will likely choose 
not to participate in those it perceives as politicized. In recent years violence against aid 
workers has increased and MSF has lobbied against the blurring distinction between 
militarized and humanitarian aid. As stated by Orbinski in his Nobel speech, the "moral 
intention of the humanitarian act must be confronted with its actual result.,,251 Because of 
the humanitarian failures in the 1990s in Somalia and Rwanda, MSF has become more 
249 Ibid., 151. 
250 Tong, 180. She lists these as beneficence (to do good), non-malfeasance (to not do harm), autonomy 
(informed consent, privacy and confidentiality) and justice. 
251 James Orbinski, Nobel Prize acceptance speech, 
http://nobelprize.orglnobelprizes/peace/laureates/1999/msf-lecture.html(accessed January 10, 2010). 
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introspective in evaluating its actions and has occasionally withdrawn its services when it 
determined that the provision of aid had unintended consequences such as fuelling more 
violence or was diverted for other uses.252 
From its inception, MSF expected governmental cooperation in obtaining access to 
popUlations in need and the freedom to carry out their duties without political 
interference. Considered somewhat radical at the time, MSF's assumptions about 
intervention were rooted in the French language. While unauthorized intervention was 
generally considered a challenge to sovereignty and was not regarded by states as 
legitimate, Allen and Styan suggest that in France humanitarian intervention was 
"technically legal. ,,253 The phrase used to signify the right to intervene is Ie droit 
d'ingerence, and because droit can also denote 'law' they argue that there may be an 
implied meaning of a 'law to intervene'. Furthermore, Allen and Styan argue that the 
French media frequently used Ie devoir d'ingerence or 'duty to intervene' which may 
infer the existence of a moral obligation to intervene for humanitarian reasons.254 
Similarly, DeChaine argues that MSF's conception of sansfrontierisme was based on 
this implied duty or right to intervene. He links their expectation to be allowed to 
transcend traditional state borders to their conception of humanitarianism as a universal 
rights-based activity that stands apart from the constraints of political space.255 For the 
French doctors, the justification for humanitarian intervention sans frontieres was based 
on a moral imperative toward other humans to relieve their suffering, and was not a 
political act to be subject to the constraints of defined territories. Although the right for 
252 Tong, 180. 
253 Ibid., 830. 
254 Ibid., 828. 
255 D. Robert DeChaine, Global Humanitarianism: NGOs and the Crafting o/CommunitY (US: Lexington 
Books, 2005), 91-92. 
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humanitarian intervention is still contested, the idea of facilitating access to populations 
became more accepted by the late 1980s. The need for neutral corridors was recognized 
due to the increasing number of joint operations by NGOs and the United Nations to 
provide basic necessities' in the midst of conflicts and natural disasters. Although not 
legally binding, the United Nations General Assembly eventually passed resolutions that 
affirmed the importance of the work of humanitarian groups and that recognized the need 
for ensuring relief corridors for the distribution of aid. 256 
Organizational Structure and Missions 
Initially, MSF drew its unpaid volunteers from the medical community and the media. 
Small medical teams were formed in haste to respond to crisis situations, andjournalists 
were recruited for the missions for the purpose of "dramatizing the situation and the role 
ofMSF doctors.,,257 The French media were responsive to publicizing the events, and 
the international media soon took an interest in MSF's activities. Television proved to be 
an effective medium to use the frames of human suffering and need for immediate action, 
and the reputation of the "heroic doctors" grew faster than their capacity to engage in 
missions.258 
From the beginning, an ideological cleavage had developed between core members 
about the goals and capacity of MSF. Some were uncomfortable with what critics have 
called "commodifying tragedy. ,,259 Many wanted to undertake a more professional 
approach to the delivery of aid and add logisticians and administrators to the team. The 
256 Allen and Styan, 831-832. UN General Assembly Resolution 43/131 passed in 1988 is available at 
http://www.un.orgldocuments/galresl43/a43rI31.htm and Resolution 45/100 passed in 1990 is at 
http://www.un.orgldocuments/gaires/45/a45rI00.htm 
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258 Taithe, 151. Also McDonald, 76. . 
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changing nature of conflicts brought the opportunity to engage in longer term 
humanitarian commitments, and the need for stable funding was becoming more 
pressing. MSF became more bureaucratic in organization and more democratic in its 
decision making about missions. Kouchner was alarmed at the transition and argued that 
MSF was forgetting that its mandate was to be rooted in emotive response. Finding 
himself in the minority, Kouchner and a few of the originals left MSF in 1979 and 
formed a similar NGO, Medecins du Monde.26o 
According to Bortolloni, Kouchner's departure allowed MSF to professionalize and 
begin fundraising in earnest, but the group also pursued more radical practices including 
witnessing and speaking out. Within months, MSF breached its pledge of neutrality and 
illegally entered Afghanistan to provide medical aid to the Afghan resistance after the 
Soviet invasion, and they staged a mediatised protest against the Khmer Rouge in 
Cambodia. This pattern continued and earned MSF a reputation as a "brash and fearless 
group that went where others would not go,,,261 causing MSF's popularity to spread 
throughout Europe. Between 1980 and 1985, four additional sections of MSF opened in 
Belgium, Switzerland, Holland and Spain, and an office linked to Belgium opened in 
Luxembourg. In 1990-91, MSF expanded to the United States and Canada, followed by 
several more chapters and offices throughout the world, totaling 29 national offices by 
2009.262 
MSF's missions had also expanded to include different forms of health emergencies. 
Many governments in developing countries were unable to provide for basic health 
needs, often as a result of structural adjustment programs and declining health care 
260 Taithe, 150-151. Also Bortolloni, 52-54. 
261 Bortolloni, 55-56. 
262 MSF, www.msf.orgl. Also Bortolloni, 63. 
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funding. In many cases, there was no infrastructure for the administration of health care 
and non-governmental organizations were stepping up to assist communities in longer-
term projects for their survival. For MSF, emergency medical assistance would shift to 
also include combating outbreaks of disease, providing mass vaccinations, and 
distribution of drugs and other medical supplies. Nutrition, shelter, safe water supplies 
and proper sanitation were intrinsically linked to improved health and were included in 
the humanitarian mandate. Education for prevention of illness, pre- and post-natal care 
for mothers and infants, and collecting information on ongoing health problems such as 
tropical and emerging illnesses increasingly became the role of those on the ground. 
MSF became active in working with health officials in less developed countries to set up 
and maintain more accessible clinics for communities in rural areas, and in training local 
health care providers who could continue the project upon MSF's withdrawa1.263 
A second factor that expanded the mandate of emergency aid was the increase in the 
number of civil wars. Emergency medical care was required for the growing number of 
affected populations, and included refugees and displaced persons.264 McDonald notes 
that the transformation from war between states to conflict within states meant that the 
traditional model for emergency medical relief could not be supported. Wars were no 
longer fought by armies in a designated territory; rather, civil wars were usually situated 
in populated areas and the casualties were predominantly civilian. Combatants were 
often rebel factions and ethnic groups, and the tools of war included terrorizing 
263 Mike Toole, "Frontline Medicine: The Role of International Medical Groups in Emergency Relief," in 
World in Crisis: The politics of survival at the end of the twentieth century, ed. Medecins Sans Frontieres 
(UK: Routledge, 1997). Also, Lisa Fuller, "Justified Commitments? Considering Resource Allocation 
and Fairness in Medecins Sans Frontieres-Holland," Developing World Bioethies 6, no.2 (2006): 61. 
(online) . 
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communities, ethnic cleansing, and genocide. Affected states lacked the capacity to 
provide for their people and the stability of neighbouring states was often threatened by 
migration. Caring for the injured and displaced populations of civil wars had been 
gradually taken over by humanitarian organizations.265 
The growth ofMSF into a global organization and the changing dimension of health 
needs demanded a more formalized organizational structure, and permanent staff was 
needed. Modest salaries were paid to those in the field to cover their expenses, and MSF 
was able to hire and train local caregivers and non-medical staff in many of the locales 
where they serve. By 2002, the combined budget was about US$400 million, and MSF 
employed about 15,000 national staff and 3,000 expatriates for positions in the fields of 
medicine, logistics and administration.266 This had grown to 27,000 staff by 2008.267 
To provide coordination for the growing organization, the International Council was 
formed in 1991 with a representative from each section on the council, and MSF 
International opened permanent offices in Geneva ten years later. The five European 
based sections of MSF have maintained responsibility for the operational side of the 
missions and accept larger amounts of funding from government sources. The remaining 
thirteen sections are partnered with a European office aI).d primarily perform the functions 
of recruitment, fund raising, public education and public relations although the U.S. has 
recently participated in joint operations with its partner, France.268 
265 McDonald, 75. 
266 Bortolotti, 27. He also notes on page 65 that over half of the expats are from the 5 European states in 
charge of operations. Almost 60% of the staff is medically trained. 
267 MSF-USA, "Annual Report 2008," 28, http://www.doctorswithoutborders.org/donate/policy.cfin 
(accessed February 13,2010). 
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In keeping with the goal to retain its political independence, MSF has consistently 
raised more than 80% of its overall annual funding through donations from the private 
sector.269 MSF-USA is the largest fundraiser and in 2008, raised $151 million which was 
about 20% of the overall budget. Of this amount, 84.5% was from private individuals, 
12% from foundations and only 3.5% was from corporate donations.27o MSF-USA does 
not accept any funds from the government, and it maintains a conflict of interest policy 
that prohibits donations from corporations and foundations that profit from substances 
that may contribute to poor health or that may be related to concerns addressed by MSF, 
including tobacco, arms, extractive industries, and pharmaceuticals.271 
MSF and the Issue of Access to Pharmaceuticals 
Non-governmental organizations concerned with health and poverty issues, along with 
many of the lesser-developed and developing countries, began to contest the implications 
and effects of intellectual property rights for pharmaceuticals soon after the TRIPS 
Agreement came into force. One of the major catalysts for their concern was the ever 
increasing number of infections of HIV / AIDS among the populations in developing 
countries and the lack of access by the poor to the vastly improved antiretroviral 
medicines that were being developed. 
During the late 1980s and early 1990s, the global health focus had turned towards 
HIV / AIDS. Most large pharmaceutical companies were heavily invested in the research 
and development of drugs to manage the virus and the often lethal complications that 
arose from it. In 1996, shortly after the TRIPS Agreement came into effect, an 
announcement was made at the XI International AIDS Conference in Vancouver that the 
269 Bortolotti, 66. In recent years, the Annual Reports show this figure to be as high as 89.9%. 
270 MSF-USA, "Annual Report," 42. . 
271 Ibid. 
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new combined triple antiretroviral therapies would "convert deadly AIDS into a chronic, 
manageable disorder like diabetes. ,,272 But for the patients served by MSF in the 
developing world, the new AR V treatments were not available. 
The numbers of people infected with HIV in lower income countries had spiraled 
uncontrollably and most suffered from complications due to other tropical diseases to 
which they had become even more susceptible. Unlike the demographics for those 
affected by HIV in the western world, the prevalence of the virus was almost equally 
divided between males and females, and mother-to-child transmission at birth was 
occurring at an alarming rate. In 1999, it was estimated that 16 million had already died 
of AIDS and another 33 million people worldwide were infected with HIV; of those 
infected, 26 million (80%) were living in Sub-Saharan Africa with no access to treatment. 
Although two million Africans died -from AIDS that year, less than 1 % of the market 
share of antiretroviral drugs was sold to African states. The cost of the new HIV drugs 
was well beyond the reach of poor governments at more than $10,000 per person for a 
year's supply of the patented medicines.273 
For MSF, the HIV / AIDS epidemic was only part of the burden of disease that 
threatened their patients in low income countries. Infectious and parasitic diseases 
including malaria, tuberculosis, African sleeping sickness and Chagas disease in Latin 
America were causing enormous suffering and contributed to about 25% of the overall 
disease burden in the developing world. Estimates in 1999 showed that communicable 
diseases were responsible for the death of about 14 million people, mostly in lower 
272 Orbinski, "Global Health," 34. 
273 Nathan Ford and Daniel Bennan, "Essential Medicines and Compulsory Licensing," in HAI-LIGH1S 3, 
no. 1 (1999), Health Action International, http://www.haiweb.orglpubs/hailights/may99.htinl (accessed 
April 17, 2008). 
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income countries. Again disproportionately, the developing world consisted of 80% of 
the global population, but only accounted for 20% of the market share for 
pharmaceuticals.274 In light of this, MSF leaders turned their attention to finding ways to 
cope with the diseases that ravaged the populations they were working within. 
Driven by the desire to learn why their patients' pharmaceutical needs were largely 
ignored, MSF formed its own "internal research capacity" to scrutinize the policies that 
contributed to the issue of neglected diseases.275 What MSF concluded was that while 
several diseases most prevalent among their patients could be treated by drugs, the issue 
of access was complicated and had mUltiple barriers. 
First, the newer medicines were protected under patent for twenty years and brand 
names were far too expensive; newer drugs for tuberculosis, for example, exceeded 
$15,000 per course oftreatment.276 With the implementation of the TRIPS Agreement, 
access to generic brands was becoming more difficult, and the remaining suppliers of 
generics were in developing countries including India and Brazil and were initially 
expected to comply with "TRIPS" rules as of 2000, then 2005 after the Doha 
Declaration. 277 
Second, having worked in the field, MSF knew that many older versions of drugs 
were fraught with management problems such as storage temperature, complicated 
dosages and drug combinations, as well as dangerous side effects. Many existing drugs 
had become ineffective due to increased drug resistance, as was prevalent with multi-
drug resistant tuberculosis. Some medicines, including ARVs, were formulated for adult 
274 MSF, Fatal Imbalance: the Crisis in Research and Developmentfor Drugsfor Neglected Dis~ases 
(Geneva: MSF, 2001): 8-11. 
275 Orbinski, "Global Health," 34. 
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patients, or in the case of Chagas, were only useful to treat children. Yet, MSF learned 
that only 13 of the 1,393 new drugs approved between 1975 and 1999 were indicated for 
tropical diseases and 3 were for tuberculosis.278 Moreover, diseases that affected the 
developing world were clearly not a priority since nine of the thirteen new drugs that had 
been developed resulted either from contracts with the u.s. government to treat Vietnam 
veterans or from veterinary research primarily indicated for livestock.279 
A third factor limiting access was that in some cases drugs that had been effective 
were no longer deemed profitable for the manufacturers and production had ceased. In 
addition, with the exception of the new anti-retroviral treatments, most ongoing research 
and development by pharmaceutical corporations was not indicated for diseases that were 
prevalent in the developing world.28o According to The Global Forum for Health 
Research, the leading burdens of disease in 1999 were lower respiratory infections, 
diarrheal and perinatal conditions; however, of the US$50-60 billion invested annually by 
the public and private sectors for research and development, only 10% was directed 
towards the conditions affecting 90% of the global population.281 
Based on its findings, MSF's strategy to improve access to medicines included 
engaging several actors in pharmaceutical policy using advocacy, collaboration and 
evidence-based opposition. MSF connected with governments, international and non-
governmental organizations, pharmaceutical companies and researchers to work toward a 
278 Patrice Trouiller, Piero Olliaro, Els Torreele, James Orbinski, Richard Laing and Nathan Ford, "Drug 
Development for Neglected Diseases: a Deficient Market and a Public-Health Policy Failure," Lancet 359 
no. 9324 (June 2002): 2189, 
http://download.thelancet.com/pdfs/joumals/lancetlPllSO 140673602090967 .pdf?id=3d3Sb I bSaaOec416:-
47766£9: 12836060eeb:-135b 1272220098862 (accessed April2S, 2010). 
279 MSF, Fatal Imbalance. II. 
280 MSF, Fatal Imbalance. 11. 
281 Global Forum for Health Research, The 10/90 Reporfon Health Research. [online], 
http://www .globalforumhealth.orglMedia-Publications/Publications! I 0-90-Report -on-Health-Research-
1999 (accessed April2S, 2010). 
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solution. They sponsored conferences on the access issue, produced educational 
materials highlighting the problems, counseled government officials on the flexibilities 
within the TRIPS Agreement, and lobbied for change. 
Access to Essential Medicines Campaign 
The financial boost that MSF needed to institutionalize its goal for access to 
pharmaceuticals came in the form of the Nobel Peace Prize in 1999. The Nobel 
Committee selected MSF in recognition of its international humanitarian service and 
focus on human rights, and the presentation speech highlighted the core values contained 
in the MSF Charter including independence, impartiality, and speaking OUt.282 A portion 
of the more than US$l million prize money was allocated by MSF to build on its new 
research initiative and to formally launch the "Access to Essential Medicines 
Campaign".283 
The Campaign's international office was opened in Geneva; strategically, this location 
was important for several reasons. First, Geneva is the home of many international 
organizations that are focused on trade such as the WTO, WIPO, and UNCTAD. It is 
also home to health-based organizations including World Health Organization and 
UNAIDS, as well as being the European base for the United Nations and UNHCHR 
In addition, the International Federation of Pharmaceutical Manufacturers and 
Associations (IFPMA) has its head office here. Hein refers to this as the "Geneva 
connection" and argues that it is a "microcosm of the whole complex of interfaces" that 
282 Nobel Prize Foundation, "Nobel Peace Prize 1999, Award Ceremony Speech," 10 December 1999, 
http://nobelprize.orglnobel prizes/peace/laureates/1999/presentation-speech.html (accessed November 17, 
2009). . 
283 Bortolotti, 161. 
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occur in global health governance.284 He notes that while major differences exist in the 
functions of the many organizations based in Geneva, a common thread underlies their 
interactions through respect for human rights norms and all are affected by global health 
concerns. Hein describes close ties within the 'Geneva connection' that result from both 
formal and informal networking through participation in a variety of workshops and 
events, and through personal and private contacts. In addition, Hein cites job mobility 
between international and non-governmental organizations to be a significant factor in 
"intensifying communication between different organizations. ,,285 
Initially there were four key personnel who formed the nexus of the MSF campaign: 
the head ofMSF France, Dr. Bernard Pecoul, Ellen't Hoen who was a trade lawyer and 
had worked with Health Action International and WHO on drug policy, former 
pharmaceutical marketing executive, Daniel Berman, and the MSF International 
President, Dr. James Orbinski, a Canadian physician with extensive field experience.286 
According to Orbinski, the Access Campaign was "rooted in a social justice ethic" for 
the benefit of their patients who continued to suffer from treatable infectious diseases.287 
The primary goal was to achieve "equitable access to proven effective treatments,,288 for 
people in lower income states. The campaign was focused on three areas: to overcome 
the barriers that prevented access, to encourage innovation in research and development 
for neglected diseases, and ultimately to influence international trade agreements to be 
more responsive to public health concerns. In the short term, MSF sought more 
284 Hein, 59. 
285 Ibid., 61. 
286 Orbinski, "An Imperfect Offering," 354. 
287 Orbinski, "Global Health," 34. 
288 Ellen 't Hoen, "Dying of market failure," International Journal of Risk and Safety in Medicine 13 
(2000): 137. 
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affordable drugs through persuading patent holders to engage in differential, equitable 
pricing based on parity289 and promoted the use of compulsory licensing and parallel 
importing by states without capacity to provide for their own health needs, as well as the 
use of Bolar provisions for generic manufacturers to fast track approvals for the 
production of medicines coming off patent. 290 
Advocacy and Education 
The formal MSF Campaign was built on its ongoing participation in the wider 
transnational access network and coalition. Although MSF had not traditionally been 
reputed to collaborate with other NODs, Pecoul, the Director of the French MSF, joined 
the transnational access network initiated by Health Action International and CP Tech in 
1998. The network had rapidly expanded, and CP Tech was host to an extensive online 
"listserv" for intellectual property and health, which was instrumental in the 
dissemination of • dense webs' of information to the network that was forming around the 
world.291 The addition of the MSF Campaign further aided in the development of a larger 
transnational advocacy network of more than a hundred non-governmental organizations 
and civil society groups, and the base funding allowed MSF to send volunteers to work 
with domestic health and policy NOD's in many countries?92 
As part of the access coalition, MSF was active in organizing and convening 
conferences and workshops focused on drug access. In May 1998, the World Health 
289 MSF has drawn a distinction between using terms for discounted drug pricing such as differential or 
tiered, arguing that these do not necessarily translate into equitable and affordable for a given population, 
hence purchasing power parity must be considered for fair access. See 't Hoen, Ellen, Suerie Moon and B 
Pecoul, "Pills and pocketbooks: Equity pricing of essential medicines in developing countries," 
http://data.unaids.org/Publications/IRC-pub05/pills-pocketbooks en.pdf (accessed April 23, 2010). 
290 't Hoen, "Dying of market failure," 137. For information on the Bolar exception, see WTO Fact Sheet: 
TRIPS and Pharmaceutical Patents, 
http://www.wto.org/englishitratope/tripse/factsheetpharm02e.htm#bolar (accessed April 24, 2010). 
291 CP Tech Iistserv archives are available at http://lists.essential.org/pipermail/ip-health/ . 
292 Orbinski, Imperfect Offering, 354. 
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Assembly had tabled a proposal for a Revised Drug Strategy that would formalize the 
role of the WHO in monitoring the effects of "TRIPS" and other trade agreements on 
drug access. The revision also included that part of the WHO's mandate would be to 
provide assistance to governments in ensuring the primacy of public health over trade.293 
The opposition put forth by the U.S. and other industrialized states provided a political 
opportunity for the NGOs to host a series of meetings with negotiators to educate them 
about IP rules and constraints on health policy. A year later, the 191 state members of 
the WHA unanimously passed Resolution 52.19, and the NODs released a statement that 
this was a first step toward improving health. Implementation, however, would be the 
key. 294 
For the NOD coalition, part ofimplementation would mean understanding the legal 
flexibilities in the TRIPS Agreement and how lower income states might utilize them. 
Among the first international projects for the MSF Campaign was co-convening a 
conference in Geneva with HAl and CP Tech for about 120 delegates from 30 countries 
to explore the practical implications of compulsory licensing for developing countries.295 
This conference was followed up a few months later by another in the Netherlands with 
350 participants from 50 countries, including representatives from national governments, 
industry and several intergovernmental institutions, including the World Bank and World 
293 WHO, "Revised Drug Strategy," 27 January 1998, 
http://apps.who.intlgb/archive/pdf filesiEB 10 lIpdfangVangr24.pdf (accessed April 17, 2008). 
294 MSF, HAl and CP Tech, "Joint Release on WHA Revised Drug Strategy," 25 May 1999, 
http://lists.essential.org/pharm-policy/msg00095.html (accessed April 17, 2008). See also Sell, Private 
Power, 147-149. 
295 A summary of the conference is available at MSF, "AIDS and essential medicines and compulsory 
licensing" (March 25-27, 1999), http://www .msfaccess.org/resourceslkey-publicationslkey-publication-
detail/index.html%3Ftx ttnews%5Btt news%5D=1297&cHash=7827c3de8f (accessed October 6, 2010). 
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Health Organization.296 At the conclusion of the conference the NOO organizers issued a 
formal declaration, the Amsterdam Statement to WTO Member States on Access to 
Medicine. The Statement, released just prior to the Seattle WTO Ministerial Meeting in 
November 1999, called for the creation of a standing working group to advise the WTO 
Council for "TRIPS" and "to consider the impact of trade policies on people in 
developing and least developed countries, and provide a public health framework for the 
interpretation of key features of WTO agreements. ,,297 Among the policy alternatives 
they wanted considered was the use of compulsory licensing, relaxing the administrative 
rules for generic production, and new incentives for innovative research and 
development. Disappointed with the responses from some attending the conference, 
representatives from HAl, CP Tech and MSF also lobbied the U.S., E.U. and WHO prior 
to the WTO meeting, and went to Seattle to urge member states to "recognize that public 
health takes priority over trade.,,298 Although Orbinski suggests their efforts in Seattle 
were a failure,299 it was at this meeting, coinciding with World AIDS Day, that Clinton 
announced the USTR would change its approach to health and trade policy to ensure 
''that people in the poorest countries won't have to go without medicine they so 
desperately need. ,,300 
MSF also worked with the World Healtli Organization and the Rockefeller Foundation 
to organize an October 1999 conference in Paris for the health industry that included 
296 As Sell and Prakash note on page 162, some international organizations had an instrumental reason to 
support the Access coalition. The World Bank for example purchased approximatelyUS$800 million in 
gharmaceuticals annually. 
97 CP Tech, "Amsterdam Statement to WTO Member States on Access," 
http://www.cptech.orgliplhealthlamsterdamstatement.html (accessed April 17,2008). 
298 Ellen 't Hoen, "Doctors in Seattle: The battle for access to essential drugs," Development 43, no.2 
(2000): 101-104. 
299 Orbinski, Imperfect Offering, 357. 
300 William Clinton, "US President Clinton's speech to the WTO," 1 December 1999, 
http://www.pbs.orglnewshour/bb/international/wto/clintonwto12-1.html( accessed February 14, 20 I 0). 
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pharmaceutical companies and researchers, who with the growing access coalition 
explored the need for medicines for neglected diseases. The Drugs for Neglected 
Diseases Working Group evolved from this conference with the goal to "seek new and 
creative strategies,,301 for promoting research and development for neglected diseases. 
Chaired by Orbinski, some of the initial undertakings and feasibility studies were funded 
by MSF.302 By 2003, four pilot projects had evolved, and MSF had formalized a 
relationship between five public sector groups, a research group and UNDP/World 
Bank/WHO's Special Programme for Research and Training in Tropical Diseases to form 
the Drugs for Neglected Diseases initiative (DNDi).303 Their mandate was to challenge 
the traditional logic of research and development as being market-driven and profit-
oriented, and to replace it with an alternate vision of a needs-based process that would 
respond to health priorities. As a not-for-profit venture, DNDi has continued to work to 
encourage, locate and combine research and development resources, particularly in the 
area of neglected diseases, which can be pooled to meet health needs and to assist 
governments in building local capacity. The initial projection was to register six to eight 
new drugs through this project by 2014.304 DNDi has successfully coordinated three new 
drug treatments and is overseeing several more currently in the development process.30S 
The consultations between non-governmental and governmental organizations, states 
and pharmaceutical corporations resulted in a plethora of conferences and workshops 
aimed at educating stakeholders, resolving access issues and finding innovative solutions 
301 MSF, Fatal Imbalance, 4. 
302 MSF, Fatal Imbalance, 4. 
303 DNDi. www.dndLorg (accessed April 14, 2008). 
304 MSF. "Members' Briefing on Infectious Diseases in the Developing World," Speech by Nicol;:as de 
Torrente, Executive Director of MSF-USA to the US Joint Congressional Caucus of Human Rights and 
Congressional Black Caucus Health Brain Trust, May 15, 2003. 
http://www.doctorswithoutborders.org/publications/articJe.cfm?id= 1332 (accessed February 14, 2010). 
305 DNDi, "Diseases and Projects," http://www.dndLorg/diseases.html(accessed February 14,2010). 
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for universal access to essential medicines. Initially sponsored primarily by MSF and 
other health NGOs,306 part of this role, particularly in the area of HI VIA IDS, was 
assumed by international institutions beginning in 2001. Although UNAIDS was 
established in 1996, it had limited success on its own in setting and reaching 
objectives.307 When WHO began a more concerted effort for HIV/AIDS beginning in 
200 I, the two organizations, often in concert with World Bank, focused on reversing the 
trend of increasing numbers of HIV I AIDS infections in the developing world and in 
lowering mortality rates.308 With increased leadership at the international level, the 
access coalition and MSF remained active as presenters and participants in the forums,309 
but were also able to channel their resources into an expanded campaign for neglected 
diseases. 
Through the Access to Essential Medicines Campaign, MSF has also lobbied and 
worked with intergovernmental organizations to create a better understanding of access 
needs. MSF has maintained observer status at the World Health Assembly meetings and 
is active in promoting its concerns to the European Commission, influencing E.U. 
advocacy of access issues. Through its work with the World Health Organization, MSF 
has lobbied for and succeeded at getting newer medicines onto the WHO List of Essential 
Medicines and was instrumental in pressuring WHO to create a Commission on 
306 For example, MSF and HAl sponsored a conference for 21 East African countries on patents and pricing 
in June 2000, 
307 UNAIDS did have some minimal success in negotiating with 5 drug companies for the Accelerating 
Access Initiative, however, the actual output of cheaper drugs was slow in coming and limited in scope. 
308 Lars Kohlmorgen, "International Governmental Organizations and Global Health Governance: the Role 
ofthe World Health Organization, World Bank and UNAIDS," in Global Health Governance and the Fight 
Against HIVIAIDS, ed. Wolfgang Hein, Sonja Bartsch and Lars Kohlmorgen (UK: Palgrave MacMillan, 
2007), 130. 
309 An example is Ellen 't Hoen's presentation on equity pricing at the WHO/WTO Workshop on 
Differential Pricing and Financing of Essential Drugs in Norway, April 2001, 
http://www.wto.org/english/tratopeITRIPselhosbjorpresentationselhosbjorpresentationse.htm 
(accessed April 24, 2010). 
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Innovation. The findings of the Commission are frequently cited by MSF in its 
arguments for better health outcomes. And as early as 2000, MSF, UNAIDS, UNICEF 
and WHO worked together to research and produce a drug selection and pricing guide for 
HIV / AIDS treatment. 
MSF is also one of five hundred civil society signatories to the Geneva Declaration on 
the Future of the WIPO (2004), which supported the movement for the creation of a 
development agenda at WIPO.31O On several occasions MSF has addressed WIPO 
meetings urging it to conduct an impact assessment before proceeding with IP reforms, to 
provide technical assistance to developing countries trying to use "TRIPS" flexibilities, 
and to consider new models to encourage innovation and transfer of related technology 
and knowledge.311 
MSF's role in the fight for universal access has also been acknowledged by 
international governmental organizations. In December 2003, UNAIDS and WHO 
announced the launch of their "3 x 5 initiative" to get 3 million infected persons in the 
developing world onto ARV therapy by the end of 2005. In the press release, the 
program is described as a "complement" to ongoing efforts including "the pathfinding 
work ofNGO's (like MSF).,,312 
Relationship with Pharmaceutical Corporations 
Transnational pharmaceutical corporations have maintained that patents are necessary 
to reward innovation and encouragere-investment in research and development. 
310 CP Tech, "Geneva Declaration on the Future ofthe WIPO," 
http://www .cptech.org/ip/wipo/futureofwipodeclaration.pdf (accessed April 22, 2010). 
311 Statement by MSF at the WIPO General Assembly meeting Sept. 2004 and at the Inter-Sessional 
Intergovernmental Meeting on a development agenda, April 11-13, 2005, 
http://www. who.intiintellectualproperty/topics/ip/MSF%20statement%20at%20WIPO%20GA %20%2030 
%20%20Sep%20%202004.pdf(accessed April 24, 2010). 
312 UNAIDS, WHO. "Plan to get 3 million AIDS patients on treatment by 2005," 
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Research costs are high, and it takes ye.ars to develop a new product which can, without 
the protection of patents, be inexpensively copied by generic manufacturers who do not 
share the burden of research costs. Major drug companies argue that compulsory 
licensing and other "TRIPS" flexibilities will only harm future patients by discouraging 
innovation and private sector investment. In addition, drug companies have blamed 
access issues in developing countries on poor or non-existent health care systems, tariffs, 
pilfering and mark-ups within national boundaries, and the lack of competent health care 
professionals needed to administer and supervise complex treatment programs. 
MSF has claimed that in principle it is not against patents for inventions, however, in 
the case of drugs which can save lives and end suffering, patents should not limit access 
and artificially raise prices beyond the reach of governments.313 Also, MSF has 
challenged the use of patents to extend a monopoly over a drug past the initial 20 year 
life by re-registering it for new indications or with slightly changed chemical properties 
or combinations, a commonly used technique known as 'evergreening.' MSF has argued 
that to meet the criteria for a patent, a product must be both new and inventive, which is 
consistent with WTO expectations.314 As for discouraging research, the counter-position 
offered by MSF and others has been that pharmaceutical research and development is 
focused on diseases of the North and has little bearing on the drugs needed for neglected 
diseases in developing countries. Early in the campaign, it was shown that 80% of the 
drug market share was in North America, Europe and Japan, which represented 
313 MSF, "The impact of patents on access to medicines," http://www.msfaccess.org/main/access-
patents/introduction-to-access-and-patents/the-impact-of-patents-on-access-to-medicinesl (accessed April 
24,2010). 
314 MSF, Drug patents under the spotlight: sharing practical knowledge about pharmaceutical patents, 
(Geneva: MSF, May 2003),6-7, 12-13. For the "TRIPS" definition of criteria for patentability, see WTO, 
"Fact Sheet: and Pharmaceutical Patents, Obligations and Exceptions," Article 27.1, 
http://www.wto.org/english/tratope/tripse/factsheetpharm02e.htm (accessed April 24, 2010). 
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disproportionately only 20% of the global population. Mo-reover, the coalition argued 
that research costs were greatly exaggerated by drug companies and that transparency 
was needed to determine realistic costS.315 Further inquiry has shown that many drugs 
were developed or partially funded within publicly funded institutions such as state 
sponsored laboratories and universities before being licensed to drug companies for 
manufacturing.316 MSF and CP Tech argued for example that for fourteen HIV/AIDS 
drugs in production in the late 1990s, over half of the funding for clinical trials came 
from the U.S. government.317 
Pharmaceutical companies also argued that patients in resource-poor countries would 
not be able to develop and maintain the strict regime necessary for HIV treatment, 
especially when multiple combinations of drugs taken at different times daily was the 
treatment prescribed. MSF was able to draw on its experiences to refute the claim. In 
2000, MSF set up its first HIV treatment project in Thailand and initiated similar 
programs in six countries the following year. A program jointly sponsored by MSF and 
the provincial health authority in the township of Khayelitsha, South Africa, showed that 
HIV treatment regimes, including limiting the risk of vertical transmission from mother 
to child, could be successfully managed if affordable d111gs were made available.318 
315 Ellen 't Hoen, "Access to Essential Drugs and Globalization," Development 42, no.4 (1999): 90. The 
author notes that thdFPMA has claimed that drug development could cost as much as US$500 million in 
1998 compared to the US tax office's claim ofUS$2.3 million in 1994. 
316 Sell and Prakash, 163, report that Vale University jointly holds the patent on AIDS drug d4T produced 
by Bristol-Myers Squibb. During the Access campaign in 2000, Vale was asked to grant permission for 
generics to be manufactured. Vale students held protests in support of access and were instrumental in 
forcing the drug company to reduce the price dramatically for poor countries. 
317 't Hoen, "Dying," 139. More recent estimates show that the public sector provides 44% and the private 
sector 48% of funding for research. For more on recent innovation in pharmaceutical research and 
development, see Carlos M. Correa, "Intellectual Property Rights and Inequalities," 266-269. 
318 Christian von Soest and Martin Weinel, "The Treatment Controversy: Global Health Governance and 
South Africa's Fight Against HIV/AIDS," in Global Health Governance and the Fight Against HIVIAlDS, 
ed. Wolfgang Hein, Sonja Bartsch and Lars Kohlmorgen (UK: Palgrave MacMillan, 2007): 217-218. 
Also, Orbinski, An Imperfect Offering, 359-363. 
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Concurrently, generic drug companies in Thailand, India and Brazil,· where patents 
were not yet recognized for both product and processes, developed the capacity to 
manufacture antiretrovirals for HIV and had simplified the dosage regime by creating 
combined therapy drugs. MSF publicly announced it would purchase direct from generic 
manufacturer Cipla in India, and Cipla agreed to sell MSF its ARV "cocktail" for $350, 
compared to the patented price of over $10,000 per person for a year's supply.319 MSF 
publicly challenged brand name drug companies to match this price and offer it to lower 
income states.320 The actions of MSF and others in the coalition would eventually 
contribute to a lowering of prices for developing countries. 
The MSF Access Campaign drew global attention in 2000 during the lawsuit against 
South Africa's legislation allowing for compulsory licensing and parallel importing. 
South Africa, with an estimated 4 million people infected with HIV, was attempting to 
create domestic laws and regulations to use the tlexibilities contained in the TRIPS 
Agreement. MSF joined with British-based Oxfam, CP Tech and a South African 
grassroots organization, Treatment Access Campaign (T AC), to publicize the case 
brought by 39 multinational pharmaceutical companies. The Access Campaign became a 
collaborative effort with CP Tech lobbying the US government, and Oxfam publicly 
shaming pharmaceutical companies Glaxo and Pfizer. MSF specifically targeted Pfizer 
for its refusal to lower prices and launched a publicity campaign against them in eighteen 
(mostly industrialized) countries. Their efforts brought tremendous public pressure on 
the companies by suggesting that corporate greed was taking precedence over public 
319 Sell and Prakash, 162. 
320 MSF. "AIDS Triple-Therapy for Less than a $I1Day," 7 February 2001, 
htt:.p:llwww.msfaccess.org!media-room/press-releases/press-release-
detail/?tx ttnews[tt newsl=107&cHash=fflecde155 (accessed April 24, 2010). 
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health. When the companies finally dropped the suit against South Africa, many, 
including Glaxo, Merck, Abbott and Bristol-Myers Squibb, had also dropped prices for 
specific products or had agreed to begin donations of certain drugs to poor countries.321 
MSF also teamed up with South Africa's Treatment Action Campaign in 2002 to 
import Brazilian manufactured generic ARVs for its project in Khayelitsha.322 This 
project had become central to TAC's position in the South African legal case, and had 
continued to be the focal point in pressuring the South African federal government to 
extend universal access to treatment. Drug companies were opposed to the action of 
importing generics, however, after the public relations disaster from the lawsuit the year 
before, the drug companies chose to merely observe. 
Not all of the interactions between MSF and pharmaceutical corporations have been 
contentious. Drug companies have voluntarily entered into negotiations for the 
production of essential medicines and have offered some patents for free. MSF and 
WHO partnered in 1999 to gain access to drugs for neglected diseases and realized some 
early successes when the French company A ventis agreed to produce a medicine for 
sleeping sickness that had ceased production a few years earlier because it was not 
profitable. Similarly, MSF and WHO, through the Green Light initiative,323 negotiated 
substantial discounts in pricing with Eli Lilly for treatment of multidrug-resistant 
tuberculosis in 2000 and were able to oversee the rational use of the drugs in controlled 
321 Jordi Trullen and William B. Stevenson, "Strategy and Legitimacy: Pharmaceutical Companies' 
Reaction to the HIV Crisis," Business and Society 45, no.2 (June 2006): 187. 
322 MSF, "Joint Press Release MSF, TAC and Oxfam: Importation of Generics Cuts Price in Half," 29 
January 2002, http://www.doctorswithoutborders.orglpress/release.cfin?id=54 7 &cat=press-release 
(accessed April 24, 2010). 
323 WHO started the Green Light Committee initiative in 2000 to procure good quality, inexpensive drugs 
for use in managed programs for tuberculosis. See WHO, "The Green Light Committee Initiative," 
http://www.who.intitb/challenges/mdr/greenlightcommittee/faq ] initiative/enlindex.htmr (accessed April 
24,2010). 
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programs.324 Another success was reached in 2001 when MSF asked Yale for permission 
to access generics of its patented ARV drug d4T. Yale had exclusively licensed it to 
Bristol-Myers Squibb, and after pressure mounted from the student body and others, 
Bristol-Myers not only dramatically cut its prices but also offered the license to be used 
for free by other manufacturers.325 
Other Strategies 
MSF has been aggressive in its approach to challenging what it perceives as unjust or 
uninformed, and uses the media, the internet, and conference forums to publicly disagree 
with and challenge positions taken by international organizations such as World Health 
Organization, the WTO and WIPO?26 MSF is a frequent contributor to publications such 
as The Lancet and UN Chronicle where they urge states to address global concerns. An 
example of this is a challenge they presented in October 2006 to the Executive of WHO 
to select a new leader who would "assert its leadership in view of new independent actors 
that come with vast resources," and critically asked if it would "continue to stifle 
dissenting voices from its staff, as it has done in the past?,,327 While MSF criticizes, it 
also continues to work with these organizations, and with WHO in particular, to promote 
better health outcomes. 
MSF has engaged in several online petitions that have been successful in generating 
thousands of signatures globally to assist in pressuring corporations and organizations on 
324 Orbinski, "An Imperfect Offering," 363. 
325 MSF, "Access Campaign Accomplishments 1999-2002," 
htm://www.msf.org/msfintemational/invoke.cfm?component=article&method=full html&ob;ectid=4DAO 
AB2D-B77D-4304-B2D4AED326C4EA96 (accessed April 24, 2010). 
326 Examples are WHO's "Massive Effort" project that was criticized Oct. 4, 2000for claiming that 
treatments exist and WHO needs to be more ambitious in its approach, MSF-USA, , 
htm:! /www .doctorswithoutborders.orglpress/release.cfm?id=636&cat=press-release/ (accessed July 25, 
2010). 
327 MSF, "Historic opportunity for WHO to re-assert leadership," The Lancet 368(Oct. 21, 2006): 1406, 
www.thelancet.com (accessed Oct. 8,2009). For comment on leadership at the WHO, see Ingram, 87. 
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behalf of those in need of medicines. For example, MSF collected 420,000 signatures in 
2007 through its online petition urging Novaritis drug company not to pursue its case 
against India's patent laws.328 MSF also maintains an active internal research capacity to 
compliment its involvement in pursuing access to medicines for neglected diseases, and 
has conducted some trials among its patients in resource-poor settings to challenge 
notions that treatment cannot be managed without more advanced health systems in 
place. 
MSF produces high quality brochures advocating medicines access and innovation in 
research that are widely distributed through conferences and workshops on health issues. 
MSF has also created several travelling poster displays for use in public venues, such as 
the Access to Essential Medicines EXPO based on "photographs, sound, text and 
interactions with MSF field volunteers,,329 to raise public awareness. While many of the 
materials featuring their humanitarian work tend to focus on caring for people in need, 
the visual images created specifically for the access campaign are typically based in a 
social justice framework designed to highlight the inequality between the 10% who have 
access to drugs and the 90% who do not. It would seem likely that the former are 
designed to advertise good works and elicit financial donations, while the latter are 
directed toward emotive responses to encourage protests and outrage at the inequity of 
being able to pursue a basic human right to health.33o 
328 MSF. "Promoting Generic Competition," http://www.accessmed-msf.org!main/hiv-aids/introduction-
to-hivaids/promoting-generic-competition! (accessed April 20, 2008). 
329 MSF. "Members' Briefing on Infectious Diseases." In 2002, the travelling poster exhibit was used in 
the US for about a year going to 30 cities to bring awareness of neglected diseases. About 30,000 
signatures were also collected urging the US government and pharmaceutical companies to devote new 
resources to research in this area. 
330 Examples can be seen at MSF. ''Three years of Access posters, 1999-2002," 
http://www.msf.orglmsfinternational/invoke.cfm?objectid=3A936825-06B4-4565-
9BC77C78D216E6EA&component=toolkit.article&method=full html (accessed April 24, 2010). 
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In addition, MSF continues to put pressure on pharmaceutical companies and 
produces an annual edition of "Untangling the Web of Price Reductions: a pricing guide 
for the purchase of ARVs for developing countries." First produced in 2001, the 
thirteenth edition was released in July 2010 and documents comparative information on 
differential pricing between pharmaceutical suppliers and the countries where the drugs 
are purchased. This has been instrumental in keeping prices down and more fairly 
accessed in developing countries. 33 1 
MSF has also continued to perform a watchdog function, scrutinizing and publicly 
criticizing bilateral and regional trade agreements, particularly those that contain 
"TRIPS-plus" requirements and frequently addresses this concern on its website and 
through glossy publications. A 12 page brochure produced in August 2003 addressed the 
dangers to health that could occur if the Free Trade Area of the Americas agreement was 
signed with the U.S.332 In 2004, MSF distributed a similar pUblication that warned all 
governments against entering into regional or bilateral trade agreements with the U.S. 
MSF charged that because the U.S. had been forced into concessions at the WTO with 
regard to IP protection, it was now pursuing the interests of its pharmaceutical 
corporations by including provisions that exceeded both the terms and spirit of the TRIPS 
Agreement. At that time, MSF listed seven agreements that had been concluded and 
several that were pending.333 More recently, in March 2010 MSF was calling on India to 
33J Available on the MSF website htt.p:llwww.msfaccess.org!resources/key-publicationslkey-publication-
detaillindex.html%3ftx ttnews[tt newsl=1631&cHash=le60ab329f (accessed August 16, 2010). 
332 MSF, "Trading Away Health: Intellectual Property and Access to Medicines in the Free Trade Area of 
the Americas (FT AA) Agreement," 
http://www .doctorswithoutborders.org!publications/reports/2003/FT AA Advocacy.pdf (accessed April 
24,2010). 
333 MSF, "Access to Medicines at Risk Across the Globe: What to Watch for in Free TraCie Agreements 
with the United States," Briefing Note, May 2004, 1-12, 
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avoid entering into an agreement with the European Union that would result in 
restrictions on their generic industry's ability to produce much needed medicines for the 
developing world.334 MSF has also been active in advising governments when 
formulating legislation for importing and exporting of pharmaceuticals, and has been 
critical when governments include standards beyond the TRIPS Agreement.335 
From the beginning of the Access Campaign, MSF has maintained that governments 
had the right to use the flexibilities under the TRIPS Agreement to protect public health 
goals. Orbinski argued that "civil society and the private sector cannot substitute for 
government, only government has a duty and a responsibility to provide for public 
goods.,,336 MSF recognized that this could not be achieved merely through donations of 
drugs or voluntary price reductions from benevolent pharmaceutical companies. In a 
study commissioned by the DND Working Group comparing the costs of drug access 
through models that included generic purchasing, donations, concessionary (buy 
some/get some free), discounted and differential pricing,337 it was found that 
governments could only be self-sufficient in meeting public health obligations through 
developing manufacturing capacity and using the legal means available in the TRIPS 
http://www.doctorswithoutborders.orglpublications/reports/2004/ftaa 05-2004.pdf (accessed April 24, 
2010). 
334 MSF, "Free Trade Agreements: What consequences for access to medicines?" 
http://www.msfaccess.orglmainlaccess-patents/free-trade-agreementsl (accessed March 27,2010). For 
more about US Free Trade Agreements and their TRIPS-plus requirements, see Correa, "Intellectual 
Property Rights and Inequalities," 277-280. 
335 For example, MSF-Canada testified at the committee hearings for Bill C-9, and was critical of its 
exclusion of drugs that were not on the list of essential medicines. 
336 James Orbinski, "Essential medicines for Neglected Diseases: Innovation and Access or 3 Civil Society 
Initiatives that Just might Matter ... ," speech given at the Conference of Montreal's CIDAIIDRC 
International Forum, "Diseases Without Borders: An Economic Struggle?" May 8, 2003 available from 
http://www.idrc.calen/ev-62094-201-1-DOTOPIC.html(accessed August 16,2005). 
337 Alain Guilloux and Suerie Moon, "Hidden PriceTags: Disease-Specific Drug Donations: Costs and 
Alternatives," MSF/DND Working Group Feb. 2001: 189-210, 
http://www.deolhonaspatentes.org.br/mediaifile/Publicacoesihidden price tags.pdf(accessed May 9, 
2010). 
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Agreement. Although donations and reductions in pricing could be a temporary solution, 
this tended to create a disincentive to more affordable generic production, was restricted 
in availability, type of drug and use, and was frequently dependent on conditions that 
produced additional burdens on the recipient. MSF also argued that differential pricing 
based on affordability was useful in accessing some essential medicines such as vaccines; 
however, a more sustainable system would be needed to stimulate research and 
development, particularly for neglected diseases.338 
Furthermore, financial donations to programs set up to assist in accessing medicines, 
such as the Global Fund to Fight AIDS, Tuberculosis and Malaria339 and UNAIDS, were 
not as generous or forthcoming as had been anticipated. Bartsch has argued that funding 
targets set by the Global Fund were subject to competing interests such as economic 
shortfalls, renewed security concerns, and 'donor fatigue.' In addition, she notes that the 
Fund suffered from the diversion of resources to new programs such as PEPF AR. 340 
Finally, in some cases, financial donations were further constrained because of donor 
preferences where aid was limited to certain states or tied to specific types of programs, 
such as prevention, and other performance criteria that states were not always willing to 
surrender autonomy for.341 
Orbinski's concerns have been realized as newer second and third-line treatments have 
become available but are again offered under patent at a price that lower income states 
cannot afford. Currently, many patients in poor countries are receiving first-line 
338 Ibid., 204-205. 
339 The Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria was launched in 2001 and is a public-
p,rivate partnership between governments, civil society organizations and the private sector. 
40 Sonja Bartsch, "The Global Fund to Fight AIDS, Tuberculosis and Malaria," in Global Health 
Governance and the Fight Against HIVIAIDS, ed. Wolfgang Hein, Sonja Bartsch and Lars Kohlmorgen 
(UK: Palgrave MacMillan, 2007),159. PEPFAR, the US President's Emergency Plan f~r AIDS Relief, 
was launched in 2003. 
341 For a concise overview offunding problems for The Global Fund and PEPF AR, see Ingram, 91-96. 
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HIV / AIDS treatment that is less effective, toxic, or incompatible with other health issues, 
when they would benefit greatly by the newer more expensive regimes. 342 
MSF has continued to search for innovative solutions to the problem of access, 
particularly in the area of neglected diseases, and along with WHO was a proponent of 
the idea of a patent pool where drug companies and other research institutions could 
voluntarily submit their patents in exchange for royalties.343 Among the expected results 
of a pool would be lower prices and faster development of fixed-dose formulations by 
combining drugs from different originators. The pool is currently in the negotiation stage 
and is to be administered by UNITAID.344 In October 2009 MSF again used its website 
and the transnational advocacy network to pressure drug corporations to support the pool 
and launched an online "Make It Happen Campaign" which drew over 300,000 
responses.345 
Next Chapter 
The next chapter will argue more specifically why MSF was crucial for the success of 
the access campaign. I will also examine the discursive mechanisms used by MSF and 
the coalition to frame and disseminate information, and show through a constructivist 
lens how discourse can be influential in changing state behavior. Finally, I will 
summarize my research and conclusions. 
342 MSF, "Untangling the Web of Antiretroviral Price Reductions," 
http://utw.msfaccess.orglbackgroundlovercoming challenges (accessed May 9, 2010). 
343 A discussion and recommendation on patent pools is found in WHO, Public health, innovation and 
intellectual property rights, 52-53. 
344 UNIT AID is a project that has 29 member countries located mostly in Europe, South America and 
Africa. In 2008, 72% of the funding came from 7 of the countries who have instituted a tax on air travel to 
go toward the organization. The website is http://www.unitaid.eu/en See also MSF "Untangling the 
Web." 
345 MSF, "Make It Happen Campaign," http://www.msfaccess.org!mainlaccess-patents/make-it-happen-
campaign (accessed Oct. 1,2010). 
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Chapter 4 
• I 
! 
The transnational advocacy coalition and campaign played an important role in 
placing access to affordable medicines on the agendas of states, and in highlighting the 
problems associated with intellectual property rights harmonized within the patent regime 
under the TRIPS Agreement. As a member of the advocacy coalition, Medecins Sans 
Frontieres played a seminal role by providing a leadership function and grafting its own 
formal campaign for increased drug access for HIV / AIDS and other neglected tropical 
diseases to that of the larger network. The leadership role assumed by MSF was crucial 
for this coalition and campaign to realize a measure of success for two important reasons. 
First, unlike other campaigns aimed at changing state norms, there was no leadership or 
mentorship from a developed state. Second, most rights campaigns have involved civil 
or political rights, whereas the right to health was an evolving social right and not widely 
recognized when the campaign began. 
Campaigns and changing norms 
Advocacy campaigns aimed at changing human rights norms have typically enjoyed 
substantial support from developed states. While non-state actors may be responsible for 
identifying issues and moving them onto the international agenda, successful outcomes 
have also been linked to the actions of states that champion the issue and provide a 
variety of tools to influence other states to adopt new norms. Two examples of state 
influence aimed at changing norms using a human rights lens include the diplomatic 
pressure and economic sanctions levied by powerful states against South Africa during 
the anti-apartheid campaign,346 and the leadership provided by Lloyd Axworthy and the 
Canadian government to advance the Ottawa Treaty during the International Campaign to 
346 See David Black, "The long and winding road: International norms and domestic political change in 
South Africa," in The Power of Human Rights: International Norms and Domestic Change, ed. Thomas 
Risse, Stephen C. Ropp, and Kathryn Sikkink (UK: Cambridge University Press, 1999), 78-108. 
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Ban Landmines.347 In both cases, non-governmental organizations were the initial force 
behind the movement for change. However, in the first example, it was not until certain 
states joined the campaign that a shift in policy was considered by South Africa. 
Similarly, when a few key states put their support behind the landmines ban, a larger 
number of states quickly agreed to sign the treaty.348 
The campaign for drug access differed in that it did not have support from any of the 
developed states and was in fact diametrically opposed to the more powerful states' 
preferences for strengthened intellectual property rights. Lower income and lesser 
developed states lacked the power to contest the position of wealthy states, and were only 
instrumental in resisting the claims of the pharmaceutical companies and negotiating for a 
change in the TRIPS Agreement at the WTO after the advocacy campaign provided 
educational and technical support through conferences, workshops and human resources. 
Without the support of any powerful state, the campaign required the leadership of a 
recognizable, credible and tenacious non-state actor as a necessary condition for the issue 
to progress. MSF had several attributes that allowed it to provide strong leadership for 
the access coalition. 
The second consideration is that most successful advocacy campaigns have been 
directed at issues involving human rights that fall in the category of civil and political 
rights and have targeted governments or state policies that were seen as oppressive or 
347 See Richard Price, "Reversing the Gun Sights: Transnational Civil Society Targets Land Mines," 
International Organization 52, no.3 (Summer 1998): 613-644. For a detailed account of state involvement 
in the landmines ban, see Motoko Mekata, "Building Partnerships toward a Common Goal: Experiences of 
the International Campaign to Ban Landmines," in The Third Force: The Rise o/Transnational Civil 
Society, ed. Ann M. Fiorini (Tokyo: Japan Center for International Exchange and US: Carnegie 
Endowment for International Peace, 2000), 143-176. 
348 Finnemore and Sikkink have described this phenomenon as the three stage "life cycle" of a norm: 
emergence, which ends in a tipping point, broad acceptance which includes a norm cascade, and finally, 
internalization in "International Norm Dynamics," 895-896. 
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arbitrary.349 The issue of medicines is more appropriately categorized as a social right 
encompassed within the right to health, and the target has included international 
agreements, corporations and individual government policies. Furthermore, rights 
enumerated in the International Covenant on Economic, Social and Cultural Rights have 
traditionally been viewed as secondary, and only in the last decade have gained 
widespread importance.3so 
The implications of a right to health are further complicated in that government 
involvement in the provision of health care has varied significantly between states. In 
most states several non-state actors participate in or have assumed responsibility for 
aspects of health policy and the delivery of services. National governments rely on the 
expertise of the private sector to conduct research, develop products, regulate ethics and 
standards of care, build facilities, and coordinate responses to emergencies, and this trend 
has intensified with the introduction of liberal economic policies.3S1 Furthermore, few 
governments in the developing world have had the resources to manage even a small 
portion of health service delivery, especially for those who are living in remote areas or 
are marginalized due to the nature of their illness, and it has frequently been the mandate 
of faith-based and other non-profit organizations to assume this burden. Finally, 
understandings of health care and the needs of specific populations varies by state, 
culture and region, and the allocation of resources is bound up with competing interests 
within a state. As such, the right to health has remained largely aspirational. 
349 This is evidenced in the case studies included in the edited books by Risse, Ropp and Sikkink (1999) 
and Keck and Sikkink (1998) such as women's rights, political prisoners and disappeared persons. 
350 World Health Organization, "Human Rights, Health and Poverty Reduction Strategies," Health and 
Human Rights Publications Series 5, (2008), 1. 
http://whqlibdoc.who.intlhq/2008/WHO HR PUB 08.05 eng.pdf(accessed July 25, 2010). 
351 Hans L5fgren, "The Competition State and the Private Control of Health care," in Global Health 
Governance: Crisis, Institutions and Political Economy, ed. Adrian Kay and Owain David Williams (UK: 
Palgrave Macmillan, 2009), 245-254. 
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Although international organizations including WHO and World Bank have been 
actively involved in researching and formulating health policy and in proposing state 
strategies for some time, they were frequently constrained by the preferences and base 
funding that came primarily from developed states. A breakthrough in recognizing a 
right to health came when the Millennium Development Goals (MDG) were adopted in 
2000 by the United Nations General Assembly. The MDGs are directed at the 
eradication of poverty and include eight objectives, many of which are related to health. 
Most explicitly, Goal 6 is to "combat HIV I AIDS, malaria and other diseases" and as a 
target, expressly lists "universal access to treatment for HIV/AIDS for all that need it.,,352 
Since their re-introduction through the lens of poverty reduction, social rights have 
gained more attention and acceptance by states. The launch of the MDGs presented a 
political opportunity for the health-based advocacy coalition to expand their base of 
supporters to include a wider range ofNGOs that were focused on poverty, education and 
development issues, such as Oxfam and Third World Network. 
The recognition of the obligations incumbent on all states to uphold a right to health 
was also more apparent as a result of the Millennium Goals. For MSF, this provided an 
additional political opportunity to press its agenda advocating innovative research and 
development, new global funding models and lowered drug prices. MSF had already 
been working on the drug issue with various governments, international organizations 
and other non-state actors through conferences and workshops. The adoption of the 
Millennium Goals was a good fit with the stated objectives ofMSF's formal Access 
352 United Nations Development Programme, "Goal 6: Combat HIV/AIDS, malaria and <?ther diseases: 
Targets," Millennium Development Goals, Basic Facts, Goal 6, http://www.undp.org!mdg!goaI6.shtml 
(accessed July 25, 2010). 
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Campaign launched a year earlier, and allowed it to draw on rights-based language that 
was familiar to states when framing the issue. 
Why MSF? - Filling the leadership void 
MSF lacked the traditional power of a state and could not use diplomatic means or 
coercive economic sanctions states typically employ to pressure other states, but the 
organization had strengths that would allow it to fill the leadership void. MSF was 
internationally recognized for its expertise as a humanitarian medical organization and 
was able to use its extensive field experience and knowledge of treatment deficits to add 
credibility to the coalition's demands. MSF was also widely perceived by states and civil 
society as having legitimate authority and specialized knowledge in the area of health in 
resource-poor settings. MSF had national offices in most developed states, and had been 
active in more than 80 countries, and frequently provided services that governments were 
temporarily unable to manage. MSF had a very good reputation and its work was held in 
high esteem, as was evidenced when they were awarded the prestigious Nobel Peace 
Prize in 1999 for humanitarianism. Its depth of reach into the societies it served allowed 
MSF to represent the interests of a transnational constituency of stakeholders including 
those working in the area of health and those who were recipients of health care. 
Adding to its efficacy was that throughout its history MSF had resisted state control of 
its mandate and projects by limiting its dependency on state funding and by maintaining 
decision-making ability over which missions it would embark on. The organization had 
guarded its autonomy by avoiding most types of development projects and collaborative 
missions in the field in order to operate according to its beliefs. MSF valued its identity 
as a principled and moral actor that sought to uphold the dignity of the individual, and the 
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organization embraced the use of temoignage when there was evidence of injustice. Staff 
and volunteers were able to voice their concerns and give witness publicly even when 
states were the target of their criticism. 
The history and culture of MSF was embedded in such a way that during the access 
campaign, MSF openly challenged powerful states to re-evaluate the effects of the TRIPS 
Agreement and to meet their obligations to public health. MSF criticized international 
organizations such as WHO for weak policies and lack ofleadership and publicly 
targeted the V.S. for its "TRIPS-plus" requirements in bilateral and multilateral trade 
agreements. This liberty would not have been possible for an organization that relied 
heavily on government funding and contracts, particularly from the V.S. government. 
Nor would it be possible for an organization such as the ICRC, which does not allow 
public comment from staff, and is reliant on goodwill and the cooperation of 
governments to continue its service delivery and monitoring function. 
The breadth of MSF as a transnational organization also allowed for increased 
linkages and multiple access points to government officials and other non-state actors. 
Many of the national sections of MSF had prior ties to governments and international 
organizations through their participation at conferences and as frequent contributors to 
official inquiries about state foreign policy and humanitarian activity. The strategic 
location of the international office in Geneva was also an asset for creating formal and 
informal networks. It should be noted that there were other transnational organizations 
active in the campaign, such as Oxfam, who provided similar and complementary 
linkages with mUltiple state actors, and groups such as CP Tech that targeted their 
specific home states, and this strengthened the campaign significantly. 
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MSF was also able to form an epistemic community with expertise in both the health 
and legal aspects of the access issue. It had the internal capacity to decipher technical 
information about drugs and diseases and refute claims made by pharmaceutical 
corporations. This was in part because of their professional credentials and field 
experience, and partly because they were able to develop their own research capacity. 
Specifically, MSF's formal campaign greatly benefitted from the funds that came from 
the Nobel Prize. MSF allocated the 940,000 Euros awarded to them to create a fund for 
neglected diseases for research, testing and delivery of drugs, and to fund pilot projects in 
these areas.353 This is not to suggest that MSF alone provided technical support. Many 
campaign participants were immersed in treatment or policy research, generally at the 
domestic level. As well, HIV / AIDS activists and patient groups such as the South 
African T AC and generic drug companies provided solid evidence necessary for progress 
on the issue. Others such as Oxfam and CP Tech were proficient in providing legal 
support and other research capacities.354 
As stated earlier in this paper, advocacy groups lack traditional power and must 
strategically use information and act as moral entrepreneurs in order to create influence. 
This requires a concerted effort to carefully frame messages for a targeted audience and 
the flexibility to seize upon political opportunities that arise. Using Keck and Sikkink's 
classification of information, symbolic, leverage and accountability politics,355 we can 
see that the coalition was very effective in framing and disseminating information. 
353 MSF, "MSF Calls on Public Investment to Support Neglected Disease Research," Press Release 
(October 1 0, 2000), http://www .doctorswithoutborders.org!press/release.cfm ?id=63 7 &cat=press-re lease 
(accessed July 26, 2010) 
354 Orbinski, "An Imperfect Offering," 359. 
355 Keck and Sikkink, 16. 
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Framing the Issue and Disseminating Information 
Framing issues and dissemination of information is a key function of a campaign. The 
definition of framing presented earlier in this paper was to define the issues and propose 
appropriate strategies for a specific audience. Similarly, Zald defines frames as "specific 
metaphors, symbolic representations and cognitive clues" that are used to define events 
and suggest alternative responses.356 Frames must resonate with the desired audience to 
suggest specific understandings of the issue and must be aligned to guide responsive 
behaviour.357 
For constructivists who envision that state preferences are not fixed, discourse is an 
important tool in persuading states to adopt new behaviour. States are theorized as 
becoming socialized through their interactions with international actors and seeking 
legitimacy among other states. By re-conceptualizing a problem, frames may be effective 
in persuading actors that other perceptions are valid and legitimate, and can possibly lead 
to the development of new or changed norms.358 
Information politics is crucial to building effective networks and coalitions, and 
MSF's structure of national offices and volunteers in the field was beneficial for 
circulating information and drawing supporters. Factual information, updates on 
meetings, and position papers were quickly disseminated through MSF's national 
websites and were also accessible to civil society and media outlets. Although CP Tech 
maintained a 'listserv' throughout, it detailed extensive and informal day-to-day 
communications better suited to organizers involved in the network and included other 
356 M.N. Zald, "Culture, Ideology and Cultural Framing," in Comparative Perspectives on Social, 
Movements, ed. D. McAdams, J.D. McCarthy, and M.N. Zald (Cambridge: Cambridge University Press, 
1996),262. 
357 Keck and Sikkink, 17. 
358 Finnemore and Sikkink, "International Norm Dynamics," 902-904. 
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topics affected by intellectual property rights. In contrast, MSF maintained dedicated 
campaign web pages which eventually became a permanent site for its formal campaign. 
It controlled its communications with carefully and consistently worded press releases 
and field reports that outlined new developments in the campaign, clearly re-iterated 
ongoing and new problems, proposed solutions for the 'way forward' and stated MSF's 
position on the issue. The coalition also enjoyed a sympathetic media in developed 
countries, particularly during the South African lawsuit and when Cipla's offer of 
inexpensive generics exposed the high pricing of brand name drugs. 359 
During the first two years of MSF' s Access Campaign, the official spokespersons 
were primarily Orbinski, Pecoul and 't Hoen, with comments by the presidents ofMSF-
USA and MSF-South Africa only in a couple of state specific cases. In each of the 
fifteen press releases studied, there was a perception of urgency and frequent use of MSF 
'calling on,' 'urging,' and 'demanding' that governments, international organizations, or 
corporations perform a specific action. In their communiques, MSF constantly reminded 
governments that it was the state's responsibility to solve the issue of medicines that were 
priced too high or not even available and that states had a "right" to protect public health. 
A year into the campaign, MSF often incorporated into its statements that there was a 
'moral obligation' to provide access to affordable drugS.360 Overall, the professionalism 
359 Cipla's offer was a front page headline, Donald G. McNeil Jr., "Indian Company Offers to Supply AIDS 
Drugs at Low Cost in Africa, New York Times, 7 February 7 2001, 
http://www.nytimes.com/200 1 /02/07 Iworldlindian-company-offers-to-supply-aids-drugs-at -Iow-cost-in-
africa.html (accessed July 29, 2010). 
360 My conclusions are based on my content analysis of fifteen press releases issued between November 30, 
1999 and November 14,2001 and can be found on the most extensive single-source web-based list ofMSF 
press releases, news bulletins, speeches, and open letters from November 22, 1999 to the present, 
maintained by MSF-USA, All content: Access to Medicines, . 
http://www.doctorswithoutborders.orglnews/allcontent.cfin?id=84 (accessed July 25,2010). 
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with which messages were constructed added to the perception of the 'rightness' of 
MSF's position and their authority within the issue. 
The language used by MSF in many of its communications affirmed that states and 
their agents were the primary actors for resolving the issue. By reinforcing notions of 
sovereignty and state primacy over the issue~ in both setting the rules and being 
constrained by the rules~ states might envision that the TRIPS Agreement undermined 
their autonomy and conclude that the rules needed to be revised. In additio~ moral 
leverage was used for states that were concerned about their identities in a context of 
human rights or social justice by drawing attention to the moral obligation to provide for 
all people~ both at home and abroad and may also have helped to persuade governments 
to reconsider the appropriate balance between health policy and trade interests. 
MSF also partnered with international organizations such as the World Bank and 
WHO to sponsor conferences about identifying and surmounting barriers to medicines 
and this provided a measure of leverage in persuading states to adopt a different 
perspective. In addition to educating state officials, MSF became an authoritative 
resource for future policy discussions. 
Another frame that was often utilized reinforced a link between patents and needless 
deaths. MSF cited its own involvement in these terms: its patients were dying because 
they lacked lifesaving medicines which are too expensive because of patents. This 
simplified the issue for a general audience by ignoring the concerns of the pharmaceutical 
industry, leaving the viewer to interpret the frame and draw conclusions based on prior 
knowledge and associative understandings of the world. Because corporations were 
already 'villainized' in the media for social justice issues such as the use of child labour 
114 
and environmental degradation,361 it was seamless to imagine that drug companies would 
place corporate greed before human life. This was particularly effective for attracting 
new members across the globe to the growing movement within civil society that was 
protesting more generally against the power and policies of transnational corporations, 
and put sustained pressure on governments 'from below.' 
While MSF used the frame that pointed toward corporate greed for one audience, it 
also argued that, in general, it was not against the use of patents. In this frame, MSF was 
targeting drug companies to lower their prices or allow generic manufacturing oftheir 
products specifically in poor countries, as well as to recognize states' legal right to use 
compulsory licensing and parallel importing within the TRIPS Agreement. As Orbinski 
noted, the advantage of having a decentralized access network meant that while some 
members were attacking "unjust policies and practices," others could be "negotiating 
specific arrangements with the pharmaceutical industry and pushing governments to meet 
their responsibilities. ,,362 
In what could be considered symbolic politics, many of the posters and graphics used 
in MSF's promotional materials, travelling poster display and on their website attacked 
unaffordable drug prices or the lack of research for tropical diseases. These frames were 
aimed at mobilizing populations living in developed countries where a basic tension 
exists between publicly provided health care that benefits all and privately accessed care 
founded on liberal policies. According to Lofgren, welfare state policies fostered 
"popular expectations for medicines to be available on the basis of need, not ability to 
361 Examples include the protest movements against Nike and Nestle, resource extraction methods and their 
dangers (oil spills, clear cutting forests and open pit mining) which were prevalent in the news in the late 
1990s. . 
362 Orbinski, Imperfect Offering, 373. 
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pay,,363 and in spite of the transition to the market-based economy, most wealthy states 
have retained publicly financed insurance programs to subsidize and ensure access to 
phannaceuticals.364 
Some of the materials MSF used could garner support from citizens who shared these 
expectations. Alongside the traditional humanitarian images of sick children and persons 
with bodies ravaged by tropical diseases,365 were more modem depictions that focused on 
the cure - which was being withheld - rather than the illness. The graphics were aimed 
more toward raising awareness of the issue rather than as a plea for financial donations 
for a specific crisis, and frequently set up a polarized perception of 'us' and 'them.' 
Aligned with the beliefs of the MSF founders, the images might serve to evoke an 
emotive response of anger or indignation that medicines were possible, an injustice was 
occurring toward the most vulnerable members of society, and individual actions could 
help make it right. This is consistent with the theory that by framing issues in terms of 
right and wrong, the message will appeal to those who share similar principles, and 
individuals might be persuaded to act. 366 Examples of these materials include a poster of 
a pink birthday cake with two lit candles entitled 'Millions of Babies Won't Live to See 
This Day,367 and one created for MSF-Canada that depi~ts a white pill set as a gemstone 
in a ring captioned 'Medicine Shouldn't Be a Luxury. ,368 
363 Lofgren, 254. 
364 Ibid., 254-255. 
365 For a discussion on the most prevalent imagery used for humanitarian crises, see David Campbell, 
"Poststructuralism," in International Relations Theories: Discipline and Diversity, ed. Tim Dunne, Milja 
Kurki and Steve Smith (UK: Oxford University Press, 2007), 220-225. 
366 Keck and Sikkink, Activists beyond Borders, 19. Olesen, 10-11. 
367 This poster was included in an exhibition ofMSF posters shown in Guangzhou, China in August 2009 
to bring attention to ongoing humanitarian crises, and can be viewed at 
http://www.lifeofguangzhou.com/node 10/node 35/node 116/node IIS/2009/07/24/124842172667713.sh 
tml (accessed July 29,2010). 
368 MSF, "Three years of Access Campaign posters." 
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Accountability politics is used to embarrass actors by pointing out the disparity 
between principles, commitments and actions. The coalition seized on several 
opportunities to show hypocrisy in state behaviour. An example that may have impacted 
the Doha Declaration was the coalition's public criticism of Canada and the U.S. for 
considering compulsory licensing to counter Bayer's prices for ciprofloxacin during the 
anthrax scare, while routinely opposing the right of developing states to do the same for 
HIV / AIDS. MSF's publications warning states against entering into free trade 
agreements with the U.S. and the E.U. due to their "TRIPS-plus" constraints is another 
example of calling into question commitments made by these states. 
The coalition similarly targeted pharmaceutical companies. A key factor in the 
lowering of anti-retroviral drug prices in 2001 was the announcement that Cipla would 
supply a year's supply of the generic versions to MSF for $350 per patient, a huge 
reduction from Glaxo's $10,400. MSF continues to publicly expose drug price disparities 
between countries in its online publication, "Untangling the Web of Antiretroviral Price 
Reductions. " 
Theoretical Implications of the Case Study 
In the preceding chapters, I have highlighted the progression and key motivating 
factors behind the inclusion of intellectual property rights in the international trade 
regime of the World Trade Organization. I have al-so examined the advocacy role 
performed by non-state actors, with emphasis on Medecins Sans Frontieres, through a 
campaign that challenged the claims made by pharmaceutical companies and focused on 
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mechanisms that could allow resource-poor states affordable access to essential 
medicines and new drugs for tropical diseases. 
From the viewpoint of transnational corporations, safeguarding intellectual property 
rights was crucial for controlling production and maximizing profits. Rapidly evolving 
technologies and communications systems had a profound effect on knowledge-intensive 
industries, enabling free-riding manufacturers to erode traditional market shares by 
offering lower priced copies or by developing similar goods without incurring the 
financial burden of the initial research, product testing and marketing. As.private entities, 
corporations could be expected to promote a strong IP regime to remain profitable and 
viable, and to generate resources to re-invest in research and development. 
For the more powerful states that directly benefitted from corporate activities, 
strengthened intellectual property rules were necessary for the retention of trade 
advantages in a liberalized market-driven economy and for access to the technologies that 
evolved from research and development. From the perspective of both realism and 
liberalism, states are rational actors in pursuit of gains, and they will employ a "logic of 
consequentialism" when strategically bargaining to bring about the best possible 
outcome.369 For realists, this means that states would be expected to protect their assets 
to ensure their future security, while liberal'theorists would argue that states would 
respond to domestic pressures from competing constituencies, especially corporations 
seeking to further their interests. From either perspective, it would be expected that the 
more powerful states, where the largest phannaceutical companies were based, would 
pursue and defend trade rules that served to protect and enhance economic power. 
369 Risse, "Let's Argue", 2-4. 
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The logic of consequences was also present in developing and lesser developed states, 
although they initially resisted the terms of the TRIPS Agreement. Membership in the 
WTO was based on the total package rather than the piecemeal treaty that plagued the 
GATT. A cost-benefit analysis gave preference to the gains that could be realized from 
the promised agricultural and textile markets, transfer of technology, and 'most-favoured 
nation' status over the concessions required in the TRIPS Agreement. In retrospect 
however, the substantive effects of "TRIPS" were grossly underestimated. 
Standardized patent protection in particular led to serious consequences for accessing 
pharmaceuticals and was particularly punitive for countries that lacked manufacturing 
capacity. However, the patent regime was created when new medicines were not 
expected for the diseases of the south. For example, during the early years of the 
Uruguay Round, HIV / AIDS treatments did not exist and the virus was not widely 
understood even in industrialized states. The enforcement of structural adjustment 
policies that tended to undermine national health programs and other social spending in 
developing states is evidence of how unconcerned policy makers were about health 
systems in general, focusing instead on neo-liberal economic principles to foster 
development.37o Moreover, many governments, particularly in Africa, did not have 
adequate information collection systems and had not yet acknowledged the extent of the 
HIV / AIDS crisis nor envisioned the reversing effect it would have on state 
development. 37) 
370 Caroline Khoubesserian, "Global Health Initiatives: A Healthy Governance Response," in Innovation in 
Global Health Governance, ed. Andrew F. Cooper and John J. Kirton (UK: Ashgate Publishing, 2,009), 
289-290. See also Buckley and Baker, 213-216. 
371 WHO, "HIV Surveillance Report." The lack of reporting, slow responses and denials .by key 
governments and officials in Africa is well documented by Amy S. Patterson (ed.), The African State and 
the AIDS Crisis (U.K.: Ashgate Publishing, 2005). 
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As demonstrated in this case study, wealthy states had much to gain from enforcing 
intellectual property rights. Traditional theories would expect states to protect their 
material interests therefore the norms of the liberalized market economy should logically 
take precedence over the protection of social rights. However, after intense negotiations 
at the WTO, states confirmed the right to use compulsory licensing and parallel 
importing, adjusted some of the terms of the TRIPS Agreements, and created 
mechanisms for resource-poor states to use the flexibilities. This behaviour is 
inconsistent with the expectations of traditional realist and liberal theories. 
To understand why states chose to recognize the primacy of health over economic 
gains, we can turn to a constructivist approach to international relations theory. The 
constructivist position acknowledges the importance of material concerns, yet argues that 
state identities are also an important factor in determining their actions. Constructivists 
assume that state interests and preferences are not deemed to be fixed and are subject to 
reason in a given situation. Mutually shared values and norms constitute what is 
considered to be legitimate or desired behaviour and the "logic of appropriateness" can 
become influential in shaping state interests, determining actions and outcomes.372 
In this case, it appears that wealthy states were influenced by arguments posited by the 
advocacy coalition based on ideas of what would constitute appropriate or moral 
behaviour. While the pharmaceutical lobby appealed to state-recognized norms of the 
liberalized market economy, the advocacy campaign argued for the state-recognized 
norm of the right to health. In addition, the advocacy coalition insisted that states must 
be allowed to exercise their sovereign right to provide healthcare for their people, which 
included measures needed to access essential medicines. By adopting the language of 
372 Risse, "Let's Argue," 6-7. 
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both a right to health and the sovereign right to protect health policy, the advocacy 
campaign was able to appeal to a wide constituency of states and range of interests that 
constructivists argue can be subject to change. 
Conceding that human rights should take precedence over purely economic objectives 
is also consistent with the constructivist claim that states are concerned with signaling 
their identity as a member of the community of liberal states. Theorists suggest that 
states and state leaders are concerned about reputation, want to belong, and will usually 
try to do the 'right' thing.373 In addition, the medicines issue gained salience in that it 
sought primarily to protect vulnerable populations and prevent needless suffering and 
premature deaths. 374 
A shift in state behaviour usually requires a transition between competing normative 
frameworks in belief and practice and may require an institutional response to clarify the 
new norm and its parameters.375 In this case, the coalition targeted not only states and 
corporations, but also the international organization that oversees trade. Therefore the 
institutional response is entrenched in the Doha Declaration and revised TRIPS 
Agreement which provide the primary rules for protecting drug patents, as well as the 
procedures for enforcement and adjudication of disputes. Meanwhile, the main treaty 
that enumerates the right to health is the International Covenant on the Economic, Social 
and Cultural Rights. The arguments presented by the access campaign also benefitted by 
their alignment with the Millennium Goals that reinforce social rights. 
For the most part, the constructivist approach seems to provide a more inclusive 
explanation for why states in this case were willing to adopt new policies. However, the 
373 Finnemore and Sikkink, "International Norm Dynamics," 902-904. 
374 Keck and Sikkink, Activists beyond Borders, 27. 
375 Finnemore and Sikkink, "International Norm Dynamics," 900. 
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United States remains somewhat of an outlier. While the U.S. eventually conceded to a 
revision in the TRIPS Agreement, it continued to put pressure on many states that tried to 
use the legal provisions of compulsory licensing and parallel importing through the threat 
or use of its Section 301 powers. In addition, the U.S. has continued to negotiate free 
trade agreements with several states, including some within the developing world, that 
include provisions that exceed the intellectual property provisions contained within the 
TRIPS Agreement. The explanation for this may include several factors. 
First, the U.S. had more to lose than other states in a weakened IP regime because the 
majority of large pharmaceutical corporations and knowledge intensive industries were 
US-based so the economic and technological benefits to the state were considerable. By 
entering into external free trade agreements that reflect more stringent standards, the U.S. 
could continue to protect its economic interests and signal to the corporate community 
that it is 'business as usual.' Second, negotiators for the U.S. were hesitant to concede to 
demands that would set a precedent or offer an interpretation that could be extended to 
other areas of trade law and negotiations. By entering into separate free trade agreements, 
the U.S. could tighten its control and enforcement powers over specific areas of trade 
such as pharmaceuticals on a case by case basis. Third, the U.S. found an alternative 
method to signal its commitment to the international community using means other than 
trade concessions by entering into global funding arrangements to provide medicines for 
low income states and to assist with incentives for research and development. Fourth, in 
response to domestic pressures, the U.S. also initiated its own PEPF AR program and 
funds a large number of U.S.-based development and faith-based organizations active in 
providing treatment and education for HIV / AIDS. This allows the state to maintain 
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accountability and control over the types of programs it will fund and importantly over 
the decision of who will benefit, which may provide incentives for poor countries to 
cooperate with U.S. demands in other areas. Finally, the asymmetrical power structure 
between the U.S. and most other states continues to influence the strength of bargaining 
positions in trade agreements and frequently results in states accepting constraints 
insisted upon by the U. S. in some areas in order to gain the advantages offered in other 
areas. 
Although this paper is limited to one case study, there are some generalizations that 
can be forwarded. First, this case provides evidence that states are open to policy 
considerations and collective international arrangements that recognize normative 
understandings of human rights as prior to, or equal to the norms that underpin material 
and economic gain. This is not consistent with traditional theories that place security 
issues and material concerns as the primary drivers of state behaviour, and suggests that 
other theoretical concepts are necessary for understanding contemporary state relations. 
For example, the constructivist view that state identities and interests are formed and 
subject to change as the result of ideational factors seems persuasive in this case. 
There is also evidence that the recognition of human. rights as a factor in international 
agreements is not limited to civil and political rights, but now may extend to important 
social rights. This theme was recently adopted by the WTO Director-General Pascal 
Lamy in a speech that claimed that "trade and human rights go hand in hand;,,376 and he 
drew not only on the example of access to medicines, but also linked the negotiations 
concerning agriculture to the right to food. This suggests that in future states may be 
376 WTO, "WTO News: Speeches - DG Pascal Lamy, Trade and Human Rights Go Hand in Hand," speech 
to UNITAR, September 26,2010, http://www.wto.org/english/newse/spple/sppl172e.htm/ 
(accessed October 3, 2010). 
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expected to consider the externalities created by liberal trade policies and incorporate 
concrete solutions to minimize negative impacts, particularly in poor countries. 
It is also apparent that non-state actors have a significant role to play in identifying 
issues that affect the set of rights contained in the ICESCR. What is unusual is that this 
will frequently require advocacy that is aligned with the interests of governments in the 
developing world, and may not garner much initial support from more powerful states. 
This is a departure from most prior human rights issues that featured advocacy of civil 
and political rights, and generally targeted oppressive policies in developing states. On 
the international level, this may require a more concerted effort between domestic non-
governmental organizations, affected governments, international organizations and 
transnational advocacy groups. 
The depth and breadth of collaboration that may be required is evident in the access 
campaign. Its success relied heavily on the grassroots participation ofTAC in South 
Africa and domestic groups like ACT UP and CP Tech in the US that directly confronted 
their governments' policies. In addition, the demands of the African states and Brazil at 
the WTO were instrumental in bringing the TRIPS Agreement back to the negotiating 
table. Some of this participation was possible due to the educational component of the 
campaign and the resources made available by international organizations such as WHO 
and World Bank in conjunction with the transnational coalition that had first identified 
and launched the access campaign, including HAl, Oxfam and MSF. 
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Further Research for Pharmaceutical Access and Health 
It is estimated that about a third of the world, and up to 50% in Africa, still do not 
have access to essential medicines. While some might consider this a campaign and 
policy failure, drug access is improving steadily and there is evidence that investment in 
research for neglected diseases has increased. However, donor fatigue has been noted in 
decreasing global financing, and it has been stressed that states must be proactive in using 
the flexibilities in the TRIPS Agreement and in improving domestic infrastructure and 
health delivery systems. Accordingly, the WTO periodically sponsors seminars on the 
use of the TRIPS Agreement, but further research is needed to determine what barriers 
still exist in the area of access. Barriers might include the complexities in exporting 
medicines under compulsory license as experienced by the Canadian generic 
manufacturer Apotex, or may potentially be linked to provisions in other free trade 
agreements, such as those with the U.S. 
MSF and other members of the access coalition have continued to monitor drug 
prices, free trade agreements, and research for new treatments, but concern has arisen that 
the newer drug formulas for diseases are again not reaching poor countries. In response, 
MSF has added to its campaign a medical innovation section that is in support of a new 
global framework based on need rather than the market. 377 Another addition to their 
formal campaign is malnutrition because it has been identified as a key contributor to 
premature death from other diseases.378 However, while the network may remain active 
through multiple linkages, the access coalition appears to have disbanded. This could 
377 MSF, "Medical Innovation," http://www.msfaccess.org/main/medical-innovation/ (accessed July 26, 
2010). 
378 MSF, "MSF and Malnutrition," http://www.msfaccess.org/main/malnutritionlintroduction-t0-
malnutrition/msf-and-malnutritionl (accessed July 26, 2010). 
125 
provide another area of future research to consider the impact that is possible without the 
support of a wide-reaching coalition. In particular, will MSF be able to make substantial 
progress in the newer issue-areas and if so, what resources are required to be successful? 
Recently, the World Bank and WHO have invested resources into understanding how 
health is related to development and the social determinants of health have evolved to 
include a vast range of social factors beyond food, water, housing and medicines. 
Determinants, which are intrinsically linked to poverty, are now understood to include 
such issues as gender equality, education, environmental degradation and labour 
conditions. It is widely acknowledged that the duty to coordinate services, treat disease 
and illness, and monitor outcomes goes beyond the capacity of the state and involves 
multiple levels of stakeholders. Sustainable health plans require the participation of 
states, corporations, international organizations, NGOs, private donors and foundations, 
communities and individuals.379 
This collaboration of state and non-state actors is consistent with Ruggie's conception 
of the new global public domain where the governance of certain issues that transcend 
state borders becomes the shared responsibility of a variety of social actors. Further 
research will be needed to determine what constitutes a public good and what role 
advocacy groups will play in the issues that fall within this domain of global governance. 
379 World Health Organization, "Human Rights, Health and Poverty Reduction Strategies," 14. 
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